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Abstract 
Abstract 
In this thesis I discuss a number of issues related to the evaluation of healthcare 
technologies for the treatment of venous leg ulcers. I begin by describing the current 
process of technology assessment for medical devices in wound care and point out 
some of the challenges healthcare decision makers face when trying to ascertain the 
value for money of these technologies. The main case study used in this thesis is 
then introduced (the VenUS I study). This is followed by a description of the evidence 
base concerning the clinical, cost-effectiveness and impact on health related quality of 
life of therapeutic medical devices in wound care, of which venous leg ulcers are an 
aspect. Two methods to enhance postal follow-up data collection in randomised 
controlled trials are then proposed and tested in two opportunistic studies. Previously 
identified methodological shortcomings associated with existing evidence of the 
clinical and cost-effectiveness of wound care interventions are addressed in the 
context of the largest randomised controlled trial of two compression systems for the 
treatment of venous leg ulcers. Robust statistical methods that acknowledge relevant 
characteristics associated with the primary clinical and economic measures of health 
benefit and costs are used to analyse data from VenUS I. The potential contribution 
of a recently proposed methodological framework based on Bayesian decision 
analytic modelling and Bayesian value of information analysis is investigated. Finally I 
present a discussion of the contribution of this body of work, and its impact on 
research activity, and conclude making some recommendations for future research. 
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Introduction 
Introduction 
Publicly funded healthcare systems are under increasing financial and political 
pressure. Policy makers are expected to optimise the allocation of their limited 
healthcare resources in a way that maximises society's health benefit and ensures a 
fair distribution of the benefits. To this end, several jurisdictions have set up formal 
healthcare evaluation processes to establish whether new technologies are good 
value for money. [1-3] In England and Wales the National Institute for Health and 
Clinical Excellence (NICE) has responsibility for issuing recommendations regarding 
the adoption of healthcare technologies, informed by evidence regarding their clinical 
and cost-effectiveness. [4] The availability of high quality evidence is fundamental for 
the successful completion of this process. 
This thesis discusses a number of issues associated with the assessment of medical 
devices for wound care specifically indicated for venous leg ulcers (VLUs). Unlike 
pharmaceuticals, for which a stringent evaluation process is in place, the introduction 
of therapeutic medical devices into the European market requires only evidence of 
safety and technical performance. [5] This limited requirement for evidence of 
therapeutic benefit results in the introduction of a myriad of products with similar 
indications and unproven differential effectiveness. This is true with respect to wound 
care products, most of which are licensed and marketed with relatively weak clinical 
and cost-effectiveness evidence. 
The limited incentives to demonstrate clinical and cost-effectiveness of medical 
devices provided by the current licensing system has resulted in the widespread use 
of case studies and case series as the evidential basis for marketing. Such is the 
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case for all wound care products including those indicated for VLU treatment. 
However, observational studies are widely regarded as providing lower quality 
evidence of clinical effectiveness than well conducted randomised controlled trials 
(RCTs). [6] Whilst the number of therapeutic RCTs in VLUs has increased during the 
last decade, most of them still have important methodological limitations. [7-9] These 
limitations are detailed in Appendix B- to describe them briefly here, they include: i) 
inappropriate comparisons; ii) small samples unsupported by a priori sample size 
calculations; iii) inadequate duration of follow-up ; iv) between group imbalances in 
prognostic factors at baseline; v) use of intermediate and sub-optimal outcome 
measures (for a more detailed description of these shortcomings, see Appendix B). 
Most economic evidence on the cost-effectiveness of VLU treatments is accrued from 
RCTs, and consequently the validity of any trial-based evaluation is entirely 
dependent on the quality of the RCTs. [10] Similarly, the validity of the results of 
model based economic evaluations depends on the quality of the evidence used to 
populate the model and the suitability of its structure. [1 1; 12] The generally weak 
evidence base in VLUs has therefore resulted in severe limitations associated with 
existing trial and model-based economic evaluations. Moreover, the methodological 
quality of these evaluations does not adhere to existing guidelines. [13] Frequently 
encountered shortcomings include: i) use of uninformative intermediate outcomes; ii) 
estimates of cost only based on unit cost of treatments; iii) use of medians rather than 
means to estimate average health benefits and costs (for a detailed discussion see 
Appendix B). 
It can be argued that in general the poor methodological quality of the clinical and 
cost-effectiveness evidence for medical devices generates an additional hurdle for the 
assessment of these technologies. The Health Technology Assessment (HTA) 
2 
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process has been defined as "the evaluation of the properties, effectiveness and the 
direct and indirect impacts of health technologies. "[14] In the absence of a fixed set of 
activities to be performed as part of an HTA process, activities are determined 
according to the primary aim of the evaluation which may vary and include an 
assessment of: the effectiveness of a health technology in specific populations; its 
cost; any intended or unintended consequences of a health technology for individuals, 
families, healthcare system, and society. [14] A graphical representation of HTA 
processes with a range of different objectives is described in Figure 1. The HTA 
processes in both the UK National Health Service HTA Programme (UK NHS HTA) 
and NICE primarily focus on the clinical and cost-effectiveness of health technologies 
from the perspective of the UK NHS and Personal Social Services. [4; 13] As 
represented in Figure 1, the HTA process is an iterative approach with different 
primary objectives which are intrinsically interconnected. [14; 151 
The overall aim of the research described in the published papers discussed in this 
thesis is to produce high quality research evidence to inform / facilitate HTA in VLUs. 
Specifically, this research concentrates on two aspects of HTA: the assessment of the 
clinical and cost-effectiveness of health technologies (single activities involved in this 
process with a note of those informed by our findings are listed in Figure 1) and 
methodological issues in primary research. To achieve my overall aim I pursued the 
following objectives: i) to improve the measurement of effectiveness in VLU using final 
and composite outcomes that can also be used to measure health benefit from an 
economic perspective (e. g. QALYs); ii) to optimise the collection of primary outcome 
data using postal surveys in elderly populations; iii) to rigorously assess the clinical 
and cost-effectiveness of high compression systems for VLU; and iv) to test the 
3 
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potential contribution of a recently proposed framework for the evaluation of 
healthcare technologies. 
In 1998, the UK NHS HTA programme commissioned a multicentre pragmatic RCT 
comparing the effectiveness of two high compression bandage systems for the 
treatment of VLUs (the VenUS I Study). The question addressed by this trial had 
been generated by a Cochrane review. [16] VenUS I constitutes the main research 
base for the development of this thesis (see Section 3.1 for a detailed description). 
Interestingly, following the commissioning of the VenUS I study, a number of 
industry-funded RCTs on high compression systems for VLUs were also conducted in 
the UK and Europe. [17-22] These concurrent RCTs had significantly smaller sample 
sizes and follow-up periods than the VenUS I study, and hence their findings were 
published whilst VenUS I was underway. In order to preserve a sense of the 
chronology of events and in the iterative spirit of the HTA process, I discuss the 
clinical (Section 1.4.1) and economic evidence (Section 1.6.2.1) on high compression 
for VLUs at two points in time, prior to the conception and funding of the VenUS I 
study in 1998 (Section 1.4.1) and from that point up to January 2006 (Section 5.1.3). 
VenUS I was also the first study in which preference-based HRQoL scores were used 
to estimate health benefit in an economic analysis. During its conduct, however, a 
number of cross sectional and interventional studies investigated the impact of VLUs 
from clinical and economic perspectives using personal interviews and disease 
specific and generic health related quality of life (HRQOL) instruments. [23-25] The 
results of VenUS I are set in the context of this emerging body of evidence in Section 
5.1.2 and the evidence prior to VenUS is discussed in Section 1.5.2. 
4 
Introduction 
This integrative chapter is divided into five sections. Section I provides a general 
overview of the state of the art in the area of VLUs. Section II addresses the topic of 
HRQoL: its measurement using disease specific and generic instruments; the impact 
of VLUs; and its use as a measure of effectiveness in RCTs (papers 1,2 and 3 in 
Appendix A). Section III is dedicated to the analysis of the clinical and 
cost-effectiveness of two alternative systems of high compression for VLUs (papers 4 
and 5 in Appendix A). The application of a recently proposed framework for the 
evaluation of healthcare technologies to the area of VLUs is tested in Section IV 
(paper 6 in Appendix A). Finally, a discussion of the main findings, limitations of the 
work and its contribution to knowledge are the subject of Section V. 
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Section l: General overview of the area of VLUs 
Section I. 
1 General overview of the area of VLUs 
1.1 Chronic leg ulcers 
Chronic leg ulcers have been defined as... 99 a loss of skin below the knee on the leg or 
foot that takes more than six weeks to heaf'. [26] The chronicity of the disease is 
determined by an underlying health condition, frequently venous insufficiency, that 
causes the skin to breakdown by some unknown mechanism. Effective treatments for 
venous insufficiency are not well developed, hence the chronic nature of the sequelae, 
including ulceration. 
1.2 Epidemiology 
Leg ulcers are mainly present in ageing populations, with women being more 
frequently affected than men. [27] The extent of leg ulceration in the UK has been 
investigated in a number of epidemiological studies which suggest that the prevalence 
of this condition in the British adult population is between 0.045% to 1.8%. [28; 29] The 
largest UK based study suggests that approximately 25% of the identified chronic leg 
ulcers were active (i. e. open) at any point in time. [30; 31]. Uncomplicated venous 
disease has been identified as the main underlying cause of leg ulceration with 
venous disease being apparent in 43% to 81 % of leg ulcers. [27; 29; 32; 32; 33] VLUs 
are typically a recurring condition. 
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1.3 Aetiology of venous leg ulcers 
The aetiology of VLUs is only partially understood. Deep vein thrombosis (DVT), 
which results in damage to the deep veins leading to venous insufficiency, has been 
identified as a risk factor for the development of VLUs. [34] The cellular mechanisms 
involved in the breakdown of the skin of the leg, however, have not been fully 
explained. [35] Browse and Burnand found evidence that venous insufficiency was 
associated with back flow of blood and an increased hydrostatic pressure in the 
superficial veins. [36] It is in an attempt to reduce the hydrostatic pressure in the veins 
and to aid venous return that external compression therapy is applied to the ulcerated 
leg. 
1.4 Treatment 
The first line treatment of VLUs comprises the application of wound dressings and 
external compression (standard wound care). [37; 37] The application of external 
compression through bandages, hosiery (stockings, socks, tights) or combinations of 
these, is also used to prevent further skin breakdown. [38] Standard wound care 
treatment can be complemented by use of pharmacological drugs, topical agents, 
debriding agents, laser treatment, therapeutic ultrasound, skin grafting, and venous 
surgery. [39] Prognosis and the patient's initial response to treatment should 
determine departures from the "standard treatment". For example, VLUs that fail to 
heal whilst in compression may require an adjunct therapy, such as pentoxifylline, to 
expedite the healing process. [40] 
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When all the alternative methods for compression and wound dressings indicated for 
VLUs in the British National Formulary (BNF)[41] are taken into account, there are 
approximately 130,000 potentially different clinical treatment pathways for VLUs. This 
may unnecessarily complicate healthcare decision making in VLUs. In Table 1, I have 
described all the interventions indicated for the treatment of VLUs in the UK, their 
indication, the available RCT evidence and potential different classes of products, as 
described in the BNF and Clinical Evidence. [38; 41 ] The latter is a BMJ internet based 
publication, the mission of which is to "... summarise the current state of knowledge 
and uncertainty about the prevention and treatment of clinical conditions, based on 
thorough searches and appraisal of the literature. [... ] It describes the best available 
evidence from systematic reviews, RCTs and observational studies where 
appropriate,... "[38] 
The clinical effectiveness evidence in this field is generally weak for the reasons 
outlined in the introduction and described in Appendix B. 
1.4.1 Effectiveness of compression therapy (prior to VenUS 1) 
In 1997 the evidence base for external compression in the treatment of VLUs was 
synthesised in a Cochrane systematic review [16], which indicated that, in the 
absence of arterial disease: i) compression was more effective than no compression; 
ii) high compression was more effective than low compression; iii) there was 
insufficient evidence of a differential effect associated with different high compression 
systems (multi-layered, single layered, elastomeric, non-elastomeric). To address 
these issues the review concluded by recommending the conduct of well designed 
RCTs accompanied by economic evaluation analyses. 
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1.4.2 Effectiveness of other treatments (up to date) 
Wound dressings are typically applied directly to the open ulcer underneath 
compression bandages. The superiority of any wound dressing over another has not 
been demonstrated. [7; 38] Similarly, a paucity of evidence on the effectiveness of 
other therapies indicated for the treatment of VLUs has been identified (see Table 1). 
Evidence of the clinical effectiveness of pentoxifylline, a vasodilator drug, as an 
adjunct to compression in the treatment of VLUs, was identified in a systematic 
review. [40] Indirect evidence of the effectiveness of compression hosiery to prevent 
recurrent VLUs was provided in two RCTs of compression stockings for the prevention 
of VLUs. [42; 43]. In the view of the methodological weaknesses associated with these 
studies their findings should be used / interpreted with caution. 
1.5 Health related quality of life (HRQoL) 
In 1947 the World Health Organisation defined health not only as the absence of 
disease or infirmity but as "a state of complete physical, mental and social 
well-being. "[44] Ever since, "health related quality of life" (HRQoL) has become a 
frequently used umbrella concept that encompasses a number of different dimensions 
/ domains of health. To date there is no universally accepted definition of HRQoL, 
although a range of descriptions are available in the literature. It has been argued that 
existing definitions vary depending on both, "the aims and perspective of the research 
and the instruments that are developed and applied to attain such aims. "[45] In health 
services research, measurements of HRQoL are often made from a clinical or an 
economic perspective. 
10 
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1.5.1 HRQoL from a clinical and economic perspective 
This concept has been used from a clinical perspective to explore the impact of a 
health condition on specific dimensions of health, such as: daily routine, physical, 
social, intellectual, emotional, psychological functioning, economic status, health 
status, well-being or life satisfaction, among others. Such research has used both 
quantitative and qualitative approaches. In health economics, the concept of HRQoL 
has been closely associated with "utility", [10] an economic term that describes the 
strength of preference of individuals, in this case, preference for a health outcome or 
health status under conditions of uncertainty, relative to two health states: perfect 
health and death. The more preferable a health status or health outcome, the greater 
the utility expected to be associated with it. Unlike clinical / psychometric 
measurements of HRQoL, "utility measurements" allow comparisons of the HRQoL 
impact associated with a range of different health outcomes, hence their relevance for 
HTA. 
In a clinical context, measurement of HRQoL is usually conducted in a certainty 
framework through the administration of psychometric instruments often using scaling 
methods such as rating scales, category scaling, visual analogue scales or ratio 
scales. In economics, measurement methods based on "choice under uncertainty" 
(i. e. standard gamble) are the only ones deemed to measure utility. [46] Difficulties 
with the practical implementation of standard gamble make it a less popular 
alternative than choice methods under certainty such as time trade off, paired 
t: 
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Section l: General overview of the area of VL Us 
comparison, and person trade off. [1 1] While a correlation between clinical and 
economic measurements of HRQoL is apparent, an analytically explicit description of 
the association might not be known. Thus it is relevant to consider both types of 
measurements in the context of HTA, as discussed further in Section 2. 
1.5.2 The impact of VLU on HRQoL (prior to VenUS 1) 
By 1998 three disease specific instruments had been claimed as suitable for the 
measurement of the HRQoL of individuals with VLUs. The 34-item Hyland is the only 
instrument that has specifically been developed to measure the HRQoL of individuals 
with a VLU. [47] The chronic lower limb venous insufficiency questionnaire (CIVIQ)[48] 
and the Freiburger questionnaire of quality of life in venous disease (FLQA)[49] aim to 
measure HRQoL in people with venous insufficiency who do not necessarily have an 
ulcer. The CIVIQ is a 20-item scale which measures four dimensions of HRQoL 
(psychological, physical, and social functioning and pain) with good reliability and 
validity (face, content and construct). The CIVIQ is also reported to be sensitive to 
changes in venous insufficiency status after two months. [48] The FLQA comprises 83 
items within seven scales (physical complaints, everyday life, social life, emotional 
status, therapy, satisfaction, occupation) and was associated with good validity and 
sensitivity to changes in venous insufficiency status after three months. To date, 
however, an English translation of this instrument is not publicly available. 
Prior to VenUS I, HRQoL in people with and without leg ulcers had been reported in 
two studies. Flett et al found that leg ulceration was associated with greater problems 
with activity and mobility, more pain, lower levels of self-esteem, and higher levels of 
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negative affect. [50] Roe et al observed poorer scores for pain, energy, life satisfaction 
and depression reported by individuals with leg ulcers. [51] 
1.6 Economics of VLUs 
VLUs are extremely costly; annual treatment costs to the UK NHS were estimated at 
between £230 and £650 million, at 1990-1991 prices. [52] 
1.6.1 Economic evaluation 
Economic evaluation analyses of health technologies have been recognised as a tool 
to inform the decision making process in healthcare. [4] In the context of HTA, 
economic evaluation has been defined as "the comparative analysis of competing 
alternative courses of action in terms of both the costs and benefits associated with 
them. "[10] In full economic evaluation the estimates of incremental cost and 
incremental health benefit are combined in a single measure of cost-effectiveness, 
such as the incremental cost-effectiveness ratio or the incremental net benefit. [10; 53] 
There are three different analytical approaches used in full economic evaluations of 
healthcare technologies. The main differences between these arise from the way in 
which health benefits associated with the alternative treatments under comparison are 
measured. In cost-effectiveness analyses (CEA), health benefits are measured using 
natural units (e. g. ulcer free days, absolute and relative reductions in ulcer size). 
Evaluations in which health benefits are measured using a composite measure that 
weights life expectancy with a preference-based utility score, such as EQ-5D, to 
estimate quality adjusted life years are known as cost-utility analyses (CUA). The 
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ability of CUA to compare interventions for different indications has made it the 
preferred method of evaluation by NICE. [13] In cost-benefit analysis (CBA), health 
benefits are measured in monetary terms; recently this has been done using discrete 
choice methods. [54] 
Cost-consequences analyses (CCA) are partial economic evaluations in which the 
health benefits and costs associated with the alternatives are not combined in a single 
measure of cost-effectiveness. [10] 
1.6.2 Economic evaluations in VLUs 
The economic evaluations in the area of VLUs discussed in this section were 
identified in a systematic review conducted in 2004 as a basis for an update of the 
Royal College of Nursing Guidelines for the Management of VLUs. [39] The electronic 
search strategy used, as well as a QUORUM flowchart of the evidence identified 
(Figure 2), are described in Appendix C. [55] 
In general, the validity of the economic evaluations identified is compromised by 
methodological shortcomings associated with the clinical studies on which they are 
based and by the absence of rigour in the measurement of overall treatment cost and 
health benefits. 
1.6.2.1 Cost-effectiveness of compression systems for VLU (prior to VenUS I) 
As recently as 1998, the cost-effectiveness of high compression systems for VLU had 
only been explored in one trial-based cost-consequences study[56] which claimed 
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Unna's boot (a device used mainly in the USA) was associated with higher healing 
rates and less costs than hydrogel dressing. 
1.6.2.2 Cost-effectiveness of other treatments for VL U (up to date) 
In spite of the paucity of evidence on the clinical superiority of any wound dressing 
(Section 1.4.2), several studies have claimed the cost-effectiveness of hydrocoliloids 
relative to saline gauze based on reductions in weekly nursing contacts. [57-60] 
Opportunistic CCAs have been conducted in an attempt to justify both the 
cost-effectiveness of larval therapy to remove sloughy / necrotic tissue (debride); [61] 
and the cost-effectiveness of managing VLU patients in co-ordinated community VLU 
clinics using multi-layer high compression versus community care. [62-65] Evidence of 
the value for money of compression stockings and an educational programme versus 
"do-nothing" to prevent future VLUs was found in a model based cost-utility 
analysis. [66] As mentioned in the introduction the evidence from these studies is 
associated with the shortcomings discussed in Appendix B, and hence their findings 
should be used / interpreted with caution. 
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Section II 
2 Measuring the impact of VLU on HRQoL 
2.1 Background 
The Hyland questionnaire is the only disease specific instrument that claims to be able 
to measure HRQoL in individuals with VLUs. [47] As mentioned in Section 1.5.2, other 
disease specific HRQoL instruments used in this population focus primarily on venous 
insufficiency (a sequela of which is venous ulceration). The Hyland, while constructed 
using sound psychometric methodology, was developed in a relatively small sample of 
50 people with VLUs. The VenUS I study provided an ideal opportunity to validate 
and further investigate the properties of this instrument in a larger population of 
individuals with VLUs, prior to recommending its use in treatment evaluations. 
A comprehensive investigation of HRQoL in any given population as well as the use of 
HRQoL as an outcome measure within therapeutic RCTs often requires both generic 
and disease specific instruments. However, the inclusion of multiple HRQoL 
instruments in one survey can result in lengthy questionnaires with often poor 
response rates. [67] Similarly, postal surveys have been associated with poorer 
response rates than telephone or personal interviews. [68; 69] In spite of this, postal 
surveys are often the only feasible method for collecting follow-up clinical and 
economic data in RCTs. Using any other survey methodology (e. g. personal or 
telephone interviews) within RCTs may be inefficient since it would require substantial 
human and financial resources. Furthermore, it has been argued that the quality of 
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responses to postal surveys could be enhanced by ensuring the face validity 
(readability) of HRQoL instruments. [67] 
During the implementation of the VenUS I trial a small pilot study was conducted to 
verify the readability of a HRQoL booklet to be used as a data collection tool. The 
booklet initially contained the VLU specific Hyland questionnaire, two generic 
instruments (EQ-5D and SF-12) and the McGill pain questionnaire. [70-72] The SF-12 
and the EQ-5D are both well known generic HRQoL instruments that allow the 
investigation of HRQoL from a clinical and economic perspective, respectively. Over 
a period of 2 consecutive days, one of the VenUS I Research Nurses asked all her 
scheduled VLU patients to complete these four HRQoL instruments. 
Eight consecutive individuals (mean age 74 years) with VLU agreed to participate. As 
an observer during these consultations I made written comments about the 
interviewees' individual reactions and their comments about the booklet. All the 
participants stated that they found the survey took longer than they initially expected. 
In addition, it was noted that the layout of the SF-12 was confusing. Three of the eight 
interviewees missed or only partially responded to questions with a "steam and leaf' 
format in the SF-12. This suggested the readability of specific items within a 
questionnaire could differ according to variations in the question layout and the 
specific characteristics of the population of interest. 
Based on the results from the eight initial interviews, it was considered that potential 
future respondents may find it difficult to complete this long and complex 
questionnaire. As a result, the McGill pain questionnaire was removed from the 
booklet and the original layout of the SF-12 modified by the candidate into twelve 
single closed questions; see paper 2 in Appendix A. This new booklet was re-tested 
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in the three older participants who had had difficulties with the previous one and 8 new 
participants. The quality of the responses to this second version of the HRQoL 
booklet improved. The three participants who previously failed to provide adequate 
responses now provided complete responses to the second version of the booklet. 
This small pilot study suggested a shortened questionnaire with a simplified layout 
might be more acceptable to participants in the VenUS I study. It was important, 
however, to investigate these findings in larger studies as it was not possible to test, 
statistically, the reliability of the new measure or its expected overall completion rates 
on such a small sample. Large RCTs in populations similar in age to that of the 
participants in the VenUS I trial were necessary to formally investigate both: i) the 
reliability of this alternative-form (layout) of the SF-12, its overall response rates and 
quality of responses; and ii) whether longer questionnaires did adversely affect 
response rates in older participants. 
To optimise the collection and measurement of HRQoL data from individuals with 
VLUs in postal surveys conducted as part of RCTs, the following research questions 
were tested: 
a) Does the length of a questionnaire affect the rates of overall and partial 
responses to health related surveys? [73] (see paper 1 in Appendix A) 
b) Does a simpler layout for the SF-12 have a positive impact on the overall and 
partial responses to this instrument? [74] (see paper 2 in Appendix A) 
c) Is the Hyland a reliable and valid instrument to measure VLU specific 
HRQoL? [75] (see paper 3 in Appendix A) 
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d) What are the properties of the Hyland, SF-12 and EQ-5D in measuring HRQoL 
in individuals with VLUs? [75] (see paper 3 in Appendix A) 
e) What is the impact of VLUs on HRQoL from both a clinical and an economic 
perspective in a UK population? [75] (see paper 3 in Appendix A) 
2.2 Methods 
The first two hypotheses were tested in opportunistic (piggy backed) studies in 
populations similar in age to that of the participants in the VenUS I trial (women aged 
70 and over) conducted during the recruitment stage of a large RCT of Hip Protectors 
for the prevention of fractures. [76] 
2.2.1 Opportunistic Study I (paper 1 in Appendix A) 
A quasi-randomised trial was conducted in women age 70 years and over recruited 
from a general practice (GP) in North Yorkshire, England, to investigate whether the 
inclusion of multiple HRQoL instruments, on top of a clinical questionnaire of 
osteoporotic risk factors, was detrimental to the overall response rates of postal 
surveys within RCTs. 
Four different survey booklets were compared. The first contained the clinical 
questionnaire; the second the EQ-5D and clinical questionnaire; the third contained 
the clinical questionnaire, EQ-5D and SF-12; and the fourth booklet was the same as 
third but the SF-12 had the alternative layout described in Section 2.1. A table 
describing the way in which the "steam and leaf' questions in the SF-12 were modified 
is provided in paper 2 in Appendix A. [74] 
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A total of 856 questionnaires were sent to a GP in Yorkshire where staff labelled and 
posted the questionnaires to women potentially eligible to participate in the Hip 
Protector Study. [76] Alternation was used to produce equivalent groups since there is 
evidence that, if strictly adhered to, alternation is as effective in preventing selection 
bias as random allocation. [77] In this instance we can be assured that alternation was 
adhered to, as the opaque envelopes were delivered to the practice staff and they had 
no knowledge that the survey was also testing questionnaire length. 
2.2.2 Opportunistic Study // (paper 2 in Appendix A) 
The second quasi-randomised trial investigated whether the two different layouts of 
the SF-12 had a differential effect on overall response rates in a large sample. One 
thousand five hundred questionnaires were mailed out; 750 questionnaires with the 
original layout of the SF-12 and the EQ-5D; and 750 with the EQ-5D and an 
alternative layout of the SF-12. Alternation was used again to produce equivalent 
groups. Sealed envelopes were sent to the participating UK GPs, where they were 
labelled and posted. 
2.2.3 VenUS / HRQoL data (paper 3 in Appendix A) 
Formal investigation of the third and fourth aims required data from a population with 
VLUs. Data from VenUS I were used to investigate the validity of the Hyland 
questionnaire and the discriminative and responsive characteristics of the EQ-5D, 
SF-12 and Hyland HRQoL instruments (see Section 3.1 for further details of the 
VenUS I study). 
21 
Section ll: Measuring the impact of VLU on HRQoL 
2.3 Results 
The results from the first pilot study suggested that shorter postal surveys are more 
likely to have higher overall response rates. Increasing the length of a questionnaire 
from five to seven pages reduced overall response rates from 49% to 40% (an 
absolute difference of 9%, 95% Cl 0.3% to 16.6%) in a population of women aged 70 
years and over. The findings from the second pilot study indicated that while similar 
overall response rates were associated with the two layouts of the SF-12 
questionnaire, partial responses were statistically significantly reduced with the 
simplified layout of the SF-12. 
Baseline HRQoL data from the 387 participants in the VenUS I study suggested a 
two-factor solution for the third section of the Hyland. Factor one related to practical 
limitations, and factor two to emotional perceptions. Both factors were negatively 
affected among individuals. At baseline, detriments in the practical and emotional 
components of 47% and 36% were observed. 
No statistically significant differences in Hyland (practical and emotional), EQ-5D and 
SF-12 (physical and mental) scores between bandage groups were observed, hence 
the evaluative and responsive characteristics of these instruments were investigated 
combining the data from both groups. The Hyland questionnaire was associated with 
small and moderate ability to discriminate individuals according to age, mobility, initial 
ulcer size and ulcer duration. 
The SF-12 and EQ-5D had good evaluative properties; both instruments were 
sensitive to changes in HRQoL after ulcer healing at 3 months. During the one-year 
follow-up, improved HRQoL was reported quarterly by individuals whose VLU had 
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healed in the EQ-5D and SF-12. The difference in quarterly EQ-5D scores between 
healed and unhealed individuals was statistically significant in all four quarterly 
measurements. The conclusion of an episode of VLU was associated with an 
improvement relative to baseline scores on the mental component on the SF-12 and 
stabilisation of the physical component. EQ-5D scores suggested a statistically 
significant improvement in HRQoL associated with healing relative to active ulceration. 
High levels of bodily pain were reported in the SF-12 questionnaire, whilst only minor 
ulcer related discomfort was reported in the Hyland. 
2.4 Conclusions 
The importance of ensuring a thorough consideration of patient data collection 
instruments to be used in postal surveys within RCTs was confirmed by the results of 
the two opportunistic studies described here. The first study provided evidence that 
lengthy questionnaires and those with poor readability (face validity) are likely to have 
poorer overall response rates and a higher proportion of partial responses (missing 
items). A systematic review of best practice to design and use patient and staff 
questionnaires in health services research acknowledged a paucity of evidence on the 
impact of questionnaire appearance and design on response rates. [67] Out of 11 
identified studies on the effect of questionnaire length only two were on health-related 
topics. [78; 79] Evidence of a negative relationship between length of questionnaire 
and response rates was provided by these studies albeit non-statistically significant. 
The second opportunistic study indicated that readability can play an important role in 
maximising the quality of responses to postal surveys. In an elderly population, we 
found that shorter questionnaires with single questions may be more appropriate than 
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lengthy ones with complex question structures. To the best of my knowledge this is 
the first study looking at alternative layouts for the SF-12, and until further research is 
conducted to investigate whether this is an age related issue, we would recommend 
the use of a simpler layout for the SF-12 in postal surveys. 
The marginal contribution of the 34-item Hyland questionnaire to improve the 
understanding and measurement of the impact of VLUs on HRQoL is equivocal. 
Whilst one single VLU pain specific question from the Hyland provided valuable 
evidence to suggest that VLU related pain may be considerably lower than that 
suggested in previous studies, [50; 51] its inclusion almost tripled the overall length of 
the HRQoL booklet used in VenUS I. Furthermore, in the context of the pilot study 
described in Section 2.1, participants raised concerns regarding the appropriateness, 
subsequent to the closure of their VLU, of a large proportion of VLU specific items in 
Hyland, i. e. they questioned the responsiveness of this instrument to VLU healing. 
Hence, the research team decided to administer Hyland only to people with VLUs. 
Whist over time only minor VLU specific pain was reported in the Hyland, high levels 
of bodily pain were reported in the SF-12 by both healed and unhealed individuals. 
This may be partially explained by the fact that VLUs are more frequent among the 
elderly who are likely to have comorbidities. Reported bodily pain may be a 
consequence of these concomitant chronic health conditions. This issue needs to be 
further investigated in future RCTs in VLUs. 
Whilst no statistically significant differences in HRQoL scores between bandage 
groups were observed, quarterly HRQoL scores from the EQ-5D and SF-12 provided 
indirect evidence of improved HRQoL associated with compression systems 
associated with a faster rate of healing. Statistically significant differences in EQ-5D 
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scores between healed individuals and people with unhealed ulcers were observed, 
suggesting that treatments associated with a shorter time to VLU healing will also be 
associated with improved HRQoL. A resolution of VLU was associated with 
improvements in the mental component of the SF-12 and EQ-5D. 
In conclusion, simple and brief generic HRQoL instruments, SF-12 and EQ-5D, 
provide a comprehensive description of the impact of active ulceration in HRQoL from 
a clinical and economic perspective. Until the responsiveness to healing of the 
Hyland questionnaire is established, the use of this instrument in future RCTs in VLUs 
is not recommended. Furthermore, preference-based measurements from the EQ-5D 
allowed exploration not only of the cost-effectiveness of the two compression systems 
compared in VenUS I relative to each other (see Section 3), but potentially with an 
ample spectrum of healthcare treatments (see Section 5.2). 
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Section III. 
3 Trial-based evaluation 
3.1 Background 
In 1997 the UK NHS HTA programme commissioned the VenUS I Leg Ulcer study, 
the largest multi-centre pragmatic RCT in the area of VLUs to date. This study 
compared two high compression systems in the treatment of VLU in terms of clinical 
and cost-effectiveness, a comparison identified as a research priority in an earlier 
systematic review. [16] 
The VenUS I trial compared the 4-layer bandage, regarded by many in the UK as the 
gold standard compression therapy for VLU, and the short-stretch bandage, a 
compression therapy frequently used in the European continent and Australia. [80] 
While both compression systems apply a high degree of compression to the leg 
(40mmHg), considerable differences are associated with their required frequency of 
administration and purchasing cost. In terms of usage and cost, the short-stretch is a 
reusable bandage claimed to be able to remain in place for a week with a unit cost of 
£5; [41 ] whereas the 4-layer bandage can be used only once, can remain in place for 
one week and has a unit cost of £8. [41] Differences in the unit cost and wearability of 
these compression systems suggested that potentially substantial savings in bandage 
expenditure could be achieved, if the short-stretch bandage were shown to be of 
equivalent or greater effectiveness than the 4-layer bandage. 
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The main objectives of the VenUS I study were to: 
a) investigate the clinical effectiveness of the short-stretch bandage compared 
with 4-layer bandage in the treatment of VLUs in the UK. [81 ] (see paper 4 in 
Appendix A) 
b) determine the cost-effectiveness of short-stretch relative to 4-layer in the 
treatment of VLUs in UK practice. [82] (see paper 5 in Appendix A) 
c) explore the impact of VLUs on HRQoL from both a clinical and an economic 
perspective in a UK population. [75] (see paper 3 in Appendix A) 
This section will focus on objectives I and II. The third objective was discussed in 
Section II. 
3.2 Methods 
The VenUS I study was conceived and conducted within an academic institution 
according to rigorous methodological standards. [83] Individuals with a VLU of at 
least: 1 week duration and 1 cm in length or width, were eligible for inclusion. Length 
of follow-up was one year. Central telephone randomisation was used to ensure 
unbiased allocation of participants to trial treatments. Participants were stratified 
according to ulcer area (smaller or greater than 5 cm2); current ulcer duration (shorter 
or longer than 6 months); and centre, initially four (Cumbria, Leeds, West London, 
North Yorkshire) with other centres (Falkirk, Calderdale, East London, Newmarket, 
Southport) recruited later. 
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The primary outcome for the clinical analysis was time to healing of all VLUs on the 
trial leg. Median time to ulcer healing in both bandage groups was calculated using 
Kaplan Meier estimates of the cumulative probability of healing. [84] The log-rank test 
was used the investigate differences between bandage groups in the Kaplan Meier 
curves for time to healing and time to ulcer recurrence. [85; 86] The hazard of healing 
was adjusted by baseline covariates in a Cox proportional hazards model, where 
interactions between the treatment effect and baseline covariates were also 
investigated. [87] 
Two economic evaluations were conducted from the perspective of the UK NHS and 
Personal Social Services. Ulcer free days (Kaplan Meier estimates of mean time to 
ulcer healing) and QALYs, were the measures of health benefit in a CEA and a CUA, 
respectively. Quarterly utility scores reported on EQ-5D were used to compute 
QALYs as the area under the curve defined by these values. QALYs were adjusted 
by imbalances between bandage groups in the EQ-5D scores at baseline using linear 
multiple regression. [88] 
Total volume of four categories of resource use (nurse visits, doctor visits, hospital 
visits and bandages used) was collected prospectively from all the participants in the 
VenUS I study to estimate total treatment costs. To account for the censored nature 
of cost and HRQoL data, the Lin method was used to estimate the mean total 
treatment cost per bandage group and QALYs. [89] 
Non-parametric bootstrapping was used to estimate 95% confidence intervals for the 
mean differences in ulcer free days, QALYs and costs between bandage groups. The 
scenario approach to sensitivity analysis was implemented to explore the robustness 
of the results to variations in both: i) monthly utilisation rate of short-stretch bandages; 
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and ii) method of acquisition 4-layer bandage (as a kit rather than as single items). 
The decision uncertainty associated with the relative cost-effectiveness of 
short-stretch compared with 4-layer bandage was explored in both an incremental 
cost-effectiveness plane and a cost-effectiveness acceptability curve (CEAC). [90-93] 
3.3 Results 
Three hundred and eighty seven people from 9 centres in the UK were recruited into 
the VenUS I study. 192 were allocated to the 4-layer and 192 to the short-stretch. 
Individuals in both bandage groups were similar with respect to patient characteristics 
(age, height, weight), ulcer characteristics (area, duration, episodes, among others) 
and stratification variables (area, duration, centre). 
Clinical, economic and HRQoL measures of effectiveness indicated that relative to 
short-stretch, the 4-layer was associated with a higher instantaneous probability (i. e. 
risk) of healing, shorter time to healing, smaller treatment cost and slightly better 
HRQoL. 
3.3.1 Clinical Analysis 
The full clinical analysis of the VenUS I study is reported in paper 4 in Appendix A. 
The clinical unadjusted analysis found a non-statistically significant difference in 
Kaplan Meier median times to healing between bandage groups; 92 days (4-layer 
group) versus 126 (short-stretch group). However, when the hazard of healing was 
adjusted by prognostic factors in a Cox regression model, the short-stretch was 
associated with a statistically significantly lower probability of healing than 4-layer 
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bandage (hazard ratio 072,95% CI 0.57 to 0.91). The same model suggested a 
statistically significant interaction between bandage treatment and centre. The most 
heterogeneous results were associated with data from the smaller participating 
centres. In an analysis considering only data from the (larger) initial four centres 
participating in the VenUS I study, heterogeneity in the treatment effect by centre was 
no longer observed, i. e. the coefficient of the treatment centre interaction was no 
longer statistically significant. 
Kaplan Meier cumulative probabilities of recurrence were 0.36 and 0.39 in the 4-layer 
and short-stretch groups, respectively. A log-rank test of the Kaplan Meier curves of 
time to ulcer recurrence in both groups indicated no statistically significant differences 
between these curves. 
3.3.2 Economic Evaluations 
The two economic evaluation analyses are reported in full in paper 5 in Appendix A. 
Patients in the 4-layer group healed on average 10.9 days before those in the 
short-stretch group (95% Cl: -6.76 days to 29.06 days). Difference in mean QALYs 
between compression systems was -0.02 (95% Cl- -0.08 to 0.04). The 4-layer 
bandage cost on average £227.30 less per patient per year than the short-stretch 
bandage (95% Cl: £16.53 to £448.30). 
These results were robust to feasible variations in the monthly utilisation rate of 
short-stretch and the unit cost of the 4-layer. The CEAC suggested that considerable 
uncertainty was associated with the decision to consider short-stretch as a cost 
effective intervention relative to 4-layer for a large range of X-values [£O to £30,000], 
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i. e. willingness to pay values for an extra ulcer free day. Short-stretch was associated 
with approximately a 20% probability of being cost-effective. 
3.4 Conclusion 
This trial suggested that, in the UK, the 4-layer bandage is more likely to be clinically 
and cost-effective than the short-stretch bandage as the first line treatment for VLU. 
The economic evaluations in VenUS I indicated that despite initial expectations of cost 
savings associated with the short-stretch bandage, the 4-layer bandage was a 
"dominant" alternative, i. e. 4-layer was associated with greater health benefits and 
lower overall treatment costs. Initial expectations were based on the differential in unit 
cost between the short-stretch and the 4-layer bandages and the ability of the former 
to be re-used. The main cost driver in the treatment of VLUs, however, is nursing 
time. Hence, "potential savings" are unlikely to translate into real ones, unless 
reductions in nursing time are generated. 
In spite of claims from the manufacturers regarding the ability of short-stretch to 
remain in place for a week, the trial reported a higher frequency of nurse visits for 
patients in this group. Bandage slippage and poor rates of bandage reuse reported in 
the short-stretch group may account for this. In addition, VLUs are more frequent 
among elderly populations. The mean age of the participants in the VenUS I study 
was 71.6 (SD 13.21), and older participants reported having experienced difficulties 
washing their short-stretch bandages. 
Evidence of the ability of the short-stretch bandage to remain in place for a week has 
been provided by research conducted in Austria and the Netherlands, where the 
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short-stretch bandage is considered the standard for treatment of VLUs. [19] This 
suggests that nurses' competence in bandage application might have an influential 
role in the effectiveness of external compression systems. While more research may 
be recommended in this area, it is important to note that, in the UK, VLU care is 
provided in both at dedicated clinics and hospitals, as well as within the community, 
where patients are usually looked after by a pool of nurses rather than a single nurse. 
These intrinsic characteristics of the VLU service in the UK render unfeasible a 
rigorous evaluation of "competence in bandage application". Nonetheless, proxy 
measures of nurses' competence in bandage application, such as total number of 
patients previously treated by a nurse using a specific bandage, may be used in future 
analyses where random effects multilevel models can be used to explore these 
variations in nurse's performance. [94] 
Evidence of a potential interaction between bandage treatment and centre was 
identified in a Cox proportional hazards model. Future therapeutic RCTs in VLUs 
should acknowledge a potential for heterogeneity in the treatment effect associated 
with factors such as nurses' competence with bandage treatment; nurses' prior beliefs 
about the effects of different treatments; the degree of variation in nurses' wound care 
experience, and patients' concordance with bandage treatment. 
The VenUS I study provides evidence of the feasibility of conducting rigorous clinical 
and economic evaluations of therapeutic treatments for VLU. This high quality 
evidence can, in turn, be used to inform the evaluation of other health technologies 
using decision analytic modelling as discussed in Section IV. 
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Section IV. 
4 Research prioritisation in VLU 
4.1 Background 
Data from well conducted RCTs is considered the "gold standard" scientific evidence 
that should be used to inform treatment decisions in healthcare practice. However, in 
view of the large number of available alternative treatments indicated for VLU (Tablet) 
it would be both unreasonable and inefficient to defer the evaluation of the relative 
clinical and cost-effectiveness of these technologies until sound RCT evidence is 
available. [95] The scarcity of research and development (R&D) resources, requires 
decision makers to counter their need for further information by substantiating their 
decision on existing information, and thus to free resources which can be allocated to 
other areas of priority (i. e. take into consideration the opportunity cost of using R&D 
resources in any specific area and not another). [96] 
A framework based on comprehensive decision analytic modelling, Bayesian methods 
for evidence synthesis, and Bayesian value of perfect information (VOI) analysis has 
recently been proposed for the evaluation of healthcare technologies. [97] This 
framework aims to inform two key stages in the process of deciding whether to 
recommend the adoption of a health technology: i) whether a health technology 
should be considered clinically and cost-effective given the existing evidence base; 
and ii) whether a request for further information should be made given the level of 
decision uncertainty associated with the current evidence base. 
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The main objectives of the research described here were to investigate the potential of 
this analytic framework to: 
a) assist the formal evaluation of the clinical and cost-effectiveness of alternative 
treatments for VLU based on existing information; [98] (paper 6 in Appendix A) 
b) guide the process of prioritisation of the research agenda in VLUs identifying 
those areas where primary research is more likely to reduce the decision 
uncertainty associated with the cost-effectiveness of competing treatments. [98] 
(paper 6 in Appendix A) 
4.2 Methods 
A pharmacological adjunct therapy to external compression was used as a case 
study. Pentoxifylline, a drug that helps blood flow, has been proposed as a potential 
agent to accelerate the healing process of VLUs. [99] A systematic review of RCTs of 
pentoxifylline for the treatment of VLUs identified evidence of an additional beneficial 
effect to external compression, and a potential beneficial effect in the absence of 
compression, associated with pentoxifylline. [40] The poor methodological standards 
of RCTs on pentoxifylline, however, raised concerns regarding the validity of the 
findings from this review. Indeed, a number of relatively small RCTs on pentoxifylline 
have recently been conducted. [100; 101] 
The purpose of this work is to investigate whether the decision uncertainty associated 
with the clinical and cost-effectiveness of pentoxifylline prior to commissioning the 
largest confirmatory trial was likely to justify the expected cost of primary research. A 
comprehensive Bayesian decision model[102] was constructed to investigate the 
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cost-effectiveness of pentoxifylline as an adjunct to compression. The analysis was 
conducted at two different points in time: i) prior to the publication of the findings from 
the largest RCT on pentoxifylline in the presence of external compression (prior 
analysis) and ii) following the publication of the results from this study (posterior 
analysis). 
Potential heterogeneity between RCTs was accounted for in the model using a 
Bayesian random baseline meta-analysis[103] implemented in the freely available 
specialist software WinBugs. [104] The model was populated using information from 
both previously published data [26; 105-107] and data from the VenUS I trial. [80] 
Preference-based utility weights reported by participants in the VenUS I study with 
and without VLUs were used to estimate expected QALYs. [75] 
A non-parametric method was used to estimate the expected VOI[108] associated 
with the decision to recommend pentoxifylline as a cost effective adjunct to 
compression for a large range of willingness to pay values for an extra QALY [£O - 
£5000]. 
4.3 Results 
The prior and posterior analyses suggested pentoxifylline was a dominant therapy, 
that is, relative to placebo, pentoxifylline was associated with greater health benefits 
and was less costly. In the prior analysis, patients in the pentoxifylline group on 
average healed 8.28 weeks (95% credibility interval (Crl) 1.89 to 14.56) earlier than 
patients in the placebo group. Similarly, an average 0.02 gain in QALYs (95% Crl 
-0.12 to 0.17), and an average reduction of 
£153.4 (95% Crl -£53.11 to £354.9) in 
overall cost was observed in the pentoxifylline group relative to the placebo group. 
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Estimates of the uncertainty surrounding the cost-effectiveness of pentoxifylline and 
the VOI in both the prior and posterior analyses suggested that further primary 
research on the cost-effectiveness of pentoxifylline was unlikely to be cost-effective. 
In the prior analysis, the estimated VOI for willingness-to-pay values of £0, £100, and 
£500 per QALY were £128,200, £127,100 and £126,700, respectively. Comparing 
these values with the cost of the largest compression study in VLUs (the VenUS I 
trial), approximately £380,000[109], suggests that at the time when the Dale trial was 
funded the cost of primary research was higher than the maximum expected benefit, 
i. e. the reduction in the decision uncertainty associated with the acquisition of 
additional evidence. 
Incorporation of the information from the largest RCT on pentoxifylline did improve the 
precision of the estimate of the clinical effect associated with this drug; however this 
improvement was not large enough to reverse either the decision regarding the 
dominance of pentoxifylline or the maximum value associated with further research. 
4.4 Conclusions 
This analysis indicated that the cost of conducting further primary research on the 
effectiveness of pentoxifylline as an adjunct to compression in the treatment of VLUs 
is unlikely to be offset by the expected reduction in the decision uncertainty on the 
cost-effectiveness of this drug associated with the acquisition of additional evidence. 
Indeed, the evidence base considered in this analysis suggested pentoxifylline is 
associated with at least a 90% probability of being cost-effective for a range of values 
[: CO - £500] decision makers may be willing 
to pay for an additional QALY. 
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This case study illustrates the huge potential of comprehensive decision analysis, 
Bayesian evidence synthesis methods and Bayesian VOI analysis as a framework to 
evaluate medical devices for the treatment of VLUs, and as a tool to inform the 
research prioritisation process in this area. Had the results from this analysis been 
available before the largest RCT on pentoxifylline was funded, a more efficient 
allocation of research and development resources could have been made. To 
promote a more efficient allocation of scarce R&D resources in both the public and 
private sectors, future recommendations for primary research in the area of VLUs 
should be carefully evaluated, explicitly accounting for the cost opportunity of investing 
in an area and not another. 
Finally, recently proposed quantitative methods to synthesise evidence[110; 111 ], not 
only from studies with the same design but from a range of study types to explore the 
clinical and cost-effectiveness of all the relevant alternatives for the treatment of a 
health condition, should be explored in the area of VLUs. [112-114] 
37 
Section V: Concluding remarks and overall recommendations 
Section V. 
5 Concluding remarks and overall 
recommendations 
5.1 Contributions to knowledge 
This thesis has explored a number of relevant issues in the assessment of therapeutic 
treatments for VLUs. 
5.1.1 Optimisation of data collection 
The optimisation of clinical and economic primary data collection using postal surveys 
conducted within RCTs was explored in two opportunistic studies (papers 1 and 2 in 
Appendix A). The first analysis suggested that lengthy surveys and those with 
complex layouts may prove unnecessarily challenging. [73] As a result an alternative 
layout for the widely used generic HRQoL questionnaire SF-12 was proposed and 
found to be more suitable for the populations studied and potentially others too. [74] 
To the best of my knowledge this is the first analysis proposing an alternative layout 
for the SF-12 questionnaire. Whilst there is no consensus about the effect of 
questionnaire length on response rates, a recently conducted systematic review and 
meta-analysis of RCTs evaluating the effect of questionnaire length on response rates 
coincides with our findings that in the context of postal surveys within RCTs shorter 
questionnaires should be preferred. [1 15] 
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The applicability of the findings from our two opportunistic studies to other age groups 
could not be investigated. Such analysis would require a large survey conducted in a 
sample representative of the whole of the UK adult population. The two surveys 
discussed here, however, were piggy-backed studies conducted in the recruitment 
stages of a large RCT of hip protectors. [76] Nonetheless, in a recently published 
large population survey using the SF-12 in its standard layout, age was a significant 
predictor of missing items. [116] This suggests that the findings from our two 
opportunistic studies may be relevant to the sector of the population in which poor 
data collection is more likely to be observed. 
Our findings have not only informed the design of two new large RCTs in the area of 
VLUs recently funded by the UK NHS HTA, the Larval Therapy Study (VenUs II)[117], 
and the Ultrasound Study (VenUS III) [118], but also the simplified layout of the SF-12 
is now used in preference to the original layout in all trials within the York Trials Unit. 
5.1.2 Measurement of HRQoL in people with VLUs 
A validation analysis of the only VLU specific HRQoL questionnaire available to date 
(Hyland) indicated that the contribution of this instrument to improve understanding of 
the impact on HRQoL associated with the presence of an open VLU is marginal. We 
found the SF-12 and EQ-5D to be associated with good responsiveness to VLU 
healing, thus suggesting that generic instruments may be more suitable to measure 
changes in HRQoL associated with the presence / absence of a VLU. 
In the area of VLUs, the VenUS I study was the first one in which preference-based 
HRQoL measurements were used to estimate health benefit in an economic analysis. 
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During its conduct, a number of studies measuring the impact of open VLUs on 
HRQoL were published, see Table 2. [23-25] 
Author Area Instruments Population 
Walters 
1999[23] 
Wissing 
2001 [24] 
Franks 
2001 [25] 
UK Medical outcomes study 
short form 36 (MOS SF- 
36); 
Euroqol (EQ-5D); 
Short form McGill pain 
questionnaire (SF- 
MPQ); 
Frenchay activity index 
(FAI) 
Sweden Philadelphia geriatric 
centre multilevel 
assessment instrument 
UK Nottingham health 
profile (NHP) 
Conclusion 
233 people The 4 instruments had small to 
with venous moderate discriminative abilities. The 
leg ulcers SF-MPQ had the best 
responsiveness to healing at 3 
months and the SF-36 and EQ-5D 
were only able to detect changes in 
healing status after 12 months 
144 people VLUs were associated with 
with and significantly lower mean score for 
without leg physical health, activities of daily 
ulcers living, cognition, time use / social 
behaviour, personal judgement and 
environmental quality 
383 people NHP had a good internal consistency, 
with venous small to moderate ability to 
leg ulcers discriminate individuals according to 
age, mobility, initial ulcer size and 
ulcer duration. Unlike the SF-36 the 
NHP was sensitive (bodily pain 
dimension) to changes in healing 
status at 3 months 
Table 2. Evidence on VLUs HRQoL post VenUS I 
Two core discrepancies between these studies and the HRQoL analysis from VenUS I 
are distinguished. Firstly, the identification of the high levels of chronic pain reported 
by people with VLUs as primarily ulcer related pain in the studies published before 
VenUS I. Secondly, sole consideration in these studies of open VLUs as the main / 
only health condition negatively affecting HRQoL, thus ignoring the role of 
concomitant chronic health conditions. Conversely, our findings coincide with those 
from a study of HRQoL in people with varicose veins, a disorder encompassed in the 
venous insufficiency syndrome. Using a recently proposed disease specific 
instrument for venous disease, (the VEINES-QoL scale) Lamping et al concluded that 
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the HRQoL of individuals with varicose veins can only be reliably interpreted when 
concomitant venous disease is taken into account. [119] It is worth noting that the 
VEINES-QoL increases the number of disease specific instruments potentially suitable 
for VLUs to four, see Section 1.5.2. 
VLUs are a manifestation of chronic venous insufficiency, a syndrome encompassing 
a spectrum of disorders ranging from varicose veins through to extensive ulceration of 
the leg. Future studies aiming to describe and / or measure the impact on HRQoL 
associated with VLUs should acknowledge this by distinguishing the dimensions of 
HRQoL affected by an open ulcer, detriments in HRQoL associated with venous 
insufficiency and those mainly related with other chronic concomitant health 
conditions. 
Recent methodological developments in the estimation of preference-based measures 
from generic psychometric instruments have produced a model to estimate 
preference-based scores from the SF-12. [120] The level of agreement / disagreement 
between the preference-based scores derived from the EQ-5D and SF-12 in the 
VenUS I study should be investigated in a future study. 
5.1.3 Clinical and cost-effectiveness of high compression for 
VL Us 
The VenUS I study provided evidence of the "dominance" of the 4-layer bandage 
relative to the short-stretch bandage. On average 4-layer was associated with a 
shorter time to healing of VLUs, marginally better HRQoL and less overall treatment 
costs. Evidence of a differential bandage treatment effect by centre was identified in 
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the analysis of the clinical data from the VenUS I study. Formal investigation of this 
result using random effect multilevel models for survival data, i. e. frailty models [121 ], 
was prevented by the unavailability of data regarding factors such as nurses' 
competence in bandaging, prior beliefs, and preferences about different systems of 
external high compression. This limitation associated with the VenUS I study could be 
addressed at the design stage of future RCTs in VLUs. 
To date, in addition to the economic evaluations in VenUS I, the clinical and 
cost-effectiveness of external compression in the treatment of VLUs has been 
investigated in six partial[17; 18; 22; 122-124] and one full economic evaluation. [125] 
The cost-effectiveness of the 4-layer system was investigated in six of these studies 
the findings of which coincide with those from the VenUS I study, in that, on average 
4-layer compression systems are associated with a higher proportion of patients 
healed and a reduction in the number of nurse visits required for VLU treatment. 
In 1998, when the VenUS I study began, HRQoL had not been used as an outcome 
measure within therapeutic RCTs in VLUs. The advantages of using composite health 
outcomes that incorporate a quality of life adjustment in the evaluation of healthcare 
technologies have been well documented. [10] The use of quality-adjusted outcomes 
(e. g. QALYs), for instance, allows the direct comparison of health technologies 
indicated for different health conditions, thus enabling the comparison in terms of cost 
per QALY of, for example, the value for money of investing in cancer drugs with that of 
investing in anti-retroviral drugs. Future economic evaluation studies in VLUs should 
measure health benefit associated with the alternatives under comparison using such 
quality adjusted composite outcomes. This recommendation has already informed the 
design of the VenUS II and VenUS III studies in which QALYs have been chosen as 
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the primary outcome for the economic analyses to be conducted alongside these 
RCTs. [ 117; 118] 
5.1.4 Research prioritisation in VLUs 
The potential contribution of comprehensive decision analytic modelling, Bayesian 
evidence synthesis methods and Bayesian value of information analysis to the formal 
evaluation of therapeutic treatments for VLUs was tested in a case study. To the best 
of my knowledge this is the first application of these methods in the area of VLUs. 
These analytical tools, however, are increasingly being used to inform the decision 
making process at NICE. [126] This illustrates the ability of this framework to inform 
the decision making processes regarding both the relative cost-effectiveness of 
treatments given their existing evidence base and whether to commission further 
primary research to reduce the decision uncertainty associated with the adoption of 
treatments. 
Our analysis indicated that, given the current evidence base on pentoxifylline, there is 
a high probability that it is a cost-effective adjunct to high compression. 
Consequently, additional primary research on the cost-effectiveness of pentoxifylline 
is unlikely to be an efficient use of R&D resources. Pentoxifylline, while still officially 
unlicensed for this indication, should be considered as a valuable alternative for the 
treatment of those individuals whose VLU fails to heal with external compression. [40] 
However, the point at which an adjunct to external compression as pentoxifylline 
should be sought may be further investigated using decision analysis. 
This VOI analysis was implemented using RCT evidence only. In the last few years, 
however, powerful and versatile Bayesian statistical models for evidence synthesis 
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have been proposed in the literature to integrate coherently all the available evidence 
on the relative effectiveness of health technologies using data not only from RCTs but 
also from clinical studies with different designs, i. e. observational studies. [111; 112] 
This potential shortcoming associated with this analysis will be addressed in a future 
study in which multiple parameter evidence synthesis and networks of evidence will 
be used to synthesise all the existing evidence on pentoxifylline. [112] 
In summary, the work published as part of this thesis represents an important 
contribution to wound care research and to health services research in general. The 
contributions made are summarised in Table 3 and supported by evidence of the 
direct impact of this body of work on the research activities of our research team. 
Furthermore, our findings have informed and  or provided the basis for a number of 
successful research applications: i) NHS HTA funded VenUS II and VenUS III studies; 
ii) MRC Special Training Fellowship in Health Services Research and Health of the 
Public, in which I shall explore the use of Bayesian evidence synthesis methods for 
the regulation of therapeutic medical devices; iii) MRC funded Vacuum Assisted 
Compression (VAC) study, an analysis of the VOI associated with VAC in the 
treatment of pressure ulcers which includes a feasibility pilot study of a potential future 
RCT of VAC in the same patient population. 
Study Contribution to knowledge 
Questionnaire design Improvements to the layout of a widely used quality of life instrument, 
which will lead to more reliable data collection in future, both in wound 
care and non-wound care trials and surveys. 
HRQoL in venous leg The Hyland instrument is inappropriate to investigate treatment related 
ulceration effects within RCTs in VLUs. 
Compression bandaging Demonstrated the cost-effectiveness of the UK standard compression 
trial bandaging system compared with a widely used alternative. 
Value of information Showed that commissioning of future RCTs of pentoxifylline is unlikely to 
be an efficient use of research resources. 
Table 3. Summary of contributions to knowledge 
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5.2 Recommendations for future research 
A series of Cochrane systematic reviews in wound care management, of which VLUs 
are an aspect, highlighted both the poor methodological standards of existing clinical 
and economic evidence in this area and a need for high quality primary research in a 
number of elements of VLU care. [7-9] Research priorities identified include the need 
to: 
(i) investigate the differential effectiveness of therapeutic devices for VLUs 
(compression therapies, wound dressings, topical agents, pharmacological 
treatments, debriding agents, an other treatments) licensed for the same 
indication; 
(ii) assess the relative cost-effectiveness of alternative treatment strategies; 
(iii) explore the HRQoL consequences associated with alternative treatments for 
VLUs; 
(iv) improve methodological standards of primary research in VLUs according to 
international guidelines for the design, conduct and analysis of RCTs. 
In order to define what constitutes the efficient management of VLUs, a single 
comparative analysis of the clinical and cost-effectiveness of all existing external high 
compression systems is required. This analysis would require an evidence-based 
categorisation of all external high compression systems available. Currently, in 
addition to the level of compression delivered, a distinction is made between systems 
according to the number of layers of compression required (single, 2-layer, 3-layer, 
4-layer), the degree of elasticity (elastomeric, non-elastomeric)., and the method of 
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delivery (bandage, stockings, rigid cast, pneumatic). Evidence of the rationale for 
attributing differential effectiveness on the basis of these characteristics is needed. 
Recently, Bayesian statistical methods have been proposed as a suitable approach 
for CEA. [95] There are a number of reasons for this: i) decision analysis is intrinsically 
Bayesian; ii) probability statements relevant for decision-making "the probability that 
an intervention is clinically and / or cost-effective given the current level of evidence... " 
are only valid in a Bayesian framework; iii) Bayesian methods consent the analysis of 
newly acquired evidence in the light of previously existing data; iv) with the 
development of powerful numerical methods, i. e. Markov chain Monte Carlo 
simulations, previously unsolved analytical problems can be resolved within a 
Bayesian paradigm. [127] 
The potential contribution of these methods to the area of VLUs is considerable. For 
example, in the absence of head to head comparisons, Bayesian mixed treatment 
comparisons (of which indirect comparisons are a specific case), can be used to allow 
the synthesis of evidence from available studies in which the treatments of interest 
have been directly compared with some other treatments, in paired or multiple 
comparisons. [110] For instance, if the comparison between short-stretch bandage 
and 2-layer bandage is of interest, data on comparisons between 2-layer vs. 4-layer, 
short-stretch vs. 2-layer vs. 4-layer, and short stretch vs. 4-layer could be used to 
derive an estimate of the relative effectiveness of short stretch vs. 2-layer bandages. 
Similarly the relative clinical and cost-effectiveness of dressings, debriding agents, 
topical agents, pharmaceutical therapies and other treatments available for VLUs 
requires further investigation. In this case an evidence-based reclassification of 
available treatments will also be required. 
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Finally, there is a need to ascertain the contribution of concomitant diseases in the 
HRQoL of people with VLUs. This issue needs to be addressed in future studies in 
which the presence or development of concomitant chronic conditions is carefully 
documented. 
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Does length of questionnaire matter? A randomised 
trial of response rates to a mailed questionnaire 
Cynthia Iglesias, David Torgerson1 
Department of Health Studies and 'Centre for Health Economics, University of York, UK 
Objective: To assess whether length of questionnaire affects response rates. 
Methods: A quasi-randomised trial of women aged 70 years and over in a general practice in England. Three 
questionnaires of different lengths: a clinical questionnaire (four pages); the same questionnaire plus the EuroQol 
(five pages); the same questionnaire plus the SF-12 (seven pages). The impact of length on the proportion of 
returned questionnaires and item completion rates was assessed. 
Results In total, 847 questionnaires were mailed; response rates were 49%, 49% and 40% to the short, medium 
and long questionnaires, respectively. This difference was statistically significant when the short questionnaire was 
compared against the longest instrument (9% difference; 95% confidence interval (CI) of difference=0.3% to 
16.6%). Item completion rates for the clinical questionnaire did not differ. Respondents did not differ in age or 
self-reported health status between the three groups. 
Conclusions. Increasing the length of a questionnaire from five to seven pages reduces response rates from women 
aged 70 years and over. However, lengthening a questionnaire does not seem to affect the quality of responses to 
questions near the front of the questionnaire. 
Journal of Health Services Research & Policy Vol 5 No 4,2000: 219-221 © The Royal Society of Medicine Press Ltd 2000 
Introduction 
Many researchers are resistant to increasing the length 
of questionnaires because of the perception that they 
may lead to poorer response rates. This perception has 
been supported recently when a randomised trial 
comparing response rates to a clinical questionnaire 
plus the EuroQol with a clinical questionnaire plus the 
SF-36 showed a modest (5%) but statistically significant 
reduction in questionnaire response. ' Although it is 
commonly thought that questionnaire length influences 
response rates, there is limited evidence to support this 
view. A review of patient satisfaction surveys found 
response rates were unaffected by questionnaire length. 2 
Another review3 found only two trials of questionnaire 
length in the context of health care research, both of 
which found no effect of questionnaire length. 4 
However, non-British and non-health studies have 
found evidence supporting a negative relationship 
between questionnaire length and response rates. 6'7 
Given the importance of the topic, surprisingly few 
studies have explored the effect that length of ques- 
tionnaire has on response rate. 
Cynthia Iglesias MSc, Research Fellow, Department of Health Studies, 
David Torgerson PhD, Senior Research Fellow, Centre for Health 
Economics and Department of Health Studies, University of 
York, York 
YO10 5DD, UK 
Correspondence to: Cl. 
Researchers from different backgrounds, such as 
health economics and clinicians, often require different 
quality of life instruments. For example, economists like 
to have a measure of utility - such as the EuroQol - 
whereas other health services researchers may prefer 
instruments such as the SF-36. However, inclusion of a 
lot of instruments increases questionnaire length. 
Therefore, we would like to know whether inclusion of 
multiple quality of life instruments on top of a clinical 
questionnaire is detrimental to response rates. 
Methods 
In a questionnaire survey of osteoporotic risk factors 
among women aged 70 years or over in Yorkshire, 
women were asked about fracture risk factors and 
willingness to participate in a randomised trial of hip 
protectors. Women were encouraged to return the 
questionnaires, irrespective of whether they wanted to 
take part in the trial. General practitioners provided 
names and addresses of those patients who they thought 
could answer the questionnaires or who were not bed- or 
chair-bound. 
Four different versions of the questionnaire were 
designed. The first consisted of clinical questions 
relating to osteoporosis risk factors, the first question 
of the SF-12 and the patient's willingness to participate 
into the study (four A4 pages). The second included the 
EuroQol (without the visual analogue scale) in addition 
to the clinical questions (five A4 pages). The third 
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questionnaire comprised the clinical questions, the 
EuroQol and the original version of the SF-12. Finally, 
the fourth questionnaire was the same as the third but 
used the newest version of the SF-12 (seven A4 pages). 
To produce equivalent groups, women were random- 
ised by alternation, which, if strictly adhered to, results 
in comparable groups. 8 The questionnaires were put 
into an opaque brown envelope, were alternated, and 
given to a member of the practice staff to be addressed 
and mailed. All the patients received a package 
containing one of the questionnaires, an information 
letter describing the aim of the study, and a prepaid 
return envelope. No reminders were sent. Completed 
questionnaires were returned to the Centre for Health 
Economics. 
To detect a difference of 15% in response rate (50- 
65%) at 80% power (2FL-0.05) for a two-group 
comparison requires a total of approximately 366 
people (i. e. 183 in each group). Results were considered 
statistically significant with a Pvalue of 0.05 or less. Each 
patient received a questionnaire between February and 
April 1999. 
Results 
A total of 856 questionnaires were sent out: 278,278, 
150 and 150 of types 1,2,3 and 4, respectively. Initial 
sample size was reduced by nine patients who were 
ineligible for the trial (death, dementia, moved away 
from the study area). In the analysis a final sample size 
of 847 subjects was considered. 
The mean age for the study population was 77.7 years 
(standard deviation (SD)=6.8). As the two versions of 
the SF 12 had only trivial differences (i. e. change from 
vertical to horizontal format in one question and 
addition of two response categories for two questions), 
which did not affect its length, data on questionnaires 3 
and 4 were pooled. Therefore, the questionnaires were 
classified into three categories: short, medium and long. 
A comparison of the three groups with respect to age 
and general health status revealed no obvious differ- 
ences between the groups (Table 1). Similarly, a 
comparison between the medium and long question- 
naires in terms of EuroQol scores (0.87) showed no 
difference 
Table 2 shows that the longest questionnaire had a 
response rate about 9% lower than those of the shorter 
Does length of questionnaire matter? 
questionnaires. We found no significant relationship 
between length of questionnaire and the number of 
missing items in the clinical questionnaire (Table 3). A 
comparison between the medium and long question- 
naires in the number of completed EuroQol instru- 
ments showed a slight increase in fully completed 
EuroQols for the longer questionnaire: 89.6% 
(n=121/135) and 93.3% (n=111/129) for medium 
and long questionnaires, respectively (95% CI of 
difference: -10.5% to 3.19%). Finally, questionnaire 
length had no effect on the numbers of patients 
expressing a willingness to participate in the trial: 
7.2% (20/276), 9.0% (25/277) and 8.8% (26/294) for 
short, medium and long questionnaires, respectively. 
Discussion 
This is the first reported trial, within a UK population, 
which shows that increasing the length of a question- 
naire lowers the response. Our overall response rate was 
46%, comparatively smaller than in similar studies 
(62.1-79%). 4.5,10 We were unable to use reminders and 
this will partially explain our low response. Furthermore, 
an aim of our study was to recruit patients into a 
randomised trial, and those women who would have 
normally responded to a survey may not have responded 
if they did not wish to be included. 
Lengthening the questionnaire did not affect the 
number of missing clinical items. This might not have 
happened had the clinical items been placed at the 
back. Although the response rate to the long ques- 
tionnaire was somewhat lower than the medium ques- 
tionnaire, the completion rate for the EuroQol 
component was similar. Thus, if a respondent was 
prepared to return a long questionnaire she was likely 
to complete the EuroQol instrument in the middle of 
the questionnaire. This supports the findings of a 
similar study undertaken to evaluate various measures 
likely to increase response rates. " Of importance to 
health economists, is that lengthening a clinical ques- 
tionnaire by the trivial amount required to include the 
EuroQol has no discernible effect on response rates. 
Although our results suggest that a reduction in 
response rates is due to increased questionnaire length, 
they need to be placed in the context of our study 
population. Our results may only be applicable to older 
women. Furthermore, questionnaire length may not 
Table I Analysis of variation among different types of questionnaires with respect to age and health status 
Questionnaire type Age (years) Health status 
Mean (SD) Numbers Proportion of good, very Number' 
good or excellent (%) 
Short 77.9 (7.8) 122 33.7 133 
Medium 77.6 (6.5) 117 34.4 134 
Long 77.6 (6.1) 102 32.0 119 
Total 77.7 (6.8) 341 76.2 386 
t=0.24 
"Variations due to missing items. SD, standard deviation. 
Significance 0.691 X2=0.79 Significance 0.674 
II 
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Does length of questionnaire matter? 
Table 2 Interactions between retrieval rate and questionnaire length 
Response rates (%) 
Short Medium Long Overall 
Original research 
P value 95% Cl of 
differencea 
48.9 48.7 40.5 46 0.04 0.3 to 16.6 
(135/276) (135/277) (119/294) (389/847) 
4.1017 
Odds ratiob=1.19 CI=(1.005 to 1.401) 
Odds ratios=1.12 CI=(1.018 to 1.239) 
aComparison between the response rates to short and long questionnaires, 
bOdds ratio of long questionnaire compared with short questionnaire retrieval rates. 
°Odds ratio of long questionnaire versus short+medium questionnaire retrieval rates. 
Cl, confidence interval. 
Table 3 Partial non-response to clinical questions across question- 
naires: missing items to clinical questions 
Partial Type of questionnaire 
response 
Short Medium Long 
No 83 (61.5%) 83 (61.5%) 71 (59.7%) 
Yes 52(38.5%) 52(38.5%) 48 (40.3%) 
Total 135 135 119 
=0.11462 Significance=0.9443 
have a linear relationship with response rate: there 
could be a threshold effect in which response rates 
suddenly drop off. Given the paucity of research into the 
effect of questionnaire length on response rates more 
studies are required in a range of different populations. 
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Summary 
To assess whether changing the layout of the SF-12 
affected item response rates, we tested two SF-12 
formats in a quasi-randomized trial of women 
aged > 70 years in two general practices in North 
Yorkshire. The modified version of the SF-12 ('York 
SF-12') converted the 'stem and leaf format of 
some questions to individual items. We assessed 
the effect of the two types of questionnaires on 
item response rates. The difference in overall 
response rates to the two questionnaires (York 
SF-12 26.8%; SF-12 29.5%) was not statistically 
significant (95%Cl -1.88% to 7.22%). However, 
the modified SF-12 had a statistically signific- 
antly lower item non-response rate of 8.5%, 
compared with the 26.6% of the SF-12 (95%Cl 
11.1%-25.1%). Chronbach's alpha reliability 
scores for the York SF-12 were also slightly better 
than for the older version. The York version of 
the SF-12 is an improvement on the original 
questionnaire. We recommend that the York 
SF-12 be used in preference to the SF-12 when 
surveying an older population. 
Introduction 
The SF-36 is a widely used quality-of-life instru- 
ment. However, its length could affect response 
rates, particularly in older people. For instance, we 
previously found an 8% reduction in response rates 
in a population survey when a questionnaire was 
extended from 4 to 7 pages of A4,1 while Dorman 
and colleagues using a population from a random- 
ized trial noted a 5% reduction in response rates 
when the SF-36 was compared against the much 
shorter EuroQol questionnaire. 2 Because of possible 
problems with response rates and data entry burden 
a shortened version of. the SF-36 (the SF-123) is 
popular. Recently, both of these instruments have 
been amended. For instance, some questions that 
had a binary response have been replaced with a 
Likert response scale. In addition, the layout for 
some questions has been changed from a vertical 
format to a horizontal layout. 
We are using the latest version of the SF-12 in 
a number of ongoing randomized trials. However, 
the SF-12 (and the SF-36) has a confusing 'stem and 
leaf' layout of some of its items. Some questions are 
preceded with a general phrase such as 'How much 
during the last month: ', which is then followed 
by up to three specific questions (Figure 1). We 
noticed in a pilot study that this layout is confusing 
to older respondents. In the context of a pilot study 
for a large randomized control trial of patients with 
chronic leg ulcers, eleven elderly patients were asked 
to complete four different quality-of-life question- 
naires, presented in the following order, Euroqol, 
SF-12, pain, and ulcer-specific questionnaires. 
Even though patients were asked to respond the 
questionnaires on their own, they often asked for 
assistance with questions in the SF-12. They had 
difficulties working out the way they should 
respond to the 'stem and leaf' questions. When it 
was explained to patients that the researcher could 
not help, since this could bias their responses, 
patients tended to either miss items (questions) from 
Address correspondence to Ms C. P. Iglesias, Department of Health Studies, University of York, York YO 10 5DQ. 
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a 
b 
These questions are about how you feel and how things have been with you during the past 4 weeks. For 
each question, please give the one answer that comes closest to the way you have been feeling. How much 
of the time during the past 4 weeks... 
All of Most of Some of A little of None of 
the time the time the time the time the time 
d) have you felt calm and peaceful? QQQQQ 
e) did you have a lot of energy? QQQQQ 
f have you felt downhearted and low? QQQQQ 
1. How much during the last month have you felt calm and peaceful? 
(Please circle one number only) 
All of the time Most of the time Some of the time A little of the time None of the time 
12345 
2. How much during the last month did you have a lot of energy? 
(Please circle one number only) 
All of the time Most of the time Some of the time A little of the time None of the time 
12345 
3. How much during the last month have you felt downhearted and low? 
(Please circle one number only) 
AH of the time Most of the time Some of the time A little of the time None of the time 
12345 
Figure 1. Example of a the current 'stem and leaf' layout and b the alternative layout proposed for the SF-12. 
the questionnaire, tick the same item twice, or 
tick the descriptions of the response categories 
rather than the appropriate box (Iglesias, unpub- 
lished data). This results in loss of data and also 
leads to data entry problems. When a respondent 
ticks two categories, not only is it impossible to 
ascertain which is the true response, but when data- 
entry is through a scanner an error message is pro- 
duced, requiring the questionnaire to be manually 
checked, which increases the cost and complexity 
of data entry. Similarly, if the respondent ticks the 
description of the response category rather than the 
box, this again leads to problems with automated 
data entry. Because of these problems, we decided 
to amend the layout of the SF-12 without altering 
the existing questionnaire's length (2-sides of an A4 
page) and undertake a randomized comparison of 
our version on its response rates and validity. 
Methods 
We amended the SF-12 questionnaire by converting 
: dual items. 
This version was piloted among a small con- 
venience sample of patients at a leg ulcer clinic. 
After some slight revisions we decided to test the 
'York SF-12' in a randomized trial. 
We undertook an opportunistic study in the 
context of recruiting women aged 70 years and 
over for a randomized trial of hip protectors 
for fracture prevention. We mailed out 1500 
questionnaires, 750 of each version, York SF-12, 
and SF-12. This was to detect at least an 8% 
difference in response rate at 80% power 
(2p<0.05). The EuroQol without the analytic 
scale was also included in both questionnaires. 
Questionnaires were placed in an opaque sealed 
envelope with a prepaid reply envelope. To 
produce equivalent groups, we used alternation, 
which if strictly adhered to, results in comparable 
groups. ' The sealed envelopes were then sent to 
participating general practices. Staff at the gen- 
eral practices put address labels on the envelopes 
and posted them to the participants. No reminders 
were or could be sent. Completed question- 
naires were returned to the Department of Health 
Studies. 
talistics 
Comparisons in return and item completion rates, 
and general health status of respondents between 
the two types of questionnaires were performed 
using x2 tests. We also compared item-response 
rates between the EuroQol and the two versions of 
the SF-12 within questionnaires using the McNemar 
test for paired data. To assess the validity of the 
new version, we explored any possible psycho- 
metric differences between the York SF-12 and 
the SF-12 questionnaires by principle components 
analysis, using a varimax orthogonal rotation with 
an exclusion criteria of 0.5. The adequacy of the 
data for factor analysis was identified using Kaiser 
Meyer Olkin (KMO) test and Bartlett's test of 
sphericity. 5 Chronbach's alpha6 was used to explore 
questionnaires' internal reliability. 
Results 
Out of the 1500 questionnaires mailed out, 422 
questionnaires were returned, 221 (29.5%) and 201 
(26.8%) for the old and new versions, respectively. 
No statistically significant difference (p = 0.779) was 
found in a comparison of the general health status 
between the respondents to either version of 
the SF-12. Differences in overall response, missing 
item, and single item response rates per question- 
naire are described on Table 1. No statistically 
significant difference in the overall response rates 
were identified. 
As Table 1 shows, there were no statistically 
significant differences in the number of returned 
questionnaires (i. e. confidence interval of mean dif- 
ference includes zero). Conversely, the number of 
missing items in either version of the question- 
naire was statistically significant for the majority of 
questions with the 'stem and leaf' layout, as well as 
overall non-response to any item. 
We also compared the item response rates 
between the two versions of the SF-12 with the 
EuroQol. As expected, there were no statistically 
significant differences in item non-response rates for 
the EuroQol when combined with either version of 
the SF-12,3.1 % and 2% for SF-12 and York SF-12 
respectively, (95%CI -1.85% to 4.14%). However, 
the difference (6.5%) in the modified SF-12 item 
non-response compared with the EuroQol, although 
statistically different, (95 %CI 2% to 8 %, p<0.004), 
was substantially lower than the 23.8% differ- 
ence between the old SF-12 and the EuroQol 
(95%CI 17.8% to 29.8%, p<0.001). 
The KMO and Bartlett's tests were both satisfact- 
ory for both versions of the questionnaire (0.93049 
and 2060.2787, p<0.0001 for the York SF-12; 
0.90573 and 1455.5486 p<0.0001 for the old 
SF-12). Subjecting both questionnaires to factor ana- 
lysis yielded the expected two-factor solution. The 
internal reliability of the York SF-12 was 0.94 and 
0.91 for the physical health and mental health 
domains, respectively, measured using Chronbach's 
alpha. This was slightly better than the standard 
SF-12, which gave reliability estimates of 0.90 and 
0.88 for the same two factors. 
Discussion 
The SF-12 is an increasingly popular quality-of-life 
questionnaire. However, we found that its layout 
caused confusion among the older population in 
our studies. It would appear that this may be due to 
Table 1 Differences in response rates between the standard SF-12 and the York SF-12 
Standard SF-12, n (%) York SF-12, n (%) Difference (95 %QC! ) 
Overall response rate 221 (29.5%) 201 (26.8%) 2.7% (-1.88% to 7.22%) 
Item response rates 
Q1 219(99.1%) 199 (99%) -0.1 % (-1.95% to 1.77%) 
Q2 214 (96.8%) 199 (99%) 2.2% (-0.5% to 4.86%) 
Q3 206 (93.2%) 199 (99%) 5.8% (2.20% to 9.38%) 
Q4 209 (94.6%) 199 (99%) 4.4% (1.15% to 7.72%) 
Q5 191 (86.4%) 198 (98.5%) 12.1% (7.27% to 16.9%) 
Q6 209 (94.6%) 195 (97.5%) 2.9% (-1.36% to 6.25%) 
Q7 198 (89.6%) 196 (97.5%) . 
7.9% (3.35% to 12.5%) 
Q8 209 (94.6%) 198 (98.5%) 3.9% (0.51 % to 7.36%) 
Q9 202 (91.8%) 198 (98.5%) 6.7% (3.05% to 11.2%) 
Q10 203 (91.9%) 197 (98%) 6.1% (2.06% to 1.02%) 
Q11 205 (92.3%) 198 (98.5%) 6.2% (1.94% to 9.55%) 
Q12 214(96.8%) 194 (96.5%) -0.3% (-3.74% to 3.11 %) 
Non-response to any item 58 (26.6%) 17 (8.5%) 18.1 % (11.1 % to 25.1 %) 
items in bold are questions in the 'stem and leaf format in the standard SF-12. 
the 'stem and leaf' format of some of the SF-12 
items. Converting these items into individual items 
led to a statistically significant decrease in the 
number of missing items. The new layout of the 
York SF-12 appears to have an unambiguous 
factor structure with good reliability. Importantly, 
it improves item response by clarifying the format, 
resulting in fewer missing values, while showing 
a similar reliability. 
We accept that our overall response rates for 
both studies were relatively low. This is probably 
explained by the fact that the main aim of our 
survey was to recruit high-risk women to a 
randomized trial of hip protectors. However, there 
was only a small difference in overall response rates 
between the two questionnaires, which was not 
statistically significant. Further, if our study group 
was relatively highly motivated to complete the 
questionnaire, this would suggest that the York 
SF-12 could perform even better, compared with 
the standard SF-12, in a less-motivated population. 
It is interesting to note that in a trial comparing the 
standard version of the SF-36 with the EuroQol, 
28% of the returned SF-36 responses had missing 
data, which is similar to the 27% we found using 
the standard SF-12.2 It may be helpful to modify the 
SF-36 in a similar manner. 
In conclusion we have modified the SF-12 and 
undertaken a trial to test its item response rate and 
its reliability. We are currently exploring the 
equivalence of the Physical Component Score and 
Mental Component Score between the two versions 
of the SWF-12.7 However on the basis of the present 
analysis, we would recommend using the York 
modified SF-12, particularly among older people. 
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Abstract 
Background: Venous leg ulcers are an important source of morbidity in society. Measuring the impact of leg 
ulcers on quality of life is important within clinical and economic evaluations. In this study we report a, 
validation study of the leg ulcer disease specific Hyland questionnaire and compare its discriminative and 
responsive characteristics to general health quality of life measures: the SF-12 and EQ-5D. Methods: 
HRQoL of venous leg ulcer patients from 9 UK regions was measured using SF- 12, EQ-5D and Hyland, at 
baseline and every three months for 1 year. Psychometric analysis was used to confirm the validity of the 
Hyland questionnaire. Quarterly scores for all instruments were calculated. Effect size and standardised 
mean difference were used to investigate the responsiveness to ulcer healing and discriminative abilities of 
the instruments. Results: Three hundred and eighty seven individuals were recruited into the VenUS I 
study. Baseline health related quality of life data from the study participants suggested a two factor solution 
for the Hyland. This questionnaire was associated with small and moderate ability to discriminate indi- 
viduals according to age, mobility, initial ulcer size and ulcer duration. SF-12 and EQ-5D had good 
evaluative properties; both instruments were responsive to changes in HRQoL after ulcer healing. High 
levels of bodily pain were reported in the SF-12 questionnaire, whilst only minor ulcer related discomfort 
was reported in the Hyland. Discussion: SF-12 and EQ-5D are suitable for exploring dimensions of health 
related quality of life in people with chronic venous leg ulceration. The responsiveness to healing of the 
Hyland questionnaire is unclear. We would recommend the use of generic instruments for the measurement 
of HRQoL in patients with venous leg ulcers. 
Key words: EQ-5D, Health related quality of life, Hyland, SF-12, Venous leg ulcers 
Abbreviations: HRQoL - health related quality of life; SF-12 - Short Form 12; EQ-5D - . 
Eurogol 5 
dimensions; ES - effect size; MSD - mean standard difference; PCS - Physical Component Score; MCS - 
Mental Component Score 
Introduction 
Health related quality of life (HRQoL) in people 
with leg ulceration has been investigated in a num- 
ber of ways including indepth qualitative studies; 
cross-sectionally using generic HRQoL instruments 
(e. g. Short-Form 36 (SF-36), Nottingham Health 
Profile (NHP)) and/or leg ulcer specific measures in 
people with leg ulcers and/or people of a similar age 
without leg ulcers; and prospectively within evalu- 
ations of therapies [1-9]. 
Several studies have used inductive approaches 
such as phenomenology to inquire about life with 
a leg ulcer from the patient perspective [1-3]. 
Living with chronic pain is a theme that consis- 
tently emerges from these studies and yet venous 
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leg ulcers were traditionally not regarded as pain- 
ful [2-4). Other themes which recur are the 
restrictions to social, leisure and work activities [1- 
3], the hope and despair experienced throughout 
the long healing trajectory [1,3], and the restric- 
tions ulceration places on clothing and footwear 
that can be worn [3,4]. 
In the context of the VenUS I study (a large UK 
multicentre pragmatic randomised controlled trial 
of two bandages in the treatment of chronic 
venous leg ulcers), the health related quality of life 
of the participants was investigated using two 
generic and one disease specific quality of life 
questionnaires. At the commencement of the 
study, three disease specific measures of HRQoL 
for venous ulcers were available: the Hyland [10], 
the Chronic Venous Insufficiency Questionnaire 
(CIVIQ) [11], and the Freiburger Questionnaire of 
QoL in Venous Diseases (FLQA) [12]. 
Whilst CIVIQ and FLQA are both health 
measures for venous insufficiency (a spectrum of 
disorders ranging from varicose veins through to 
extensive ulceration of the leg), with good evidence 
of their validity and reliability [11,12], Hyland was 
claimed to measure HRQoL of people with 
ulceration [10]. The Hyland scale had been con- 
structed using sound psychometric methodology, 
however given the number of items in the scale, the 
sample size for the factor analysis in the original 
study was small [10]. The VenUS I trial presented 
an opportunity to confirm the factorial structure, 
validity and reliability of the Hyland questionnaire 
in a larger sample of UK individuals. 
Of the most widely used generic quality of life 
instruments, the SF-12 and EQ-5D were selected 
because of their conciseness and relative simplicity. 
The SF-12 measures physical and mental compo- 
nents of health related quality of life [13]. The 
EQ-5D was constructed to measure levels of utility 
associated with specific health status [14]. 
This paper presents the results of the validation 
of the Hyland questionnaire as well as a compar- 
ison of the three instruments in terms of their 
ability to discriminate between individuals who are 
experiencing different levels of health related 
quality of life (discriminative properties), and their 
ability to detect changes in HRQoL that occur as a 
result of compression therapy, i. e. the presence/ 
absence of an open ulcer (evaluative properties/ 
responsiveness). 
Methods 
Individuals were asked to complete a survey 
describing their HRQoL during the three months 
preceding recruitment into the VenUS I trial (the 
baseline assessment), and at quarterly intervals 
thereafter. The survey was designed to be com- 
pleted by study participants and returned to the 
trial office using a pre-paid envelope. Individuals 
were asked to complete up to three different 
HRQoL instruments: EQ-5D, SF-12 and Hyland. 
The SF-12 and EQ-5D had to be completed by 
all participants irrespective of the condition of 
their leg ulcer. In a pilot study of the three 
HRQoL instruments to be used in the VenUS I 
trial, the relevance of a number of questions in 
the Hyland questionnaire after ulcer healing was 
questioned by the participants. As a result, in 
order to prevent confusion in completing this 
questionnaire, the research team decided to 
administer the Hyland only to participants with 
an open venous leg ulcer. 
Hyland questionnaire 
The Hyland questionnaire comprises 34 questions 
in three sections. In the first section, individuals 
are asked whether they have been hospitalised or 
housebound because of their leg ulcer, and to 
describe the current progress of their ulcer on a 
visual scale. The second section comprises four 
items: leg ulcer pain, sleep discomfort because of 
leg ulcer, time thinking about the ulcer, and time 
spent helping the ulcer heal. The third section 
comprises a list of 29 HRQoL items concerning 
functional limitation, dystrophic mood and treat- 
ment associated with the presence of an open leg 
ulcer, e. g. 'I worry about shopping trolleys' [10]. In 
a pilot study of the three quality of life instruments 
to be used in this study, individuals with a venous 
leg ulcer identified a number of potential limita- 
tions with the original version of the third section 
of the Hyland questionnaire. Subsequently ques- 
tions in this section were rephrased using a 
more colloquial language. Furthermore, the 
four-category `never' to `always' scale originally 
used in the third section of Hyland was replaced by 
a simple yes/no scale. While reduced response 
scales can be associated with poorer longitudinal 
responsiveness it was considered that a simpler 
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response scale would minimise single item non- 
response [ 15]. 
Given the small sample size with which the 
original one factor solution for the third section of 
the Hyland questionnaire was determined (50 
individuals), baseline data from this section were 
used to conduct an exploratory factor analysis 
using principal-axis factoring in SPSS 10 [16]. The 
scree plot provides a more conservative estimate of 
the number of factors and produces less shared 
variance, so this criterion was used as an indica- 
tion of the number of factors both here and in the 
original scale construction, as opposed to the cri- 
terion of those with an Eigenvalue >1 [17]. 
Principal axis factoring using a Varimax orthog- 
onal rotation was used. This form of factor anal- 
ysis seeks to establish the least number of factors 
to account for the common variance in a set of 
variables, and is more conservative than the prin- 
cipal components analysis used in the original 
scale construction where evidence of a one factor 
solution was identified [18]. An exclusion criterion 
of 0.3 was employed [19]. Cronbach's a was used 
to explore the internal reliability of the Hyland 
tool [20]. 
A simple scoring system of adding one point for 
every `yes' response to a negative attribute was 
used to score the third section of the Hyland. 
Consequently, higher scores indicate poorer 
HRQoL the worst possible scores for the physical 
and mental factors are 12 and 14, respectively. 
EQ-SD questionnaire 
The EQ-5D is a generic measure of health status, 
where health is characterised on five dimensions 
(mobility, self care, ability to undertake usual 
activities, pain, anxiety/depression) and it is useful 
within economic evaluations because it has ratio 
properties [14]. Individuals are asked to describe 
their health on each dimension using one of three 
levels: no problems, moderate problems and severe 
problems. Each response locates a person into one 
of 243 mutually exclusive health states, each of 
which has previously been valued on the 0 (equiv- 
alent to dead) to I (equivalent to good health) scale 
based on interviews with a sample of 3395 members 
of the UK public [21]. The EQ-5D `utility' scores 
range from -0.57 to 1. Utility scores for each 
patient were calculated using the responses to the 
EQ-5D at baseline and every three months after- 
wards during the first year of follow up. 
SF-12 questionnaire 
In a pilot study of the VenUS I trial HRQoL 
instruments, it was noticed that the original `stem 
and leaf' layout of the SF-12 presented some dif- 
ficulties to older respondents. The layout of the 
SF-12 was then modified and tested in a population 
of women aged 70-year and over. The new layout 
was associated with lower item non-response and a 
reliability score slightly better than that of the 
older version [22]. This new layout was used 
throughout the VenUS I follow up period. 
The scores for the physical and mental compo- 
nents of the SF-12, as well as the scores for its 8 
individual health dimensions; general health, 
physical functioning, role physical, role emotional, 
bodily pain, mental health, vitality, and social 
functioning, were calculated at baseline and every 
three months for the first year of follow up [13]. To 
facilitate the interpretation and comparison of our 
results with those from other studies, all scores 
were norm-based to the average mean values of the 
general US population, i. e. scores were trans- 
formed to be distributed with a mean of 50 and a 
standard deviation of 10. Any values below 50 
indicate that the physical or mental components of 
the population under study are below the average 
of the general US population; the opposite is true 
for values above 50. 
Discriminative and evaluative properties 
(responsiveness to ulcer healing) 
The ability of the three HRQoL instruments to 
discriminate individuals according to age (age < 
71 years/age > 71 years), degree of mobility 
(fully/partially mobile), initial ulcer size (size 
4 cm2/size >4 cm2), and duration of current ulcer 
(duration <3 months/duration >3 months), at 
baseline was explored using the effect size (ES). 
For continuous variables, i. e. age, ulcer size and 
ulcer duration, the cut-off point to split the study 
sample into two groups was determined by the 
sample's mean or median in the case of highly 
skewed variables, such as ulcer's size and 
duration. ES was calculated as the ratio of the 
difference in means between the two groups, de- 
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fined by the characteristic of interest (i. e. age, 
mobility, etc), to the full sample standard devia- 
tion at baseline [23]. 
The evaluative properties of the Hyland ques- 
tionnaire with respect to venous leg ulcer healing 
could not be explored. The relevance of many of 
this instrument's items after ulcer healing was 
unclear. Thus, this questionnaire was only 
administered to individuals with an open ulcer. 
The responsiveness of the two generic instruments 
to changes in HRQoL associated with the healed/ 
not healed state with respect to baseline scores 
was investigated using the ES and standardised 
response mean (SRM). In this case, ES was esti- 
mated as the ratio of the mean change between 
baseline and three-month scores to the standard 
deviation of the scores at baseline [23]. Similarly 
SRM is the ratio of the mean change between 
baseline and 3-month scores to the standard 
deviation of the difference in means [23]. 
Repeated measures model 
Patterns of missing data were explored following 
the procedure described by Fairclough [24]. 
Logistic regression was used to investigate the 
association of missing data with baseline covari- 
ates and previously observed HRQoL. This anal- 
ysis indicated that the only statistically significant 
predictors of non-response at any specific follow 
up time were whether they had previously 
responded, thus suggesting that the pattern of 
missing data was not missing completely at ran- 
dom but missing at random [24]. Descriptive 
analysis also indicated that the patterns of missing 
data were non-monotonic. Consequently, a 
Bayesian two level random effect model was con- 
structed in WinBugsl. 4 software package to esti- 
mate mean scores for SF-12, EQ-5D and Hyland 
at each follow up point, as well as to perform 
hypothesis testing [25-27]. The first level of the 
model was given by the quality of life scores 
reported at different follow up points by the same 
individual, these in turn were clustered within 
individuals which defined the second level of the 
model. Vague priors were fitted to all unknown 
parameter within the model [28]. Missing data 
were treated as parameters thus imputed/predicted 
with the posterior predictive distribution of the 
mean scores at each time point [29]. 
An exploratory analysis indicated no statisti- 
cally significant differences in HRQoL scores 
between bandage groups over time for any of the 
three different instruments. In order to simplify the 
presentation of the analysis the data from both 
bandage groups were combined in a single dataset 
of individuals with venous leg ulcers. 
Results 
Three hundred and eighty seven individuals were 
recruited in the VenUS 1 study. Demographic and 
ulcer specific characteristics of the participants at 
baseline are provided in Table 1. The clinical and 
economic analyses of the trial have been reported 
in detail elsewhere [30]. 
Response rates 
The number of participants expected to have 
completed the Hyland, SF-12 and EQ-5D ques- 
tionnaires over the first year of follow up are 
described in Table 2. Complete (i. e. every single 
item) and partial (i. e. at least one item) response 
rates for the three HRQoL questionnaires indicate 
that the response rates to SF-12 were the highest 
and ranged from 93% at baseline down to 61 % at 
12 months. Conversely, the poorest response rates 
were associated with the Hyland questionnaire 
which ranged from 92% at baseline to 49% after 
1 year. Despite the EQ-5D's brevity and its position 
in the booklet (beginning of the HRQoL survey), its 
response rates were not better than those for the 
SF-12; range 91-59%. When only questionnaires 
with complete responses were considered, response 
rates were reduced by between I% and 24%. 
Factor analysis 
Since the original analysis had described the third 
section of the Hyland as unidimensional scale, a 
one factor solution was examined; all 28 items 
loaded. Items 14 (`Because of my ulcer I try to keep 
away from cats etc) and 19 (i. e. `I think my ulcer 
will not get better'} loaded below a 0.3 criterion. 
The factor explained 28.75% of the variance and 
had an internal reliability of 0.88. 
While six factors had Eigenvalues above 1.0, 
examination of the scree plot indicated a two-factor 
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Table 1. Baseline demographic variables and leg ulcer characteristics 
Continuous variables N Mean (SD) [range] 
Patient characteristics 
Age (years) 
Height (m) 
Weight (kg) 
History of ulceration 
Duration of ulceration (years since onset) 
Episodes (since onset) 
Leg and ulcer characteristics 
Ankle circumference (cm) 
Duration of current ulcer (months) 
Area (cm2) 
Categorical variables 
387 71.6 (13.21) [23-97] 
379 1.7 (0.11) [1.4-2.0] 
377 79.8(19.8) [33.1-142.4] 
372 3* [0-75] 
375 2* [041 
380 23.9 (2.90) [16.0-34.0] 
377 3* [0-768] 
386 3.8* [0.2-254.6] 
N% 
Patient characteristics 
Male 159 (41%) 
Female 228 (59%) 
Fully mobile 238 (62%) 
Walks with assistance 142 (37%) 
Immobile 3 (0.77%) 
Ankle mobility (full motion) 259 (67%) 
Ankle mobility (reduced motion) 117 (30%) 
Ankle mobility (fixed) 5 (1.3%) 
*For highly skewed distributions medians are shown. 
Table 2. Quarterly response rates for SF-12, EQ-5D and Hyland 
Baseline 1st quarter 2nd quarter 3rd quarter 4th quarter 
Numbers eligibles 387 382 380 376 370 
Death 0 5 7 11 17 
SF-12 
Partial response 93% 77% 67% 63% 61% 
Complete answers 88% 70% 62% 56% 57% 
EQ-5D 
Partial response 91% 73% 66% 60% 59% 
Complete answers 85% 68% 63% 59% 56% 
Numbers eligibleb 387 216 149 116 97 
Healed 0 166 231 260 273 
Death 0 5 7 11 17 
Hyland 
Partial response 92% 68% 58% 53% 49% 
Complete answers 64% 44% 36% 34% 40% 
'Number of alive individuals in the study who should have completed an EQ-5D or SF-12 questionnaire. 
bNumber of individuals with an open ulcer who should have completed a Hyland questionnaire. 
solution for the third section of the Hyland. The 
three highest loading items on each factor are 
shown in Table 3. Factor one accounted for 
28.94% of the variance and factor two for a further 
5.21 %. In total the scale accounted for 34.15% of 
the variance. Unlike in the one factor solution, 
items 14 and 19 failed to load on either factor, 
consequently these items were removed from 
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Table 3. Factor analysis of Hyland quality of life questionnaire (section 3) 
Three highest loading items on each factor 
Item Description Factor Loading 
11 My ulcer makes getting on or off a bus difficult 1 0.735 
18 My ulcer restricts where I can travel to, e. g. restricting 1 0.708 
holidays or business trips 
9 My ulcer stops me from shopping in crowded places. 1 0.678 
24 My ulcer makes me ask myself, `Why meT 2 0.655 
23 My ulcer makes me feel depressed 2 0.654 
25 Because of my ulcer it feels as though my legs/feet dominate my body 2 0.630 
Double loaded items 
Loadings 
Item Description Factor I Factor 2 
21 Because of my ulcer I can't be bothered to do anything 0.419 0.446 
20 My ulcer gets in the way of personal relationships 0.332 0.367 
16 My ulcer prevents me from wearing the type of shoes I prefer 0.337 0.365 
Table 4. Correlations between baseline HRQoL scores 
Hyland practical Hyland emotional SF-12 physical SF-12 mental EQ-SD 
Practical (n) 1 (247) 0.67** (247) -0.22** (242) -0.55** (242) -0.61** (233) 
Emotional 1 (247) 0.02 -0.60** (242) -0.47**(233) 
Physical 1 (339) -0.12* (339) 0.25** (317) 
Mental 1 (339) 0.58**(317) 
EQ-SD 1 (328) 
**Correlation is statistically significant at 0.01 level (2-tailed). 
*Correlation is statistically significant at 0.05 level (2-tailed). 
further analysis. Several items double loaded on 
factors. In most cases these items were sufficiently 
different in their loadings on the two factors for it to 
be apparent where they belonged. In three cases 
however the items were very closely loaded. There 
would be an argument for discarding these items as 
the loadings on each factor were so close but for the 
purposes of this study it was decided to retain them 
as part of the emotional factor to maintain as far as 
possible the structure of the original scale. These 
three items are shown in Table 3. 
Both factors proved to be reliable using coeffi- 
cient alpha to establish this. Factor one and factor 
two had coefficients alpha of 0.82 and 0.79, 
respectively. Factor one appeared to measuring 
some of the more practical perceptions of limita- 
tions and factor two more emotional responses to 
the ulcer. While the reliability was high in the one 
factor solution, more variance could be explained 
using the two factor solution with the added ben- 
efit of being able to identify perception of practical 
limitations as well as emotional issues. Thus, the 
scale was scored using two factors; a practical and 
an emotional one. 
To test the criterion validity of the factors the 
practical and emotional factors were correlated with 
the physical and mental heath components of the 
SF-12, see Table 4. The practical and emotional 
factors of the Hyland scale correlated at 0.67. These 
factors also correlated in the expected direction with 
the SF- 12 subscales: the practical factor correlated 
-0.22 with SF-12 physical subscale and -0.55 with 
the SF-12 mental health subscale, the emotional 
factor was not significantly correlated with the 
physical subscale of the SF-12 but correlated at 
-0.60 with the SF-12 mental health subscale. 
Hyland 
This section refers to the two-factor solution, 
however the statistics of the one-factor solution 
are available on request from the correspond- 
k 
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Table 5. Responses to Hyland (section 2) 
Ulcer paina Sleep disturbance 'b Thinking about ulcer` Help ulcer heald 
Baseline 
Median [range] 3 [1-7] 2 [1-5] 3 [1-10] 5 [1-8] 
N 339 335 338 168 
15t quarter 
Median [range] 2 [1-7] 2 [1-5] 2 [1-10] 4 [1-8] 
N 139 138 137 140 
2"d quarter 
Median [range] 3 [1-5] 2 [1-4] 2 [1-10] 4 [1-10] 
N 82 82 82 80 
3`d quarter 
Median [range] 2 [1-5] 2 [1-5] 2 [1-10] 4 [1-8] 
N 56 56 56 59 
4rd quarter 
Median [range] 2 [1-5] 1 [1-5] 3 [1-10] 4 [1-8] 
N 47 47 46 47 
'Pain: 1. Don't notice it; 2. Uncomfortable rather than painful; 3. Hurts a little; 4. Painful; 5. Very painful; 6. Excruciatingly painful; 
7. More pain that I can manage. 
bSleep: 1. Doesn't disturbs me; 2. Disturbs me only when going to sleep; 3. Sometimes wakes me up; 4. Keeps me awake a lot; 5. Keeps 
me awake most of the night. 
`Thinking: 1. I don't think about my ulcer at all; 2. Less than 15 minutes; 3. About half an hour; 4. About an hour; 5. About an hour an 
a half; 6. About two hours; 7. About three hours; 8. About four hours; 9. Most of the day; 10. Most of the day and night. 
dHelp: 1. I don't spend any time at all trying to help my ulcer heal; 2. Less than 15 minutes; 3. About half an hour; 4. About an hour; 5. 
About an hour an a half; 6. About two hours; 7. Three or more hours, 8. Most of the day. 
ing author. At baseline 63 (18%) participants 
indicated `to have ever stayed in hospital because of 
their leg ulcers'. One hundred and seventeen 
reported to be `largely housebound these days'; 81 
(69%) of them indicated that this was because of 
their leg ulcers. Responses for section two of the 
Hyland are summarised in Table 5. The levels of 
pain, sleep disturbance, and amount of time spent 
looking after and thinking about their ulcer 
reported by the individuals on the VenUS I trial 
remained relatively constant over time. During the 
first year of follow up people reported on average 
that their ulcer `hurt a little', `disturbed them. only 
when they were going to sleep', `spent less than 15 
minutes thinking about their ulcer', and `spent about 
an hour trying to help their leg ulcer heal'. 
Quarterly practical and emotional scores for 
individuals with an open ulcer are described in 
Table 6. The results indicate that individuals with 
an open venous leg ulcer experienced a detriment 
in both practical and emotional dimensions of 
health related quality of life. Quarterly mean 
scores during the first year of follow up remained 
relatively stable around 5 for both practical and 
emotional factors, i. e. a detriment of 40% in the 
practical and 36% in the emotional dimension. 
Over time no statistically significant differences 
with respect to baseline scores were identified with 
either the practical or emotional factors. The 
poorest scores in both factors were reported after 
six months of follow up. 
SF-12 
Mean estimates over a year's follow up of the 
physical (PCS) and mental components (MCS) of 
the SF-12 irrespective of healing status are 
described in Table 6. These data indicate detri- 
ments in both physical and mental components of 
quality of life in individuals with a venous leg 
ulcer. The scores for both components are below 
the average mean value (50) of the general US 
population, i. e. the health-related quality of life of 
the individuals in the VenUS I study was poorer 
than that of an average member of the US popu- 
lation. However, comparing baseline PCS and 
MCS scores, with those of an average US indi- 
vidual aged 75 years and over (mean age of 
VenUS participants was 71 years), the initial large 
difference in the PCS, was no longer observed [31]. 
On average there was a two-point difference 
between the mean PCS and MCS of the VenUS I 
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Table 6. Mean scores estimates irrespective of healing status1 
Period Hyland' SF-12b EQ-5D` 
Practical 
factor 
Emotional 
component 
Physical 
component 
Mental 
component 
Utility scores 
Baseline (N d) 248 248 341 341 329 
Mean (SE) 5.58 (0.25) 5.10 (0.25) 35.89 (0.45) 48.45 (0.64) 0.62(0.02) 
Ist quarter (N d) 95 95 266 266 261 
Mean (SE) 4.64 (0.32) 4.59 (0.29) 34.92 (0.46) 50.56 (0.76) 0.69 (0.02) 
Difference from -0.94 [-1.76 to -0.13] -0.51 [-1.29-0.19] -0.97 [-2.22-0.31) 2.11 , [0.12-4.05] 0.07 [0-02-0.11) baseline [95% CI] 
2nd quarter (N d) 53 53 235 235 238 
Mean (SE) 5.36 (0.40) 4.85 (0.35) 34.81 (0.52) 50.77 (0.77) 0.70 (0.02) 
Difference from -0.22 [-1.13-0.71] -0.25 [-1.21-0.60] -1.08 [-2.43-0.24] 2.32 [0.31-4.25] 0.08 [0.04-0.13] 
baseline [95% CI] 
3th quarter (N d) 40 40 212 212 221 
Mean (SE) 4.95 (0.42) 4.15 (0.39) 35.17 (0.55) 50.89 (0.84) 0.70 (0.02) 
Difference from -0.62 [-1.59-0.31] -0.95 [-1.80 to -0.10] -0.72 [-2.17-0.67] 2.44 [0.32-4.48] 0.08 [0.03-0.12] 
baseline [95% CI] 
4th quarter (N d) 39 39 212 212 208 
Mean (SE) 4.37 (0.41) 3.74 (0.38) 34.63 (0.53) 50.91 (84) 0.72 (0.02) 
Difference from -1.21 [-2.17-0.26] -1.36 [-2.33 to -0.45] -1.26 [-2.67-0.08] 2.46 [. 42-4.54] 0.10 [0.05-0.15] 
baseline [95% CI] 
'Higher scores indicate poorer quality of life. 
bScores below 50 indicate quality of life is below average of US population. 
`Lower scores indicate poorer quality of life. 
'Missing scores were imputed for individuals known to be alive with the posterior predictive distribution of the mean scores at each 
time point. 
participants and those of an average American 
aged 75 years and over, see Table 7. 
Among the 8 health dimensions on the SF-12, 
bodily pain had the biggest impact on health 
related quality of life. This was also reflected in the 
low physical component score observed at baseline, 
according to which between 12% and 21 % of our 
population were experiencing `severe' or `very 
severe' pain. Interestingly, bodily pain was also the 
only dimension that showed a negative trend over 
the whole study period, i. e. reported levels of pain 
actually increased with respect to those observed at 
baseline. This trend remained true irrespective of 
whether individuals were ulcer free and was not 
bandage related. 
The conclusion of an episode of ulceration was 
associated with an improvement relative to base- 
line scores on the mental component of the SF-12 
and a stabilisation of the physical component, see 
Table 8. Healed individuals on average experi- 
enced an improvement of between two and four 
points in their MCS with respect to baseline 
scores. This difference in scores was statistically 
significant at 6-month and 12-month follow up. 
The improvement in the MCS suggests that after 
healing individuals reported to have more fre- 
quently had lots of energy, emotional problems 
caused less disruption in their ability to accomplish 
and perform daily activities, less frequent episodes 
of feeling downhearted and low, and an improved 
ability to carry on their social activities despite 
physical health and/or emotional problems. 
EQ-5D 
Utility scores, as measured by the EQ-5D followed a 
similar a similar pattern to that observed in the 
SF-12 physical and mental components. After the 
first 3 months of follow up an improvement in 
the utility scores was observed; this change in scores 
of 0.07 with respect to baseline was statistically 
significant, 95% credibility interval: [0.02-0.11]. 
Scores became stable around 0.70 thereafter, see 
Table 6. 
Closer examination of the scores indicated that 
after healing, EQ-5D scores improved on average 
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Table 7. Comparison with norms-based scores for individuals 
aged 75 and over 
Baseline Physical Mental 
component (PSC) components (MSC) 
VenUS study population 
Mean (sd) 35.87 (7.97) 48.50 (12.29) 
Range (4.75-55.27) (13.11-70.07) 
N 339 339 
US general population 
Mean (SD) 37.89 (11.16) 50.44 (11.66) 
Range (13-59) (18-71) 
Difference -2.02 -1.94 
21 % relative to the scores reported at baseline, see 
Table 8. Conversely, unhealed individuals over 
time reported utility scores very close to those 
reported at baseline. This suggested that the 
completion of an episode of ulceration was asso- 
ciated with improvements in the degree of mobil- 
ity, self-care, usual activities, pain/discomfort, and 
anxiety/depression reported on the EQ-5D ques- 
tionnaire. Relative to their baseline responses at 
subsequent follow up contacts, a higher propor- 
tion of healed individuals reported no problems 
with walking about, no problems with self care, no 
problems with performing usual activities, no pain 
or discomfort, and no anxiety or depression. 
Discriminative properties 
Hyland was associated with a small (ES = 0.2) to 
moderate (ES = 0.6) ability to discriminate indi- 
viduals according to age, mobility, leg ulcer size, 
and current ulcer duration, (see Table 7). Unlike 
the Hyland, the EQ-5D was only associated with a 
moderate ability to differentiate between individ- 
uals in relation to their degree of mobility 
(ES = -0.7). The SF-12 was associated with small 
(ES = 0.3) to large (ES = 0.9) ability to differen- 
tiate between individuals on the basis of their age, 
degree of mobility and duration of present ulcer, 
see Table 9. 
Evaluative properties (responsiveness to healing) 
The responsiveness of EQ-5D and SF-12 to changes 
in HRQoL following the ulcer healing at 3 months 
was confirmed by the ES and SRM estimates. Small 
to moderate ability to detect changes in individuals' 
health related quality of life following the closure of 
their venous leg ulcer, was associated with both 
SF-12 and EQ-5D at three months, see Table 10. 
Whilst evidence of an improvement on the scores of 
healed individuals was observed in seven of the 
eight individual dimensions described by the SF- 12, 
the bodily pain dimension was associated with a 
moderate worsening. 
Discussion 
In the context of the largest randomised controlled 
trial of compression therapy in the treatment of 
venous leg ulcers (VenUS I), the health related 
quality of life of this group of individuals was 
measured using one disease specific (Hyland) and 
two generic (SF-12 and EQ-5D) instruments. 
The validity and reliability of the Hyland ques- 
tionnaire was confirmed in a sample of 387 indi- 
viduals with venous leg ulcers. Unlike the original 
scale construction, our data suggested a two factor 
solution for the third section of the Hyland ques- 
tionnaire. A one-factor solution was associated 
with poorer discriminatory abilities and respon- 
siveness over time than the two-factor one, 
detailed results not presented, but available on 
request from the corresponding author. Factor 
one appeared to measuring perceptions of more 
practical limitations associated with the ulcer, 
whilst factor two was measuring more emotional 
responses. Descriptive analysis of the practical and 
emotional factors suggested a worsening in both 
health related factors associated with venous leg 
ulceration. 
The responsiveness to healing of the Hyland 
questionnaire is ambiguous. Individuals partici- 
pating in a pilot study of the VenUS I HRQoL 
instruments raised concerns regarding the rele- 
vance of a number of items in the Hyland ques- 
tionnaire for individuals without an open venous 
leg ulcer. The research team considered that unless 
the Hyland questionnaire was substantially modi- 
fied the validity of the responses to the Hyland 
questionnaire after healing could be compromised. 
Consequently, and to prevent confusion by 
requesting partial response to a questionnaire after 
healing and to minimise the burden on the study 
participants, the team decided to administer the 
Hyland questionnaire only to individuals with an 
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Table 9. Effect sizes according to baseline characteristics 
Agea 
ES` P 
Mobilityb 
ES P 
Area` 
ES P 
Durationd 
ES P 
EQ-5DF 0.1 0.0 -0.7 0.0 0.0 0.3 0.0 0.2 
Hyland g 
Practical 0.0 0.2 0.6 0.3 0.2 0.3 0.2 0.2 
Emotional -0.1 0.6 0.3 0.3 0.2 0.3 0.2 0.7 
SF-12f 
General health -0.2 0.3 -0.7 0.8 0.0 0.5 -0.1 0.2 
Physical functioning -0.4 0.0 -1.1 0.0 -0.1 0.3 -0.2 0.5 
Role physical -0.2 0.0 -0.9 0.1 -0.2 0.5 -0.1 0.4 
Role emotional -0.1 0.6 -0.4 0.0 -0.1 0.5 0.0 0.7 
Body pain -0.2 0.1 0.5 0.4 0.0 0.5 -0.1 0.5 
Mental health 0.0 0.3 -0.3 0.6 0.1 0.9 0.0 0.3 
Vitality -0.2 0.8 -0.5 0.7 -0.1 0.5 -0.2 0.2 
Social functioning -0.2 0.6 -0.8 0.1 -0.2 0.5 -0.1 0.2 
Physical score -0.4 0.0 -0.9 0.2 -0.1 0.9 -0.3 0.5 
Mental score 0.0 0.5 -0.4 1.0 -0.1 0.5 0.0 0.4 
'Cut-off point = sample mean age. Group 1 71 years; group 2> 71 years. 
bMobility: group I= fully mobile; group 2= partially mobile. 
`Cut-off point = sample median initial ulcer size. Group 1 <4 cm2 group 2>4 cm2. 
dCut-off point = median duration of current ulcer. Group 1 <3 months, group 2>3 months. 
'Effect size = (mean in group 2- mean in group 1)/Overall SD. 
1Higher scores indicate better quality of life (qol). A positive ES indicate that the qol of individuals in group two is better. 
gHigher scores indicate poorer quality of life. A positive ES indicates that the qol individuals in group two is poorer. 
Table 10. Responsiveness at first 3-month follow up 
Unhealed Healed 
N ESa SMD N ES* SMD 
SF-12 
General health 153 -0.1 -0.1 119 0.0 0.1 
Physical functioning 155 0.0 0.0 119 0.0 0.1 
Role physical 151 0.2 0.2 118 0.3 0.3 
Role emotional 158 -0.1 -0.1 124 0.2 0.2 
Body pain 153 -0.3 -0.3 125 -0.5 -0.5 
Mental health 154 0.1 0.1 126 0.1 0.1 
Vitality 155 0.0 0.0 124 0.0 0.0 
Social functioning 154 0.2 0.2 125 0.1 0.2 
Physical score 140 -0.2 -0.2 113 -0.2 -0.2 
Mental score 140 0.1 0.1 113 0.2 0.3 
EQ-5D 134 0.1 0.1 108 0.5 0.4 
*Negative values indicate a decline in HRQoL with respect to baseline values. 
open ulcer. Further research work is required to 
warrant the responsiveness to venous leg ulcer 
healing of the Hyland questionnaire. 
Our results coincide with those of Walters et al. 
[8] and Franks et al. [9] i. e. in that generic mea- 
sures (SF-12 and EQ-5D) have poor abilities to 
discriminate individuals according to baseline 
ulcer characteristics; no unexpected given the 
generic nature of these instruments. In contrast to 
the findings of Walters et al. [8], and similarly to 
those from Franks et al. [9] our data indicated that 
the two generic instruments were responsive to 
changes in HRQoL in relation to ulcer status 
(healed/unhealed), irrespective of the follow up 
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period. On average individuals whose venous leg 
ulcer healed and remained so within the first year 
of follow up reported higher SF-12 and EQ-5D 
scores than those whose ulcer remained unhealed. 
This suggests that the resolution of an episode of 
open ulceration results in an improvement on the 
HRQoL of venous leg ulcer patients. Differences 
in the time points for follow up could account for 
the inconsistencies in the results from these three 
studies. The VenUS I is the only study in which 
quarterly measurements were made. 
A number of studies have highlighted the impact 
of pain in people with venous leg ulcers [5,6,9]. In 
this analysis high levels of bodily pain were 
detected by the SF-12 irrespective of whether 
ulcers were healed or unhealed. Conversely, levels 
of pain specifically associated with the presence of 
an open venous leg ulcer reported in the Hyland 
questionnaire were moderate; in the first year of 
follow up 50% of individuals indicated that their 
ulcer only `hurt a little'. This suggests that the high 
levels of bodily pain reported by this population 
are likely to be primarily due to something other 
than their open venous leg ulcer. The exploration 
of the contribution of alternative co-morbidities to 
the high levels of bodily pain was prevented by the 
unavailability of such data from the VenUS I 
study population. Future venous leg ulcer studies 
should collect data which differentiates between 
ulcer related and unrelated pain, and attempt to 
determine the sources of pain unrelated to 
ulceration. 
The Hyland questionnaire was associated with 
the lowest partial and complete response rates 
49% at 1 year of follow up. Response rates to the 
EQ-5D and SF-12 also reduced over time to 59% 
and 61 % at 1 year, respectively. A number of 
measures were implemented to improve response 
rates during the study's follow up period. For 
example, non-respondent participants were sent 
monthly reminders accompanied by a new copy of 
the quality of life questionnaire. Only individuals 
who indicated their unwillingness to provide any 
further information were taken off the mailing list. 
Participants were not contacted by phone since 
pooling health related quality of life data reported 
at two different points in time may result in 
inconsistencies with the data. 
The relevance of disease specific instruments to 
the acquisition of a deeper understanding of the 
impact of different health care conditions in 
HRQoL is widely recognised. In the area of 
venous leg ulceration such an instrument would 
need to consider the chronic nature of venous leg 
ulcers. In other words, it will have to describe the 
main aspects/dimensions of HRQoL that are 
altered as consequence of the open ulcer, as well as 
from its underlying causes, and consider both the 
impact of fear of recurrence and measures taken to 
prevent recurrence. Bearing that in mind, it is 
important to recognise that venous leg ulcers are 
mainly present among elderly people. This popu- 
lation group is likely to be affected by co-mor- 
bidities. The ability of a venous leg ulcer disease 
specific instrument to disentangle the changes in 
HRQoL solely attributable to the open ulcer, and/ 
or its underlying causes is unclear. For example; 
CIVIQ [11] and Frieburg. [12] questionnaires are 
both health measures for venous insufficiency, 
however this condition covers a spectrum of dis- 
orders ranging from varicose veins through to 
extensive ulceration of the leg, thus it can not be 
argued that the changes in health related quality of 
life captured by these instruments are principally 
related to venous ulceration and/or its underlying 
causes. 
While disease specific instruments can provide a 
deeper insight into the effect of different health 
conditions on health related quality of life, this is 
usually done at the cost of increasing question- 
naire's length. The three existing disease specific 
instruments available in the area of venous leg 
ulcers - Frieburg, CIVIQ and Hyland - are con- 
siderably longer than the generic instruments used 
in this study (SF-12 and EQ-5D). In the context of 
randomised controlled studies where one of the 
main objectives is to minimise potential sources of 
bias, there is always a trade off between the 
quantity and the quality of information to be 
collected. Previously published studies indicate 
that by decreasing the overall length of quality of 
life questionnaire booklets, response rates and 
quality of responses may be improved [32]. 
In conclusion, this study suggests that HRQoL 
in individuals with venous leg ulcers can be effec- 
tively measured with generic instruments. Evi- 
dence of the impact of venous leg ulceration on 
health related quality of life was provided by both 
generic and disease specific instruments. The dis- 
ease specific Hyland questionnaire had good 
110ýf., 
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discriminative abilities, however it was associated 
with considerably poorer response rates than the 
SF-12 and the EQ-5D. Moreover, the responsive- 
ness to healing of the Hyland questionnaire is 
unclear. The two generic instruments, SF-12 and 
EQ-5D, performed reasonably well, both had 
response rates between 93% and 54% and were 
responsive to changes in health related quality of 
life occurring after the closure of a venous leg 
ulcer. Consequently, in the context of randomised 
controlled trials in the area of chronic venous leg 
ulcers, we recommend the use of generic mea- 
surements of HRQoL. 
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Randomized clinical trial of four-layer and short-stretch 
compression bandages for venous leg ulcers (VenUS f) 
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Background: A randomized clinical trial was undertaken to determine the relative effectiveness of 
four-layer and short-stretch bandaging for venous ulceration. 
6J ethads: A total of 387 adults with a venous ulcer, who were receiving leg ulcer treatment either in 
primary care or as a hospital outpatient, were recruited to this parallel-group open study and randomized 
to either four-layer or short-stretch bandages. Follow-up continued until the patient's reference leg was 
ulcer free or for a minimum of 12 months. The primary endpoint was time to complete healing of all 
ulcers on the reference leg. Secondary outcomes included proportion of ulcers healed, health-related 
quality of life, withdrawals and adverse events. Analysis was by intention to treat. 
Fese ts: Unadjusted analysis identified no statistically significant difference in median time to healing: 
92 days for four-layer and 126 days for short-stretch bandages. However, when prognostic factors were 
included in a Cox proportional hazards regression model, ulcers treated with the short-stretch bandage 
had a lower probability of healing than those treated with the four-layer bandage: hazard ratio 0.72 
(95 per cent confidence interval 0.57 to 0.91). More adverse events and withdrawals were reported with 
the short-stretch bandage. 
Conclusion: Venous leg ulcers treated using a four-layer bandage healed more quickly than those treated 
with a short-stretch bandage. 
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kntroductfon 
Leg ulceration affects 15-18 per 1000 adults in developed 
countries, and is associated with pain and lower quality 
of life, '. The majority of leg ulcers are secondary to 
venous insufficiency (venous ulcers). It has been estimated 
that the management of venous ulcers in the UK costs 
£100-300 million every year, nursing time accounting for 
most of this cost; {. 
Systematic reviews have found that compression therapy 
heals more ulcers than dressings alone, and that high- 
level compression systems are more effective than lour- or 
moderate- compression systems'. However, it has not been 
possible to determine from previous research which high- 
compression regimen - four-layer bandaging, compression 
hosienr, Unna's boot or short-stretch bandaging- is the 
most clinically or cost effective'. Four-layer bandaging 
is probably the most widely used method in the UK 
whereas short-stretch bandaging is the system of choice 
in much of continental Europe. Thus four-layer and 
short-stretch bandages were chosen for comparison. Short- 
stretch bandage is washable and reusable (unlike four- 
la), er bandages), comparatively simple to apply, and its 
effects are thought to be less reliant on the skill of the 
bandager6. Furthermore, it is inelastic, a feature that 
may reduce the likelihood of damage to the skin and 
underlying tissue occasionally induced by inappropriately 
applied elastic high compression. To determine the relative 
effectiveness and cost-effectiveness of four-layer and short- 
stretch bandaging systems, a pragmatic randomized clinical 
trial «-as undertaken. 
Patients and methods 
Patients were eligible for the trial if they had been 
diagnosed clinically tiºith as enous leg ulcer at least 
Copyright O 2004 British Journal of Surgery Society Ltd 
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Compression bandaging for leg ulcers 
I cm in diameter. Exclusion criteria t; -ere: age less 
than 18 years, significant arterial disease (ankle : brachial 
pressure index (ABPI) less than 0.8), diabetes mellitus, 
previous unsuccessful use of a trial bandage, patient unable 
or unwilling to have high compression, and patient unable 
or unwilling to provide written, informed consent. 
Between kpril 1999 and December 2000, patients with 
venous leg ulcers treated in the community (leg ulcer 
services, district nursing or general practice) or as an 
outpatient (vascular surgery) were recruited from nine 
UK centres. After obtaining written informed consent, 
participants were allocated to either four-layer bandages 
(4LB group) or short-stretch bandages (SSB group) using 
a concealed, remote telephone randomization service. 
Randomization was stratified by clinical centre, previous 
ulceration (yes or no), ulcer area (less than or greater than 
10 cm'), and ulcer duration (more or less than 6 months)'. 
The randomization code was developed using computer- 
generated permuted blocks (randomly sized 4 or 6). Both 
patients and nurses were aware of the allocated treatment 
after assignment. 
Bandaging 
Four-layer bandages consisted of one layer of orthopaedic 
wool padding, covered by three retention/compression 
bandages, all applied with 50 per cent overlap (Table 1). 
The original four-layer bandage system and two propri- 
etan, U- ts, Profore® (Smith and Nephew Healthcare, Hull, 
Lei) and System 40 (SSL International, Knutsford, UK), 
both 10 cm wide, were randomly allocated in this prag- 
matic trial as a previous study that compared these systems 
found no significant difference in effectiveness'. Standard 
modifications were used for participants with large (cir- 
cumference greater than ZS cm) or small (circumference 
less than 18 cm) ankles (Table 1)9. Bandages were used once 
and discarded. 
Table 1 Four-layer bandage system and method of application 
Type of bandage Method of 
Layer (ankle circumference 18-25 cm) application 
1 Padding (e. g. Velbar dß*, Johnson & Spiral 
Johnson) 
2 Retention (e. g. Crepes BPI) Spiral 
3 Class 3A compression (e. g. Elsetlý, SSL Figure of eight 
International) 
4 Cohesive compression (e. g. Cobane', 3M) Spiral 
Two layers of padding (layer 1) were used for participants with an ankle 
circumference of less than 18 cm. The third bandage layer was replaced 
with a high-compression (class 3C) bandage for participants with an ankle 
circumference greater than 25 an. 
Copyright 0 2004 British Journal of Surgery Society Ltd 
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Short-stretch bandaging comprised one layer of 
orthopaedic wool padding covered with one or two coin- 
pression bandages, either Compri]an` (Beiersdorf UK1 
Milton Keynes, UK) or Rosidal K® (Vernon-Carus, Pre- 
ston, UK) 100 per cent cotton short-stretch bandages. The 
standard techniques of spiral, figure of eight or modified 
Putter were used10. The different techniques are thought to 
deliver similar sub-bandage pressures. The bandages were, 
whenever possible, washed by the patient and reused. 
In both groups the ulcers were cleansed using tap w2ter 
or saline, and covered with a simple, low-adherent dressing, 
such as N-A Dressing' (Johnson & Johnson Medical, 
Ascot, UK). Dressings and bandages were renewed by the 
regular nursing staff; any changes to dressings and the 
frequency of renewal were decided by the patient's usual 
nurse. As this was a pragmatic trial, the schedule of patient 
visits was not dictated by trial protocol, except to say that 
patients should be seen at least once a week. 
Data collection 
Nurses completed a dressing log at each leg ulcer dressing 
visit, which recorded whether or not an ulcer was healed, 
the date of the visit, all materials used, and reasons for 
any changes in treatment. Health-related quality of life 
was assessed by means of Short Form SF-1211, EuroQol- 
5D12, and Hyland leg and foot ulcer questionnaire 13 
Economic data were also recorded and are reported 
elsewhere'4. Follow-up of all participants continued from 
randomization until December 2001 (12-21 months). 
The primary endpointwas time to healing of all ulcers on 
the reference leg, defined as the leg with the largest eligible 
ulcer. Secondary outcomes included the proportion of 
ulcers healed at 12 and 24 week, withdrawals and adverse 
events. A healed ulcer was defined as complete epithelial 
cover in the absence of a scab. At healing, a nurse took 
a PolaroidTM photograph of the ulcer and sent this to 
the trial office where an investigator blinded to bandage 
allocation confirmed ulcer-healing. Standard methods of 
photography were used throughout the study centres to 
reduce error15. 
Sample size calculation and statistical analysis 
Because previous studies had not reported time to event 
data, the required sample size was estimated using data for 
the proportion of patients healed at 12 weeks. This was 
viewed as a conservative approach in the light of 2 planned 
survival analysis. The sample size calculation was based on 
an estimate from previous trials of 50 per cent of ulcers 
healing by 12 weeks with the four-layer bandage, and an 
v-"". bjs. co. ul: British Journal of Surgery 2004; 91: 12922-1299 
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absolute increase in healing of 15 per cent at 12 weeks 
using short-stretch bandage. The required sample size 
(80 per cent power, a=5 per cent) was therefore 400 (2 00 
patients in each arm)5. 
The primary analysis was by intention to treat and the 
time to complete healing of all ulcers on the reference leg 
was compared. Time to censoring was defined as the time 
point at which the follow-up of a patient ceased without 
the ulcer healing. The primary analysis was a simple 
Table 2 Baseline characteristics of patients and ulcers 
E. A. Nelson, C. P. Iglesias, N. Cullum and D. J. Torgerson 
comparison of the healing rates using Kaplan-Meier 
survival curves for the two bandage groups; differences 
between the two curves were tested by means of the log rank 
test16. To investigate the effects of previously identified 
prognostic factors for ulcer healing, a Cox regression model 
was fitted to the data on time to complete healing. Potential 
prognostic factors considered were: treatment centre, ulcer 
area, ulcer duration, ulcer episode, age, -weight, mobilityT, 
ankle mobility and ABPI. Identification of the variables 
SSB 4L6 
Patient characteristics 
Age (years)' 71.3(14.1) (23-96) 71.9(12.3) (25-97) 
Height (m)' 1.68(0.11) (1.42-1.96) 1.69(0.11) (1.45-2.03) 
Weight (kg)' 79.0(20.3) (38.1-142.4) 80.6(19.3) (33.1-139.7) 
Sex ratio (M: F) 80: 112 79: 116 
Ulcer location 
Left leg 82(42-7) 88 (45.1) 
Right leg 108 (56.3) 107 (54.9) 
Patient mobility 
Fully mobile 115(59-9) 123 (63.1) 
Walks with assistance 70(36-5) 72(36-9) 
Immobile 3(1-6) 0 (0) 
Ankle mobility 
Full 128 (66.7) 131 (67.2) 
Reduced 58 (30.2) 59 (30.3) 
None (fixed) 2(1-0) 3 (1.5) 
Short form 12 score` 
Physical component 35.6(7.6) (18.3-52.4) 36.1(8.3) (4.7-55.3) 
Mental component 48.4(12.3) (16.8-68.4) 48-6(12.3) (13.1-7D) 
Leg and ulcer characteristics 
Time since onset of first ulcer (years); 4 (0-75) 3 (0-60) 
No. of episodes (since onset) f 2 (0-64) 2 (0-50) 
Ankle circumference (cm) 23.9(2.9) (16.0-32.3) 23.9(2.9) (16.2-34.0) 
Duration (months) i 3 (0-768) 3 (0-456) 
Area (cm2)1 3-82 (0"35-143.93) 3.81 (0.19-254.58) 
Ankle : brachial pressure index 1.04(0.14) (0.80-1.62) 1.05(0.15) (0.80-1.90) 
Ulcer type 
Sloughy 108 (56.3) 130(66-7) 
Granulating 115(59-9) 127 (65.1) 
Epithelializing 25 (13.0) 27 (13.8) 
Skin features 
Eczematous 49(25-5) 59 (30.3) 
Macerated 26 (13.5) 31 (15.9) 
Cellulitis 15 (7.8) 15(7-7) 
Lipodermatosclerosis 86(44-8) 88(45-1) 
Stratifying variables 
Ulcer area (cm2) 
< 10 - 158 (82.3) 158 (81.0) 
10 34 (17.7) 37 (19.0) 
Previous ulcer on the trial leg 
Yes 114(59-4) 115(59-0) 
No 78 (40.6) 80 (41.0) 
Ulcer duration (months) 
<6 143 (74.5) 138(70-8) 
6 49(25-5) 57 (29-2) 
Values in parentheses are percentages unless indicated otherwise; `values are mean(s. d. ) (range); '-Flues are median (range). 4LB, four-layer bandages; 
SSB, short-stretch bandages. 
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Fig, 1 Flow chart for VenUS I trial. -ALB, four-layer bandages; SSB, short-stretch bandages; ABPI, anlae : brachial pressure index 
that best described the hazard of healing the leg ulcers 
was performed using a procedure described by Collette', 
in which the difference between the - log likelihood 
statistic associated with the models being compared was 
used as the criterion of best model fitting. For completeness 
of the anal sis interactions were investigated, but the 
trial was not designed to test for these. The assumption 
of proportionality of hazards between treament groups 
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was checked using log cumulative hazard plots, that is 
log(- log(S(t)) plotted against logt, where S(t) values were 
the Kaplan-Aleier estimates of the cumulative distribution 
of healing times. Missing data on demographic and clinical 
variables considered in the Cox model were inputed using 
the meari/mode. The largest number of inputed values for 
any single variable was 12 (3.0 per cent) and the minimum 
was one (0.3 per cent). 
Results 
E. A. Nelson, C. P. Iglesias, N. Cullum and D. J. Torgerson 
Table 3 Recruitment at each of the trial sites by treatment group 
Centre 4LB SSB 
Cumbria 35 (17.9) 35(18-2) 
Leeds 54 (27.7) 52 (27.1) 
West London 18 (9.2) 2000-4) 
North Yorkshire 53 (27.2) 55(28-6) 
Falkirk 9(4-6) 6 (3.1) 
Calderdale 4 (2.1) 5 (2.6) 
East London 7 (3-6) 2 (1.0) 
Newmarket 4(2-1) 4(2,1) 
Southport 11 (5-6) 13(6-8) 
Total 195 192 
Of 988 patients assessed for trial eligibility, 387 were 
recruited (Fig. 1). Baseline descriptive data were similar for Values in parentheses are percentages. 4LB, four-layer bandages; SSB, 
both groups (Table 2). Table 3 shows recruitment by centre. short-stretch bandages. 
Time to healing 
The median time to ulcer healing in the 4LB group was 
92 (95 per cent confidence interval (c. i. ) 71 to 113) days, 
compared with 126 (95 per cent c. i. 95 to 157) days in 
the SSB group. Fig. 2 shows the unadjusted Kaplan-Meier 
curves. The difference in the distribution of cumulative 
healing times between the two groups was not statistically 
significant (log rank x2 = 2.46, P=0.117). 
Hazard function 
As -, well as including type of treatment, the final best model 
for the hazard of healing also included treatment centre, 
number of previous episodes, weight, natural logarid-im 
of baseline ulcer area, ulcer duration and ankle mobility. 
Estimated coefficients for each of the explanatory co- 
variates and for the overall adjusted treatment effect are 
shown in Table 4. Having adjusted for these explanatory 
variables there was a statistically significant increase in the 
probability of healing in the 4LB group: hazard ratio 0.72 
(95 per cent c. i. 0.57 to 0.91). 
For completeness of the analysis, interactions between 
treatment and the six relevant co-variates in the model 
were investigated. The only interaction that statistically 
significantly reduced the - 21og likelihood statistic (by 
18.99) was that between treatment and centre (P < 0.015). 
However, given the small number of patients in some of 
the centres, a further analysis was conducted on only the 
four centres with the largest number of patients, namely 
Cumbria, Leeds, West London and North Yorkshire. The 
centre effect was no longer observed in this latter analysis. 
Proportion of ulcers healed 
Most previous trials of compression bandaging have 
not described a survival analysis but reported merely 
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No. at risk 
4LB 195 100 5B 4B 37 25 
SSB 192 114 77 51 43 30 
Fig. 2 Kaplan-leier analysis showing proportion of ulcers 
healed by treatment with four-layer (4LB) and short-stretch 
(SSB) bandages 
the proportion of ulcers healed at 12 or 24 weeks. 
Corresponding data for the present study are shown in 
Table 5. 
Withdrawals and adverse events 
A total of 112 patients withdrew from their original 
bandage allocation (Fig. 1), 46 in the 4LB group and 
66 in the SSB group. Of these 20 (4LB) and 30 (SSB) 
were patient-initiated «-ithdr2 Wals (Fig. 1). There-were also 
«u-%; '. bjs. co_ul: British. Jottrnal crf Surgcrn' 2004; 91: 1292-1299 
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Compression bandaging for leg ulcers 
Table 4 Treatment effect adjusted for explanatorp co-variates 
Standard error Exp (ßl) 
Bandage (SSB versus 4LB) -0.33 0.12 0.72 (0.57,0.91) 
Previous episodes - 0.04 0.02 0.97 (0.94,1.00) 
Weight -0.01 0.00 0.99 (0.99,1-00) 
Ulcer area -0-30 0.06 0.74 (0.66,0.63) 
Duration -0-02 0.01 0.98 (0.97,0.99) 
Ankle mobility 0.43 0.14 1.53 (1.17,2.00) 
North Yorkshire 1 
Leeds -0.00 0"16 0.10 (0-73,1-37) 
Cumbria 0.70 0.17 2.00 (1.43,2.82) 
West London 0.3B 0.23 1.46 (0.93,2.29) 
Southport -0-10 0.25 0.90 (0-55,1-47) 
Falkirk -0-17 0.33 0.85 (0.45,1.60) 
Calderdale 0.41 0.38 1-50 (0.72,3.16) 
East London - 0-63 0.43 0-53 (0.23,1.25) 
Newmarket -0-13 0.52 0.8B (0.32,2.43) 
Values in parentheses are 95 per cent confidence intervals. The sign of 
each regression coefficient (ß; ) gives an indication of whether the hazard 
increases (positive sign) or decreases (negative sign) for subjects with 
higher values of that variable. For continuous co-variates the estimated 
regression coefficient refers to the increase in the log hazard for an 
increase of 1 in the value of the co-variate. SSB, short-stretch bandages; 
4LB, four-laver bandages. 
Table 5 Proportion of legs healed during trial 
Proportion of legs 
ulcer free (%) 
4LB SSB Difference (%} 
12 weeks 46.3 36.7 9-6(0,20)- 
24 weeks 67.5 55-4 12.1 (2,22)t 
halues in parentheses are 95 per cent confidence intervals. 4LB, 
four-layer bandages; SSB, short-stretch bandages. `P = 0.1. 
iP = 0.02. T-test. 
significantly more nurse-initiated withdrawals in the SSB 
group (30 versus 16; P=0.035). A higher proportion of 
patients experienced non-bandage-related adverse events, 
such as health problems, change in ulcer diagnosis or death, 
in the SSB group (39 vernrs 33), but this was not statistically 
significant (P = 0.468). 
Overall, 592 adverse events in 167 patients were classified 
as possibly bandage related (Table 6). More patients had 
clinically diagnosed infected ulcers in the SSB group than 
in the 4LB group (46 and 32 respectively) but this was 
not statistically significant (x22 = 3,1 d. f., P=0.084). In 
the majority' of these patients it was the clinical impression 
of the nurse that the ulcer was infected; ulcers were not 
routinely swabbed for infection as there is no consensus on 
how to define or detect infection in chronic wounds. 
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Table 6 Adverse events possibly related to compression treatment 
4LB SSB Total 
Maceration 18 17 35 
Excoriation 10 14 24 
Skin damage 49 55 104 
Bandage failure 37 36 73 
Ulcer deterioration (including 91 166 257 
infection) 
Skin deterioration 3D 27 57 
Surgical intervention to leg 4 5 9 
Dryness 2 1 3 
Non-surgical hospitalization 2 0 2 
related to leg ulceration 
Occurrence of new ulcer 11 13 24 
Medical event relating to leg 1 3 4 
Total no. of adverse events 255 337 592 
Total no, of patients with 76 91 167 
adverse events 
4LB, four layer bandages; SSB, short-stretch bandages. 
Table 7 Healing rates at various time points in trials comparing 
four-layer and short-stretch bandages 
Proportion of ulcers healed (%) 
12 weeks' 16 weeks 52 weeks 
Reference Year 4LB SSB 4LB SSB 4LB SSB 
Duby et a1.19' 1993 44 40 -- -- 
Scriven et al. 20` 1998 34 41 -- 53 56 
Partsch et al 21 ; 2001 - - 62 73 -- 
Ukat et a!. 22 2003 30 22 -- -- 
VenUSI; 2004 46 37 55 45 78 72 
*In these trials the legs of several patients with bilateral ulceration were 
randomized independently. -'Primar}- outcome in these trials was 
complete healing of all ulcers on trial leg (in the presence of multiple 
ulcers this would tend to underestimate the outcome of ulcer healing), 
4L$, four-layer bandages; SSB, short-stretch bandages. 
Discussion 
This trial demonstrated that venous ulcers treated with 
four-layer bandages were significantly more likely to heal 
than those treated with short-stretch bandages; the median 
time to healing was 34 days less with four-layer bandages. 
There was a statistically significant interaction between 
bandage and centre, but there was no reason to suspect a 
centre effect beforehand and so this had not been planned 
as part of the primary analysis18. The reasons for this 
interaction are unclear. However, heterogeneity in the 
results «was no longer observed when the centres that 
recruited the smallest number of patients were excluded 
from the analysis, suggesting that the interaction effect was 
more likelvv to be a chance finding. 
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Real centre differences relating to nursing factors such 
as previous bandage experience and bandage skill cannot 
be discounted. During the trial set-up phase, training 
in the application of both bandages was provided as 
required. Nurses were more likely to have previous training 
and experience of four-layer bandaging, although it only 
became prescribable in primary care shortly before the 
trial commenced. Future trials should assess the bandage 
application skills of participating nurses at baseline, and 
either reduce the heterogeneity in skill through training or 
analyse the effects of these differences. 
Although fewer ulcers deteriorated during four-layer 
bandaging and there were more nurse-defined ulcer 
infections with short-stretch bandaging, the differences 
between groups were not statistically significant. However, 
the possibility of a real difference in infection rate cannot 
be excluded as the trial was underpowered for this outcome. 
The lack of agreed and objective criteria for defining ulcer 
infection in chronic wounds (which are usually colonized 
by bacteria but not infected) means that nurses relied on 
their clinical impression. Patients in the SSB group were 
at greater risk of infection as their ulcers were open for 
longer, and the (unblinded) nurses applying short-stretch 
bandaging may have been more vigilant in the detection 
and reporting of infection. The significantly higher number 
of nurse-initiated w=ithdrawals in the SSB group may also 
have been related to the lack of blinding of nurses and 
patients. 
Unlike most other wound care trials, time to healing 
was the main outcome measure, rather than proportion 
healed at a specific time point. Any choice of a discrete 
time point is largely arbitrary, and the outcome may 
depend on the time point chosen. Furthermore, patients 
are more likely to want to know ho-, v long their ulcer 
wil] take to heal than whether it is likely to be healed 
in a certain number of weeks. In this trial there was no 
significant difference in the proportion of ulcers healed 
at 12 weeks, but a statistically significant difference at 
24 weeks. The fact that the primary, unadjusted time to 
healing analysis did not identify a significant difference 
between the bandages, -whereas the Cox regression analysis 
determined the difference to be statistically significant, 
is worthy of comment. It is standard practice to adjust 
the analysis for factors deemed likely to influence healing 
(they are also stratifying variables at randomization). Minor 
imbalances between treatment groups at baseline for factors 
such as ulcer duration can affect the precision of the 
estimate of the difference in healing times, and may lead 
to the difference not being statistically significant. In this 
study, adjustment of the analysis for prognostic factors 
did not reverse the main result, but merely increased the 
Copyright 0 2004 Brirish Iournal of Surgery Society Ltd 
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precision of the estimates, with the difference becoming 
statistically significant18. 
Four other randomized clinical trials have compared 
short-stretch and four-layer bandages, two of which 
were published after this trial commenced recruitment 
(Table . D19-22. ill of these trials were small, involving 317 
participants in total (compared with 387 in this trial). 
Only the largest trial by Partsch et al. 21 conducted a 
survival analysis, but no statistically significant difference in 
ulcer healing between the bandages was shown. The other 
studies reported crude proportions healed at 3 or4 months. 
The present study followed patients for a minimum of 
12 months and captured the healing of most ulcers. 
The healing rates achieved in this trial were similar 
to those reported in the four previous studies (Table 7). 
Patient eligibility criteria for the five trials were broadly 
similar. The trial by Ukat et al. 22 included only ulcers with 2 
baseline area greater than 4 cm2, which may in part account 
for the lower rate of ulcer healing at 12 weeks than in the 
other trials. Of studies that reported proportions of ulcers 
healed, with no adjustment for baseline differences, those 
by Duby et al. '9 and Scriven et al. 20 both had an imbalance 
in baseline ulcer area that may have contributed to the final 
differences in healing rates between the bandages. The 
average ulcer size in the study of Partsch et a/. - was lower 
than that in the other trials, which partly explained their 
superior healing rates at 16 weeks. 
Combining data from the VenUS I and Partsch'' 
studies resulted in a pooled hazard ratio that favoured 
four-layer bandaging, although this was not significant: 
hazard ratio 0.85 (95 per cent confidence interval 0.49 
to 1,48). The two trials may in fact have investigated 
the impact of the introduction of a high-level compression 
bandage system into a setting where an acceptable mode 
of compression was already in use. A balanced conclusion 
could be that, where four-layer bandages are currently in 
use, they should remain the system of choice. However, 
short-stretch bandaging may be a useful alternative for 
patients who do. not tolerate the four-la}, er system. Where 
short-stretch bandages are already use, an audit of bandage 
renewal frequency and healing rates'should be conducted 
to ascertain whether such bandaging is cost effective14. 
Ackreaw edgerrents 
The VenUS I collaborators (past and present) are: Una 
Adderley, Peter Anderson, David Berridge, Nicky Cullum, 
Alun Davies, Amanda Farrin, Andrew Garratt Lesley 
Godfrey, Cynthia Iglesias, June Jones, Andrea Nelson, 
Diane Reddington, Julian Scott, Nikki Stubbs, David 
Torgeson and Mike Walker. 
-, r, A-v. bjs. co. uk British Jozrrnal of Surgrn' 2004; 91: 1292-1299 
Compression bandaging for leg ulcers 
This trial "'2S funded by the UK National Health Service 
(\-HS) Research and Development HTA Programme but 
the views and opinions expressed do not necessarily reflect 
, hose of the YHS Executive. Trial-related education 
,;!, as provided by Beiersdorf, a supplier of short-stretch 
bandages. 
The authors thank the participants for taking part in 
the trial; district nurses and hospital outpatient staff for 
recruiting patients into the trial and completing trial 
documentation; research nurses at the initial four centres 
(Una Adderley, Sharon Hailes, Nikki Stubbs and Angela 
Williams) and local investigators at satellite sites Gane 
Best, Sian Coupe, Caroline Do , sett, Val Duncan, June 
Jones, Robert Smith and Gerry Young) for coordinating 
local patient recruitment and helping ensure follow-up 
data were returned. 
peEeterices 
I Dale JJ, Callam MJ, Ruckley CV, Harper DR, Berrey PN. 
Chronic ulcers of the leg: a study of prevalence in a Scottish 
community. Health Bull 1983; 41: 310-314. 
2 Roe B, Cullum N, Hamer C. Patients' perceptions 
of chronic leg ulceration. In Leg Ulrcrs: ý'ý'urcirýg 11rr1Jageimnt, 
Cullum N, Roe B (eds). Scutari Press: London, 1995; 
125-134. 
3 Laing W. Chromic Venous Diseases of the Leg. Office of Health 
Economics: London, 1992. 
4 Bosanouet N. Costs of venous ulcers: from maintenance 
therapy to investment programmes. Pblehulogy 1992; 
I (Suppl 1): 44-46. 
5 Cullum 1T, Nelson EA, Flemming K, Sheldon T. Systematic 
reviews of wound care management: (5) beds; 
(6) compression; (7) laser therapy, therapeutic ultrasound, 
electrotherapy and electromagnetic therapy. Health Technol 
A. cesc 2001; 5: 1-221. 
6 Hampton S. Venous leg ulcers: short-stretch bandage 
compression therapy. Br jNu s 1997; 6: 990-992,994, 
996-968. 
7 Margolis DJ, Berlin JA, Strom BL. Risk factors associated 
with the failure of 2 venous leg ulcer to heal. Arch Dc»wtol 
1999; 135: 920-926. 
8 Hoffart CJ, Simon DA., Franks PJ, Connolly Al, Fielden S, 
Groarke L et al. Randomised trial comparing two four-layer 
bandage systems in the management of chronic leg 
ulceration. Pb/cbology 1999; 14: 139-142. 
Cupv ii! rht S0 ? OW British Journal of Surgery Sociery Ltd 
Published b, -. lohn Wiley 8: Sons Ltd 
1299 
9 . 
Moffatt CJ, O'Hare L. Venous leg ulceration: treatment by 
high compression bandaging. O. ctomýy IW%ound . 
1-1n»nge 1995; 
41: 16-25. 
10 Charles H. Short-stretch bandaging in the treatment of 
venous leg ulcers. I Wound Care 1999; 8: 303-304. 
11 Jenkinson C, Lavte R, Jenlcinson D, Lawrence K, Peterson S, 
Paice C et al. A shorter form health survey: can the SF-12 
replicate results from the SF-36 in longitudinal studies? 
I Public HealthMed 1997; 19: 17/9-186. 
12 Hurst NP, Kind P, Ruta D, Hunter M1, Stubbings A. 
pleasuring health-related quality of life in rheumatoid 
arthritis: validity, responsiveness and reliability of the 
EuroQol (EQ-SD). Br) Rheuntatol 1997; 36: 551-559. 
13 Hyland ME, Thomson B. Quality of life of leg ulcer patients: 
questionnaire and preliminary findings. 1 Wound Care 1994; 
3: 294-298. 
14 Iglesias CP, Nelson EA, Cullum NA, Torgerson DJ on 
behalf of the VenUS team. Economic analysis of a 
randomized trial of two bandages for treating venous leg 
ulcers. Br y Sung 2004; 91: 1300-1306. 
15 Adder ley U. Nelson EA. NT Know how: clinical 
photography. Nurs Times 2000; 96(45): NTT Plus 14-15. 
16 Altman DG. Practical Statistics for . 11edical Research. Chapman 
and Hall: London, 1991. 
17 Collett D. iv! odelting Survival Data in Medical Research. Text in 
Statirtical Science. Chapman and Hall: London, 1994; 78-85. 
18 Grouin JA. 1, Lewis J, Committee for Proprietary Medicinal 
Products (CPMIP). Points to consider on adjustment for 
baseline covariates. Stat; kfed ; 004; 23: 701-709. 
19 Duby T, Cherry G, Hoffman D, Cameron J, 
Dobloff-Brown D, Ryan T.. A randomized trial in the 
treatment of venous leg ulcers comparing short stretch 
bandages, four layer bandage system, and a long stretch-paste 
bandage system. If ännde -A Cunipcrnditcnn of Cliniatl Research 
Practice 1993; 5: 276-279. 
20 Scriven JßM, Taylor LE, WN'ood AJ, Bell PRF, Naylor AR, 
London NJM. A prospective randomised trial of four-layer 
versus short stretch compression bandages for the treatment 
of venous leg ulcers. Ann R Coll Sorg Eng11998; 80: 215-220. 
21 Partsch H, Damstra R), Tazelaar Dj, Schuller-Petrovic S, 
Velders Aj, de Rooij MJ et al. Multicentre, randomised 
controlled trial of four-layer bandaging tvsus short-stretch 
bandaging in the treatment of venous leg ulcers. Vasa 2001; 
30: 108-113. 
22 Ukat A, Konig Al, Vanscheidt W, Munter KC. Short-stretch 
vcrcus multilayer compression for venous leg ulcers: a 
comparison of healing rates. Y Wound Care ? 003; 12: 
139-143. 
«ýr%r. bjs. co. uk British Journal ofSurgeryy 2 004; 9 1: 1292-1299 
Randomized trial v= 
Economic analysis of VenUS 1 ,a randomized trial of two 
bandages for treating venous leg ulcers 
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Background. The study investigated the cost-effectiveness of four-layer and short-stretch compression 
bandages for treating venous leulcers. g 
Methods: Cost-effectiveness and cost-utility analyses were performed using patient-level data collected 
alongside the \TenUS I leg ulcer study. The perspective for the economic analysis was that of the UK 
National Health Service (NHS) and Personal Social Service. The time horizon for the analysis was 1 year 
after recruitment. Health benefit was measured as differences in ulcer-free days and quality-adjusted life 
years (QALYs). 
Resorts: The mean healing time for ulcers treated with four-layer bandages was 10.9 (95 per cent 
confidence interval (c. i. ) - 6.8 to 29.1) days less than that for ulcers treated with short-stretch bandages. 
Mean average difference in QALYs between compression systems was - 0.02 (95 per cent c. i. - 0.08 
to 0.04). The four-layer bandage cost a mean of £227.32 (95 per cent c. i. £16.53 to £448.30) less per 
patient per year than the short-stretch bandage. 
Canctusior On average, four-layer bandaging was associated with greater health benefits and lower 
costs than short-stretch bandaging. 
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Leg ulceration remains a common condition, particularly 
in older women. Studies in people with leg ulceration 
suggest that quality of life is significantly reduced owing to 
problems with activity and mobility, pain and lower levels 
of self-esteem'. 
The different compression bandage systems used to 
treat leg ulcers have different performance and economic 
characteristics which make their comparison in a large 
randomized trial worthwhile. Two high-compression sys- 
tems are generally employed. The short-stretch system is 
widely used in continental Europe and the four-layer high- 
compression bandage system is used in the Ü-K. Although 
both methods apply high compression, the purchase costs 
of short-stretch bandages are substantially lower. This 
study reports an economic analysis of the UK National 
Health Service (NHS) HTA programme-funded VenUIS I, 
a large multieentre pragmatic randomized trial that com- 
pared the clinical and cost effectiveness of four-layer and 
short-stretch compression bandages for healing venous leg 
ulcers. 
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The perspective for the economic analysis was that of the 
UK NHS and Personal Social Sen-ice3. The time horizon 
for the analysis was I year after recruitment. 
Study description 
Full details of the VenUS I study have been described 
elsewhere4. In brief, 387 patients were recruited to a 
pragmatic randomized trial from nine geographical areas in 
Britain. Patients with new, existing or recurrent ulceration 
of at least 1 week's duration, at least 1 cm in diameter, and 
with an ankle : brachial pressure index of at least 0.8 were 
eligible. Patients with diabetes and those «-hose ulcers had 
previously failed to improve while using one of the trial 
bandages were excluded. 
The mean age of the patients recruited was 71 (range 
23-97) ), ears. The majority of patients in this trial 
(81.7 per cent; 316 of 387) had a reference ulcer with 
an area of 10 cm2 or less. 
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Data collection 
Data on the use of resources, including the reason for 
the visit and the total number of new bandages used, 
were collected prospectively by nurses during visits for the 
primary purpose of leg ulcer care. A questionnaire on health 
and social care resource use was completed monthly by 
patients, indicating how many times in the precious month 
they had used health services (for example, seen a doctor 
or nurse, received care in hospital, outpatients, community 
clinic or their own home). As this was a pragmatic trial, the 
schedule of patient visits was not dictated by trial protocol, 
except to say that patients should be seen at least once a 
week. 
Cost estimation 
Four different types of resource were included in the 
estimation of costs: number of nurse visits, number of 
doctor visits, number of hospital visits, and number of 
bandages used. Information regarding wound cleansers, 
number and size of primary and secondary dressings, 
and the use of skin preparations was not included in 
the economic analysis as these were common to both 
compression systems, so their effect should cancel out in 
the incremental analysis of costs'. 
All costs were measured using 2001 prices. Cost and 
duration of nurse and doctor visits were estimated using 
the unit cost of community-based healthcare staff 6. In the 
base-case analysis it was considered that a nurse visit for 
leg ulcer care took 22 min in a clinic and 40 min at home'. 
Costs of hospital visits u, -ere based on average outpatient 
costs per day'. Acquisition costs of the different bandage 
systems were taken from the retail prices quoted in the 
Bi itish National Fol7nula, y7. Unit cost estimates used in the 
economic analysis are described in Table 1. 
Health benefits 
Health benefits ; giere measured in two ways. First, 
Kaplan-Meier estimates of mean time to healing over 
12 months in each trial arm were calculated. These in turn 
were used to estimate the difference in ulcer-free days from 
the trial data on the basis of intention to treat4. Second, 
quality-adjusted life years (Q_gLYs) were estimated using 
patients' responses to the EuroQol (EQ) 5D questionnaire. 
EQ-SD scores for each patient at baseline and every 
3 months thereafter during the first -, tear of follow-up were 
calculated using liK social tariffs8. Q_4LYs were calculated 
for each patient using the area under the curve defined 
by his or her EQ-S D scores over time. To account for 
censoring, QALYs were adjusted by the Kaplan-, Mier 
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Table 1 Unit costs and sources 
Unit cost' Reference 
Nurse Visit 
Home (40 min) £37 6 
Clinic (22 min) £15 6 
Doctor visit 
Home (13.2 min) £59 6 
Clinic (12.6 min) £26 6 
Hospital visit (outpatient) other £74 6 
reasons 
Four-layer bandage system 
Soffbanc' £0.61 7 
Softex'I' £0.60 7 
Velband/Soffband' £0.72 7 
Softcrepe" £1.18 7 
Setocrepe® £1.12 7 
Crepe £0.87 7 
Utepress6 £3.44 7 
Elset° £2.46 7 
Co-plus' £2.85 7 
Coban® £3.01 7 
Four-layer bandage system (kit) £8.88 Smith & Nephew 
Short-stretch bandage system, 
Comprilan('/Rosidal K 12"' £4.08 7 
Compriian'/Rosidal K 10`' £3.43 7 
Comprifanl/Rosidal K 121 £3.08 7 
Soffbane' £0.61 7 
Softex" £0.60 7 
Velband® £0.72 7 
Other bandages 
Setopress'3' £3.29 7 
Tensopresse £3.24 7 
Surepress&' £3.18 7 
Tubigrip4D £9.00 www. westonshealth. 
co. uk 
't'ear of pricing 2001. tRosidal K"' cannot be prescribed by the INTIS 
but 
could be bought over the counter he nurses or patients, thus it was 
included in the costing exercise. The official SSB in the VenLS I study 
was Comprilan'`. 
Soffban', Soffcrepe', Litepress", Co-Plus', Tensopresst, Smith ýC 
Nephew, Hull, UY.; Vclband", Johnson 3, Johnson, Berkshire, UK; 
Softexe', Setocrepe', Elser3, Setopress", Tubigrip4, SSL, Cheshire, UK; 
Coban', 3M, Leicester, UK; Comprilan", Beiersdorf, Bucks, UI:; Rosidal 
K", Vernon-Carus, Preston, UX Surepres?, Conw°atec, Uxbridge, L-1ti. 
estimates of patients' survival over a year using the method 
of Lin et al. 9. 
Economic evaluation analyses 
The two compression systems were compared in terms 
of both the costs and the health benefits associated with 
their use. The exact form that an economic evaluation 
takes depends mainly on the way in which health benefits 
associated with the technology are measured, so that 
the measurement is both clinically and economically 
relevant10. In this trial two different types of analysis 
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were conducted: a cost-effectiveness analysis in which 
health benefits were measured in `natural' units (ulcer-free 
days), and a cost-utility analysis in which health benefit 
measurement was adjusted by changes in quality of life. 
Taken that the analysis concerned a single year, both costs 
and benefits were left undiscounted. 
Statistical analysis 
The economic analysis was conducted using Stata 7. The 
quantity of resources used per month «was summarized 
using simple descriptive statistics. Given the censored 
nature of cost data (information regarding a patient's 
resource use may be truncated at any point in time before 
the end of the study because of healing of the ulcer, loss to 
follow-up, or patient's request), the method of Lin et al. 9 
was used to estimate mean total treatment cost in each 
trial arm. The event of interest for this analysis was ulcer 
healing; it was assumed that no further costs occurred after 
an ulcer had healed. 
To account for the skewed nature of cost data, 
95 per cent confidence intervals (c. i. ) for the adjusted total 
cost and the average mean cost difference between bandage 
treatments were estimated using non-parametric boot- 
strapping techniques (1000 replications). Bias-corrected 
and accelerated confidence intervals were estimated". 
Non-parametric bootstrapping techniques were also used 
to estimate the confidence interval around the estimated 
mean difference in ulcer-free days, and mean difference in 
Q_ALYs. Linear multiple regression was used to adjust the 
differential QALYs for any imbalances in the EQ-SD score 
at baseline. 
Sensitivity analysis 
The total costs of compression therapy in the treatment 
of venous leg ulcers are drive' mainly by three items: the 
number of nurse visits, the setting in which leg ulcer care 
is delivered, and number of bandages used. The number 
and setting of nurse visits required by 2 patient are issues 
mainly related to the way in which service is provided in 
the UK, so no sensitivity analysis on these mo variables 
was justified. In urban areas patients with a venous leg 
ulcer are often treated in a specialized clinic, whereas in 
rural areas ulcers are treated mainly by domiciliary visits 
from community nurses. To explore the robustness of 
the base-case analysis results, the scenario approach to 
sensitivity analysis was used'2. '3. Three clinically plausible 
modes of bandage use and supply were explored. In the first 
scenario, for all the patients allocated to treatment with 
the short-stretch bandage, the history of resources used 
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per month was analysed individually. Each time bandages 
were replaced, the quantity of new bandages reported was 
replaced with the patient's reported minimum number of 
bandages used over the interval of treatment. The second 
scenario considered the possibility of acquiring the four- 
layer compression system as a kit. though the four-layer 
lcit was not available on prescription in the UK during the 
trial, leg ulcer clinics commonly purchase kits and supply 
them from stocks. In the third scenario, the two options 
described above were considered simultaneously. 
Cost-effectiveness planes were used to explore changes 
in the distribution of the incremental costs and health 
benefits associated 'with the different sensitivity analyses. 
The level of uncertainty associated with the cost- 
effectiveness of the short-stretch bandage compared 
with the four-layer bandage was explored using cost- 
effectiveness acceptability curves. Acceptability curves 
represent the probability of an alternative being cost 
effective for a range of willingness to pay values for an extra 
'4 unit of health benefit associated with the alternative. 
Resu is 
Information from 387 patients was included in the analysis, 
195 allocated to the four-layer bandages (4LB) group and 
192 allocated to the short-stretch bandages (SSB) group. 
Effectiveness 
In a Kaplan-Meier survival analysis of cumulative healing 
times there was a trend towards increased healing in the 
4LB group, although this was not statistically significant 
(log rank x22 = 2.46, P=0.117). Analysis using a Cox 
proportional hazards model to adjust for the effects of other 
variables that may influence healing (treatment centre, 
baseline ulcer area, duration) episodes, ankle mobility, 
weight) suggested a statistically significant treatment effect 
in favour of four-layer bandaging. The hazard ratio for 
healing, 0.72 (95 per cent c. i. 0.57 to 0.91), suggested that 
individuals in the SSB group had a significantly lower 
probability of healing than those in the 4LB group. 
Costs 
Descriptive statistics of monthly volume of resources used 
in both bandage groups are shown in Table 2. Between 
one and two extra nurse visits per month were required 
by patients in the SSB group. No marked differences in 
monthly volume of other resource items were observed 
between groups. 
A summary of the adjusted total mean annual costs 
estimated for both treatments is presented in Table 3. 
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Table 2 Monthly resources used per trial arm during the first year These estimates showed a statistically significant difference 
of follow-up in favour of the four-layer bandage. Treatment with 
four-layer bandages cost a mean £227.32 (95 per cent 
Resource 41-13 SSB 
c. i. £16.53 to £448.30) less per patient per year. There 
Nurse visits was no statistically significant difference in Kaplan-Meier 
.} Me 
5.14(3-26) '03(4 6-03(4-09) . 09) estimates of the mean time to healing over a year; ulcers 
in 
dian ( range) Median ( 
Doctor visits 
4(0-21) 5(1 - 29) 
the 4LB group healed a mean of 10.9 (95 per cent c. i. - 6.76 
Mean(s. d. ) 0.23(2.17) 0.34(1.44) to 29.06) days before those in the SSB group (Table 3). 
Median (range) 0 (0-62) O (D-14) \-Zean average adjusted QALYs gained per bandage Hospital visits 
group are shown in Table 3. Having adjusted for baseline Mean(s. d. ) 0.40(1.04) 0 33(1.10) 
Median (range) 0 (0-7) 0(0-15) utility scores and censoring, there was no statistically 
Wool bandages significant difference in the QALYs after the first year. 
.) Me 4.93(3.55) 5.57(5.61) Individuals in the 4LB g1-oup had, on average, a better dian (range) Median 
e Crepe bandages 
4(o-2z} 4(0-54) 
Quality of life than those in the SSB group; the annual 
Mean(s. d. ) 3.34(2-83) 0.79(2.30) difference in Q_ALYs was - 0.0? (95 per cent c. i. - 0.08 to 
Median (range) 3 (0-18) 0 (0-20) 0.04). 
Elset bandages The base-case analysis showed that four-layer bandaging Mean(s. d. ) 3.57(2.94) 0.59(1.86) 
Median (range) 4 (0-20) O(D-17) Was the superior strategy, and was associated on average 
Cohan bandages with a greater health benefit and lower costs than the short- 
Mean(s . d. ) . 08(3 . 02) 4.08(3-02) . 83(2 . 22) 0.83(2-22) stretch bandage; an incremental analysis was therefore not Median ( range) 4(0 20) - 0(0 -1 6) 
Justified. Cornprilan 12 bandages 
Mean(s. d. ) 0.00(0.14) 0.48(2.31) 
Median (range) 0 (0-3) 0 (0-25) 
Comprilan 10 bandages Sensitivity analysis Mean(s. d. ) 0-Oß(0.92) 2.71(4 "B8) 
Median (range) 0 (0-16) D(0-52) 
Comprilan 8 bandages Point estimates of the difference in costs between four- 
Mean(s. d. ) 0.01(0.19) 0.60(1.86) layer and short-stretch bandages for the three scenarios Median (range) 0 (0-4) O (D-18) 
are shown in Table 4. In all three scenarios the difference Other bandages 
Mean(s. d. ) 0.03(0.30) 0.03(0.41) in total treatment cost over a year was smaller than that 
Median (range) 0(0-5) 0 (0-9) estimated in the base-case scenario (£227.32). In none of 
the three scenarios considered was the difference in costs 
ALB, four-layer bandages; SSB, short-srreuh bandages. statistically significant at the 5 per cent level (Table 4). 
Table 3 Mean adjusted annual costs and health benefits 
4LB 
Costs (2) 1298-41 (1187.83,1471.9D) 1525-73 (1373.92,1716.66) 227.32 (16.53,448.30) 
Time to heal (days) 96.7 (85.3,111-6) 107.6 (95.9,122-2) 10.9 (- 6.8,29.1) 
QALYs 0.69 (0-66,0.74) 0.67 (0.63,0.72) - 0.02 (- 0.08,0.04) 
Values in parentheses are 95 per cent bias-corrected and accelerated confidence intert-als. 4LB, four-layer bandages; SSB, short-stretch bandages; QALY, 
quality-adjusted life year. 
SSB Difference 
1303 
Table 4 Mean adjusted annual costs for different scenarios 
4L6 - SSB Difference 
First scenario (£) 
Second scenario (£) 
Third scenario (£) 
1298.41 (1187.83,1471.90) 
1385.92 (1270.11,1565.79) 
1385.92 (1270.11,1565.79) 
1486.47 (1339-77,1666-03) 
1525.73 (1373.91,1716.66) 
1486.47 (1339.77,1668.03) 
188"D6 (-15.36,41 D"DO) 
139-81 (- 62.11,369.09) 
1 DO"55 (-105.13,321.62) 
Values in parentheses are 9; per cent bias-corrected and accelerated confidence intervals. 4LB, four-layer bandages; SSB, short-stretch bandages. 
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Fig. 1 Cost-effectiveness plane (sensitivit 7 analysis) 
The robustness of the results was tested using a scenario 
approach to sensitivity analysis, which indicated that even if 
the quantityof short-stretch bandages used in the treatment 
of a patient was lower than that reported in this trial, and 
the acquisition price of the four-layer bandage was at its 
maximum level, on average the four-layer bandage was still 
the dominant alternative. Cost-effectiveness planes for the 
three sensitivity analysis scenarios are compared with the 
base-case analysis in Fig. 1. 
The main effect of considering feasible variations in 
the number of bandages used and the unit costs of the 
compression systems was to reduce the mean difference in 
costs between the two treatments, shifting the distribution 
of point estimates towards the third quadrant, where 
short-stretch compared with four-layer bandaging was still 
associated with less health benefit but now also fewer 
costs. However, in all three scenarios the vast majority of 
point estimates fell in the upper left quadrant, suggesting 
that even under these conditions four-layer bandaging was 
a dominant strategy. The cost-effectiveness acceptability 
curve for the short-stretch bandage suggested that, even for 
considerably high willingness to pay values for an ulcer-free 
15 
25 
day, the short-stretch bandage wwas associated with only a 
20 per cent probability of being cost effective. 
Discussion 
Venous leg ulcer is a costly chronic condition. Management 
is currently provided within specialized clinics and in the 
home by community nurses. Given the large amount of 
human and medical resources that such services demand, 
it is essential to ensure that provision of healthcare 
is clinically and economically efficient. Compression 
therapy is considered to be the key component in the 
effective treatment of venous ulcers. The cost-effectiveness 
of alternative methods of service provision has been 
investigated previouslyh'. This analysis investigated the 
cost-effectiveness of short-stretch compared with four- 
layer bandaging, using two different methods of measuring 
the health benefit associated with these two compression 
systems: natural units (cost-effectiveness) and quality of life 
(cost-utility anal)7sis). 
Both economic analyses showed that short-stretch 
bandaging was inferior to four-layer bandaging; on average 
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short-stretch bandaging Was associated with smaller health 
benefits and greater costs. Patients in the 4LB group healed 
a mean of 10.9 days before those in the SSB group and the 
mean average difference in QALYs between compression 
systems was 0.02. The mean difference in total cost betr; 'een 
compression systems was M7-32 per patient per year in 
favour of four-layer bandaging. A. lthough some of these 
differences were not statistically significant at the 5 per cent 
level, it has been argued, from an economic perspective, 
that decisions should be made on the basis of the expected 
mean difference in health benefits and costs between the 
alternative programmes under evaluation, irrespective of 
their statistical significance'6. 
On average, patients in the SSB group required one more 
visit per month than patients in the 4LB group. Across all 
centres most care was delivered via domiciliary visits. This, 
combined with the substantial difference between the cost 
of clinic (£l5) and home (£37) care, meant that even slight 
imbalances in the number of visits between the bandage 
groups resulted in a substantial increase in the total costs 
of the treatment. According to the information from the 
manufacturers, both compression systems were able to 
remain in place for 1 week, so there was no reason to 
believe that there would be an imbalance in the number 
of visits. Consequently no detailed information regarding 
the reasons for the increased frequency of nurse visits 
was collected. In future studies, the factors that determine 
the frequency of nurse contacts with patients should be 
investigated. 
The number of short-stretch bandages used per patient 
per month was substantially higher than that recommended 
by the manufacturers; this recommendation was based 
on the effect of laundering on bandage performance. 
According to nurse reports, the higher usage of these 
bandages was mainly explained by the characteristics of the 
study population; elderly patients often found it difficult 
to wash the bandages, and nurses preferred not to reuse 
the bandages from patients with slough), exuding ulcers. 
This showed the importance of undertaking an economic 
analysis alongside a clinical trial, as these economically 
significant data were only revealed within the context of 2 
pragmatic trial. 
The centres that participated in this trial had a 
range of methods of delivering venous leg ulcer care in 
the community. Specialist leg ulcer services, integrated 
vascular services and community nurse-led services were 
all represented, and so the findings of this study can 
be applied across the LK. However, when attempting 
to extrapolate from these results to individual leg ulcer 
services there are important considerations to be made, 
particularly with regard to e. sting skills and competencies 
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in bandage application as the relative clinical effectiveness 
of the compression systems is likely to be heavily influenced 
by these factors. 
In this analysis the relative cost-effectiveness of two 
compressions systems to resolve an acute episode of 
ulceration «las explored over a 1-year internal. Given the 
chronic nature of venous leg ulcers, it can be argued that 
to explore the cost-effectiveness of alternative methods 
of managing venous leg ulcers one should take into 
account not only the resolution of isolated episodes of 
ulceration, but also consider the health benefits and costs 
associated with preventive measures, and the frequency of 
new ulceration episodes. Such an analysis should be the 
subject of future modelling exercises, rather than the result 
of an evaluation conducted alongside a randomized study. 
The present analysis supported the use of four-layer 
bandages in preference to short-stretch bandages, on the 
basis of clinical and economic superiority. Ho«wev-er, for 
centres in which short-stretch bandaging is currently used, 
a careful audit of the frequency of district nurse visits 
and healing rates is recommended. If the size of a leg 
ulcer is reducing, but domiciliary visits for short-stretch 
rebandaging are required more than once per week, then 
the care is not cost effective. However, if the ulcer size 
is reducing, and patients and/or their carers are able to 
launder and reapply the bandage, then the short-stretch 
bandage is likely to become cost effective. Short-stretch 
bandaging remains a reasonable alternative for patients 
who prefer it or will not tolerate four-layer bandages. 
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Comprehensive Decision-Analytic 
Model and Bayesian 
Value-of-Information Analysis 
Pentoxifylline in the Treatment of Chronic Venous 
Leg Ulcers 
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Abstract Objective: To conduct a Bayesian value-of-information analysis of the cost 
effectiveness of pentoxifylline (vs placebo) as an adjunct to compression for 
venous leg ulcers. 
Methods: A probabilistic Markov model was developed to estimate mean clinical 
benefits and costs associated with oral pentoxifylline (400mg three times daily) 
and placebo. Clinical data were obtained from a systematic review and 
synthesised using Bayesian methods. The decision uncertainty associated with the 
adoption of pentoxifylline as well as the maximum value associated with further 
research were estimated before and after the completion of the largest `definitive' 
treatment trial. Resource use was obtained from a UK national audit and unit costs 
applied (£, 2004 values). 
Results: The prior and posterior analyses suggest that pentoxifylline is a domi- 
nant therapy versus placebo. In the prior analysis, patients in the pentoxifylline 
group healed an average of 8.28 weeks quicker than patients in the placebo group 
(95% credibility interval [CI] 1.89,14.56), had a 0.02 gain in QALYs (95% CI 
-0.12,0.17) and an average reduction in cost of £153.4 (95% CI -53.11,354.9). 
Estimates of the uncertainty surrounding the cost effectiveness of pentoxifyl- 
line and the value of perfect information in both analyses did not suggest further 
research was justified. In the prior analysis, for willingness-to-pay values of £0, 
£100 and £500 per QALY gained, the estimated values of perfect information 
were £ 128 200, £ 127 100 and £ 126 700, respectively. 
Incorporation of the information from the largest randomised controlled trial 
on pentoxifylline did improve the estimate of the clinical effect associated with 
this drug; however, the variation was not large enough to reverse either the 
decision regarding the dominance of pentoxifylline or the maximum value associ- 
ated with further research. 
Conclusion: Bayesian value-of-information analysis represents a valuable tool 
for healthcare decision making. Had the results from this analysis been available 
before the largest trial was funded, a more efficient allocation of research and 
development resources could have been made. 
466 Iglesias & Claxton 
Randomised controlled trials (RCTs) are consid- 
ered the `gold standard' for collecting information 
about the clinical and cost effectiveness of health- 
care interventions. However, large confirmatory 
RCTs are often expensive and difficult to undertake, 
and can take considerable time. In therapeutic areas 
where a definitive treatment trial is not available, 
systematic reviews and meta-analyses of existing 
evidence from (often insufficiently powered) trials 
are commonly used as an interim solution to the lack 
of evidence. However, it is widely believed that the 
results of a systematic review and meta-analysis 
ought to be confirmed subsequently in a large rigor- 
ously designed RCT. 
The replication of RCTs has frequently been 
justified by the need to demonstrate the clinical 
effectiveness of a treatment at conventional levels of 
statistical significance (i. e. p<0.05). However, it 
has been argued that, in the context of healthcare 
decision making, traditional rules of statistical infer- 
ence, from either a Bayesian or frequentist view- 
point, are not consistent with the objective of a 
publicly funded healthcare system that operates 
under a fixed budget)] If the objective is to max- 
imise health benefit within a given budget, decision 
makers in the health sector should base their deci- 
sions regarding the adoption of new health technolo- 
gies on the mean `net benefit', which is defined as a 
linear function of the expected clinical benefits and 
costs associated with the technology. [1°21 By re- 
jecting a new health technology associated with a 
positive mean `net benefit' merely on the grounds of 
a lack of statistical significance, healthcare decision 
makers will be automatically surrendering the po- 
tential mean clinical benefit associated with the new 
technology. ['] 
Research funding bodies (such as the UK NHS 
Health Technology Assessment Programme and the 
Medical Research Council) routinely consider the 
scientific excellence of a research proposal, and 
often require evidence of the degree of uncertainty 
regarding clinical and cost effectiveness of health 
technologies through systematic reviews. An esti- 
mate of the actual value associated with the reduc- 
tion of this uncertainty is not a formal requirement. 
This current procedure ignores the fixed cost of 
research and places an unlimited value on its associ- 
ated benefits, that is, the reduction in decision uncer- 
tainty. If the maximum value associated with the 
reduction in decision uncertainty is exceeded by the 
fixed cost of research, the acquisition of further 
information is unlikely to be an efficient use of 
already scarce research and development re- 
sourcesJl1 Furthermore, undertaking research in one 
therapeutic area has a direct opportunity cost be- 
cause it deprives another research area of vital eval- 
uative resources. 
It has been argued that the question of whether 
additional clinical trial research is needed ought to 
be informed by an assessment of the relative costs 
and benefits of undertaking such a trial. 131 A formal 
framework, based on decision-analytic models and 
Bayesian value-of-information analysis, to estimate 
the maximum value associated with additional re- 
search has been proposed. [4,5 This approach can 
inform two key stages in the process of deciding 
whether to recommend the adoption of a health 
technology: (i) whether a health intervention should 
be considered clinically and cost effective given 
existing information and; (ii) whether a request for 
further information is justified. In other words, this 
framework enables healthcare researchers to address 
decisions regarding an efficient provision of health- 
care services based on available evidence, and helps 
to identify those areas where the acquisition of fur- 
ther information, through primary research, is more 
likely to reduce the uncertainty surrounding the de- 
cision about whether or not to adopt a new health- 
care technology. 
In this paper we demonstrate the application of 
the above methods by conducting a Bayesian 
value-of-information analysis to evaluate the cost 
effectiveness of oral pentoxifylline (400mg three 
times daily) compared with placebo as an adjunct to 
compression therapy in the treatment of chronic 
venous ulcers. The objectives of this analysis were 
as follows. 
1. To explore the decision uncertainty regarding the 
cost effectiveness of oral pentoxifylline (400mg 
three times daily), based on the available evidence 
before the publication of the largest study conducted 
in this area; we shall refer to this as the `prior 
analysis'. 
2. To evaluate the efficiency of the decision made to 
mount the largest RCT on oral pentoxifylline 
(400mg three times daily). 
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3. To determine the contribution of the findings 
from the latter trial to reduce the decision uncertain- 
ty regarding the cost effectiveness of oral pentoxi- 
fylline (400mg three times daily); we shall refer to 
this as the `posterior analysis'. 
4. To provide information regarding future research 
on pentoxifylline. 
Case Study 
Venous leg ulcers are a chronic and recurrent 
condition affecting approximately 1.5 per 1000 of 
the UK population aged >_ 18 years or 62 000 people 
with a history of leg ulceration at any time. [61 Ve- 
nous leg ulcers are managed primarily by nurses in 
hospitals, leg ulcer clinics and in the community. In 
1992 the total annual cost for the UK NHS for 
venous ulcers was estimated at around £400 mil- 
lion. [7] 
Current practice in the treatment of venous leg 
ulcers involves the application of topical agents (e. g. 
wound dressings, hydro gels, etc. ) and compression 
therapy (e. g. two-, three- and four-layer bandages, 
Unna's boot or stockings). Whilst the aetiology of 
the disease has not been explained fully, most leg 
ulcers are associated with venous disease. Deep vein 
thrombosis is thought to cause damage to the deep 
veins, leading to venous insufficiency and ulcera- 
tion. Whilst no pharmacological treatment is indi- 
cated for venous leg ulcers, it has been suggested 
that improving venous deficiencies may accelerate 
ulcer healing. N Pentoxifylline, a drug that helps' 
blood flow, has been postulated as a potential phar- 
macological agent to speed up the healing process of 
venous leg ulcers. A systematic review of the evi- 
dence on pentoxifylline for the treatment of venous 
leg ulcers concluded that this drug provides addi- 
tional benefits to compression and is possibly effec- 
tive for patients not receiving compression. f93 
The largest RCT conducted on pentoxifylline to 
date was published in 1999 by Dale et a1. f10) Prior to 
the dissemination of the results from this study, 
three RCTs provided evidence on the effectiveness 
of oral pentoxifylline (400mg three times daily), as 
an adjunct to compression, relative to placebo in the 
treatment of chronic venous leg ulcers (table I). 
These three studies randomised 232 participants in 
total. ýl1-131 A statistically significant positive effect 
was only reported in the study by Colgan et al. 021 
However, using a Bayesian random baseline fixed- 
effect meta-analysis to estimate a pooled odds ratio 
of healing at 24 weeks with the data from these three 
studies, a statistically significant benefit for pentoxi- 
fylline versus placebo was calculated at 2.12 (95% 
credibility interval [CI] 1.29,3.34). However, the 
small sample sizes, unclear descriptions of 
randomisation method and short follow-up periods 
reported raised concerns regarding the validity and 
reliability of the findings from these studies. 
The study by Dale et al., 1101 which addressed 
many of the methodological shortcomings associat- 
ed with previous studies, found a positive but non- 
statistically significant effect for pentoxifylline (vs 
placebo) on ulcer healing rates (table I). When the 
results from Dale et al. 1'°1 were included in the meta- 
analysis described above, the estimate of the pooled 
odds ratio of healing at 24 weeks changed to 1.93 
(95% CI 1.41,2.61). Whilst the results from the 
trials by Falanga et al. )131 and Dale et a1. E10) were 
published in the same year (1999), we shall assume 
for illustrative purposes that the findings from 
Table I. Main characteristics of randomised placebo-controlled studies on pentoxifylline (Pent) 1200mg daily in the presence of compres 
Sion for the treatment of venous leg ulcers 
Studya Intervention Compression type (nb) 
group (n) 
Mean age 
(y) 
Follow-up 
(wk) 
Ulcer healing 
Pent placebo 
Falanga et al. 1133 Pent (83) Unna's boot (45) 58 24 62/83 28/45 
Colgan at aIJ12 Pent (38) Two-layer system (42) 71 24 23/38 12/42 
Schurmann and Eberhardt"] Pent (12) Unspecified (12) 65 8 2/12 3/12 
Dale et al. 1101 Pent (101) Single- or four-layer system (99) 69 24 65/101 52/99 
a The prior analysis included data from Falanga et al., t13) Colgan et al. t121 and Sch urmann and Eberhardt. ["] The posterior analysis 
included data from Dale et al. J101 in addition to the other three studies. 
bn refers to number of patients treated with compression alone in the placebo group; all patients treated with pentoxifylline also 
received compression measures. 
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Falanga et al. I131 were available at the time that the 
Dale et al. J10 study was submitted for funding. 
Methods 
A probabilistic Markov model was used to esti- 
mate expected mean clinical benefits and costs asso- 
ciated with two alternative treatments: (i) oral 
pentoxifylline 400mg three times daily in addition to 
`usual wound care' (compression therapy and 
wound dressings); or (ii) placebo in addition to 
`usual wound care'. Venous leg ulceration prognosis 
was represented by three mutually exclusive health 
states: healed, non-healed and death (figure 1). Pa- 
tients were allowed to transit between health states 
at weekly periods. Leg ulceration recurrence was 
represented by allowing patients to transit between 
the healed and unhealed states in both directions. 
Total follow-up for the base-case analysis was 52 
weeks (it was considered unlikely that pentoxifyl- 
line would be used for >1 year). Given that the time 
horizon for the analysis was 1 year, estimated total 
costs and benefits were not discounted. Table II 
describes the sources and characterisation of all 
stochastic and deterministic model parameters. 
To simultaneously address the four stages of 
decision-analytic modelling'f51 (systematic review of 
relevant data incorporating a meta-analysis, estima- 
tion of model inputs, sensitivity analysis for data and 
model specifications and evaluation of the model), a 
comprehensive decision-analytic model was con- 
structed and evaluated using Markov Chain Monte 
Carlo simulation implemented in the specialist 
software WinBUGS. 1201 
Systematic Review and Meta-Analysis 
The search strategy described in the Cochrane 
systematic review193 of pentoxifylline for venous leg 
ulcers was used to identify all existing RCTs pub- 
lished before January 2000 comparing oral pentoxi- 
fylline with placebo in addition to compression. The 
Dale et al. [") study was published in October 1999 
and was therefore included in the review. 
Four RCTs were identified (see table 1). [10-131 In 
the prior analysis, the results from Schurmann and 
Eberhardt, M) Falanga et al. J13) and Colgan et al. J12) 
were included in a meta-analysis performed on the 
odds-ratio scale. Despite some expected variability 
between studies, there was no reason to believe that 
the effectiveness of pentoxifylline should differ be- 
tween trials. The potential heterogeneity was re- 
flected into the meta-analysis by using a random- 
effect model to estimate the natural logarithm of the 
pooled odds of healing in the placebo group and a 
fixed-effect model to estimate the natural logarithm 
of the pooled odds of healing with pentoxifylline. A 
posterior analysis that included the data from Dale et 
al J103 was then conducted to update the pooled odds 
ratio of healing. 
The structure of the Bayesian random baseline 
fixed-effect meta-analysis used is outlined in equa- 
tion 1: 
Placebo Pentoxifylline 
ri` - binomial(n!, pi) ri' -- binomial(ni, pi ) 
logit(pi )=6; 
Ar - normal(µ, ti2) 
or` = exp(µ) 
µ- nornuzl(0.0,1, OE - 6) 
2_ 1 
62 
logit(p) =6i+ 
or` = exp(µ +ý) 
E -- normal(0.0,1. OE - 6) 
ß- normal(0.2,400 ) 
Fig. 1. Stochastic Markov model: graphical description of health 
states for venous leg ulceration. 
(Eq. i) 
Where '' is the number of healed individuals of 
n= in the ith study in group j= placebo (c) and 
pentoxifylline (t); Pi is the estimated healing rates in 
the ith study and jth groups; ors are the odds of 
healing in the jth groups; and ß2 is the between- 
study baseline variability or heterogeneity. This pa- 
rameter estimates the variation in the healing rates 
observed in the placebo groups that may exist be- 
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Table II. Characterisation of model parameters (costs are in 2004 values) 
Parameter Prior distribution Source 
Stochastic variables" 
Odds of healing µ- normal(O. 0,1.0E - 6) 
S-- normal(0.2,400) 
Probability of death g- normal(0.0,1.0E - 6) 
Probability of recurrence µ- normal(0.0,1.0 - 6) 
Probability of using alternative types d- multinomial(p, n) 
of dressings; six alternativesb p- dirichlet(1,1,1,1,1,1) 
n= total number of responders 
Probability of using alternative types b- multinomial(p, n) 
of bandages; nine alternativesd p -- dirichlet( 1,1,1,1,1,1,1,1,1) 
n= total number of responders 
Number of visits; three frequenciese v- multinomial(p, n) 
p- dirichlet(1,1,1, ) 
n= total number of responders 
Nurse visit duration; three categories' t- multinomial(p, n) 
p -- dirichlet(1,1,1, ) 
n= total number of responders 
Nursing grade; five different gradeso g -- multinomial(p, n) 
p- dirichlet(1,1,1,1,1) 
n= total number of responders 
Visit setting; two potential settingsh s- mu/tinomial(p, n) 
p- dirichlet(1,1) 
n= total number of responders 
Deterministic variables 
Bandage mean cost (£)d 3.07,2.65,3.04,3.28,6.16,3.51,7.60,21.25,6.32 
Dressing mean costb 2.73,5.69,3.31,2.29,0.3,2.86 
Nurse mean salary9 17 945,20 122.50,23 200,26 447.50,29 305 
Discount rate 6% per annum 
Research life cycle 10 years 
Schurmann and Eberhardt (1986)111) 
Falanga et at. (1999)113) 
Colgan et al. (1990)112) 
Dale et at. (1999)110) 
Actuary's Government Statistics Interim life 
tables (2003)114) 
Franks et al. (1995)115) 
RCN National Audit (2000)['6) 
RCN National Audit (2000)116) 
RCN National Audit (2000)1'6) 
RCN National Audit (2000)1161 
RCN National Audit (2000)[161 
RCN National Audit (2000)[16) 
BNF September (2004)[171 
BNF September (2004)[17) 
Booth (2003)[1e1 
UK TreasurP) 
Expert opinion 
Venous ulcer incidence 1.5 per 1000 population aged ? 18y Callam et al. (1985) 6) 
Population projections Projections for years 2004-13 ranged from 59.5 to Population projections by the UK 
60.7 million Government Actuary (2003-based) I'41 
a All normal distributions are characterised in terms of their mean and precision. Multinomial distributions are characterised in terms 
of sample size and probability parameters re-scaled so that their sum equals 1. 
b Dressing type: NA, hydrocolloid, loam, alginate, tulle grass, other. 
c RCN, unpublished data. 
d Bandage type: Setopress®, Surepress®, Tensopresss, Comprilan®, Ultra Four, Rosidal K®, four-layer, hosiery class 2/3, other. 
e Frequency of visits: one, two or three visits per week. 
f Nurse visit duration: (a) <20 min, (b) 30 min, (c) z40 min. 
g Nurse grades: D, E, F, G, H. 
h Visit setting: clinic or community. 
BNF = British National Formulary, NA = knitted viscose primary dressing; RCN = Royal College of Nursing. 
tween studies. It has been argued that a small num- 
ber of studies do not provide sufficient evidence to 
accurately estimate the between-study standard 
deviation; in these circumstances substantial judge- 
meet is required. ý21.223 Following a previously pub- 
lished example, we assumed that variations in the 
system of compression used produced considerable 
heterogeneity in the baseline healing rates between 
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studies J233 Thus 62 was assigned a prior normal 
distribution with mean 0.2 and standard deviation 
0.05. This corresponds to expecting ±50% variabili- 
ty in true odds ratios between studies, with 95% 
uncertainty limits of 20-80%. [221 
Estimation of Model Input Parameters 
Transition Probabilities 
The probabilities of healing with pentoxifylline 
and placebo were estimated using equatiop 2: 
phc _ 
or 
ph t_ 
or 
(1 + or`) (1 + or') 
phw ` =1- (1 + ph ` )1/24 phw `= 1- (1 + ph `)1124 
(Eq. 2) 
Where phi represents the 24-week cumulative 
probability of healing with j= placebo (c) and 
pentoxifylline (t) and on are the odds of healing in 
the jth group estimated from the meta-analysis. 
Weekly transition probabilities phwi were estimated 
from the cumulative probabilities of healing assum- 
ing that the true transition probabilities remained 
constant over the 24-week period. No residual effect 
of pentoxifylline was assumed (i. e. once individuals 
in the intervention group had experienced a healing 
episode, their probabilities to transit between health 
states, e. g. moving from unhealed to healed etc, 
became those of the placebo group). 
Probability of Recurrence 
Given the chronic nature of venous leg ulcers, the 
probability of an ulcer re-occurring had to be incor- 
porated into the model. A weekly probability of 
recurrence was estimated from an 18-month 
(78-week) rate of recurrence reported in a previous- 
ly published study. ["] The odds of recurrence were 
estimated using a fixed-effect model; in turn this 
was used to estimate the weekly probability of re- 
currence using equation 3: 
or 
pr = (1 + or) 
prw =1- (1 + pr)1178 
(Eq. 3) 
Where or is the odds of recurrence estimated in a 
fixed-effect meta-analysis, pr is the 18-month 
probability of recurrence and prw is the weekly 
probability of recurrence. 
Probability of Death 
Whilst leg ulcers are not a life-threatening condi- 
tion, they mainly occur in the elderly. Therefore 
annual mortality rates for the British general popula- 
tion aged 66 years were used to estimate the weekly 
probability of dying, following the same methodolo- 
gy used to estimate probabilities of recurrence. ["] 
The age was set at 66 years to reflect the average age 
over the four studies of pentoxifylline. 
Health Benefits 
Effectiveness was measured in terms of both 
QALYs and ulcer-free weeks. The utility weights 
associated with the healed and unhealed states were 
assigned beta distributions, the parameters of which 
were based on data from a previously published 
RCT and estimated using the methods of mo- 
ments. [24,25] 
Resource Use 
To estimate the likely volume of resources used 
in the treatment of venous leg ulcers we used data 
from a UK national audit (Royal College of Nursing, 
unpublished data). 1161 Total number of resources 
used per week in the placebo and pentoxifylline 
groups were estimated in terms of the number and 
type of bandages used and dressings applied, num- 
ber and duration of nurse visits to patients in the 
community and in a clinical setting and nurse grad- 
ing in the first and subsequent visits. 
The audit provided detailed information about 
the frequency with which these resources were usu- 
ally required in the treatment of venous leg ulcers. In 
turn, this allowed us to stochastically characterise 
relevant costing items; for example, the mean num- 
ber of nurse visits per week was estimated as a 
weighted average of the three potential frequencies 
of visits considered in the national audit (i. e. one, 
two or three visits per week). The weights were 
assumed to follow a multinomial distribution. An 
uninformative prior conjugate Dirichlet distribution 
was assigned to the parameter of the multinomial 
(table II). A similar procedure was followed to esti- 
mate type of bandage and dressing used, treatment 
setting and duration and nursing grading for pa- 
tients' first assessments and subsequent visits. 
Nursing salaries were characterised as uniform 
probability distributions defined in the range of the 
minimum and maximum salary points for each 
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grade. Annual salaries were obtained from the re- 
view body for nursing staff, midwives, health visi- 
tors and professions allied to medicine. 1181 
The frequency of dressing and bandage changes 
was determined by the number of visits per week. 
Total weekly costs were calculated by applying av- 
erage unit prices to total volume of resources 
utilised in each strategy. Unit prices were obtained 
from the British National Formulary. E17' The year of 
pricing was 2004. 
Cost Effectiveness 
A cost-utility (base-case) and a cost-effective- 
ness analyses were conducted. Cost effectiveness 
was determined using the net benefit approach, ac- 
cording to which the optimal alternative is the one 
that yields the highest expected 'net benefit'. Net 
benefits in monetary terms were estimated in equa- 
tion 4: Eel 
NB(t, 0)= 7ý, *B(t, 8)-C(t, 0)>0 
(Eq. 4) 
Sensitivity Analysis 
The sensitivity of the pooled estimate of clinical 
effectiveness to variations in total length of follow- 
up between studies was explored in a sensitivity 
analysis, where weekly transition probabilities of 
healing were estimated from the proportion of pa- 
tients healed at 8 weeks rather than the 24-week 
data. 
Sensitivity analyses were also conducted on prior 
distributions assigned to the following parameters: 
mean pooled odd ratios of healing, and heterogenei- 
ty between studies. 
Model Evaluation 
Markov Model 
To evaluate the Markov model, a cohort of 1000 
individuals aged 66 years was entered into the 
model. At each cycle, the total number of individu- 
als in each state was multiplied by the state's associ- 
ated utility weights and costs, and then summed 
across all states and cycles to estimate mean QALYs 
and mean total cost in the placebo and pentoxifylline 
groups. This model was evaluated simultaneously 
with the meta-analysis and the decision tree. 
According to preliminary runs, it was decided to 
use a burn-in of 40 000 iterations in order to reach 
convergence, and base inferences on a sample of a 
further 10 000 iterations. Model convergence was 
confirmed using two sets of rather dispersed starting 
values and by visual examination of the plot of the 
Gelman Rubin statistic in WinBUGSJ241 The two 
chains provided similar results, suggesting conver- 
gence had been achieved. 
where NB is the net benefit in monetary terms 
under treatment t, 2 is the decision maker's willing- 
ness to pay for an extra unit of health benefit 
(QALYs or ulcer-free weeks in this case), B is the 
health benefits under treatment t, C is the cost under 
treatment t, t is an index for treatment type and 0 is 
the set of unknown parameters of a decision model. 
The estimated mean QALYs, ulcer-free weeks 
and total costs associated with placebo and pentoxi- 
fylline were combined with a feasible range of val- 
ues for decision makers' willingness to pay (?, ), to 
obtain distributions of net benefits at different levels 
of X. The uncertainty surrounding the decision to 
adopt pentoxifylline as a cost-effective treatment at 
different levels of willingness to pay was represent- 
ed in acceptability curves. Cost-effectiveness ac- 
ceptability curves are a graphical representation of 
the probability of an intervention being cost effec- 
tive (on the vertical axis) for a range of willingness- 
to-pay values ?J (on- the horizontal axis) associated 
with the health outcome of interest. [261 
Value-of-Information Analysis 
The expected value of perfect information 
(EVPI) associated with the decision to recommend 
pentoxifylline as a cost-effective adjunct to com- 
pression in the treatment of venous leg ulcers was 
estimated at different levels of willingness to pay for 
an extra unit of health benefit (? ) using the follow- 
ing non-parametric method: [271 
" EVPI for an individual evaluating a set of alterna- 
tive treatments (t =1,2..., T) is as seen in equation 
5: 
EVPI = Eg max, NB(t, 6) - max, Ee VB (t, 0) 
(Eq. 5) 
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Table Ili. Model stochastic parameters 
Parameter Mean estimate 
(95% CI) 
Prior analysis 
Probability of healing (weekly basis) 
pentoxifylline 0.046 (0.034,0.059) 
placebo 0.025 (0.016,0.036) 
Posterior analysis 
Probability of healing (weekly basis) 
pentoxifylline 0.044 (0.036,0.052) 
placebo 0.027 (0.020,0.036) 
Common to both analyses 
Probability of re-occurring (weekly basis) 0.006 (0.005,0.007) 
Probability of dying (weekly basis) 0.0003 (0.0002, 
0.0005) 
Healing utility weight 0.75 (0.12,0.99) 
Open ulcer utility weight 0.64 (0.07,0.99) 
Death utility weight 0 
Proportion on Setopress® a bandage 
Proportion on Surepress® bandage 
Proportion on Tensopress® bandage 
Proportion on Comprilan® bandage 
Proportion on Ultra Four® bandage 
Proportion on Rosidal K® bandage 
Proportion on four-layer bandage 
0.02 (0.01,0.03) 
0.03 (0.01,0.04) 
0.13 (0.11,0.16) 
0.01 (0.005,0.02) 
0.01 (0.005,0.02) 
0.01 (0.008,0.01) 
0.58 (0.55,0.62) 
Proportion on hosiery class 2/3 0.08 (0.06,0.10) 
Proportion on other bandages 0.13 (0.11,0.15) 
Proportion on NA dressing 0.51 (0.47,0.54) 
Proportion on hydrocolloid dressing 0.14 (0.12,0.17) 
Proportion on foam dressing 0.06 (0.04,0.08) 
Proportion on alginate dressing 0.05 (0.04,0.07) 
Proportion on tulle grass dressing 0.02 (0.01,0.03) 
Proportion on other dressing 0.22 (0.19,0.25) 
Proportion of grade D nurses 0.04 (0.02,0.05) 
Proportion of grade E nurses 0.47 (0.43,0.52) 
Proportion of grade F nurses 0.04 (0.03,0.06) 
Proportion of grade G nurses 0.44 (0.40,0.48) 
Proportion of grade H nurses 0.01 (0.003,0.02) 
Proportion visited once a week 0.67 (0.63,0.70) 
Proportion visited twice a week 0.23 (0.21,0.27) 
Proportion visited thrice a week 0.10 (0.08,0.12) 
Proportion visited for 20 minutes 0.35 (0.31,0.38) 
Proportion visited for 30 minutes 0.51 (0.48,0.55) 
Proportion visited for 40 minutes 0.14 (0.11,0.16) 
Proportion visited at home 0.47 (0.43,0.50) 
Proportion visited at a clinic 0.53 (0.50,0.57) 
a The use of trade names is for product identification purposes 
only and does not imply endorsement. 
Cl = credibility interval; NA = knitted viscose primary 
dressing. 
where Ea = expectation over 0, maxt = maximum 
over t, t= fixed number of treatments (t = 1,2.... T) 
and 0= unknown number of parameters. Thus, 
Eg maxtNB(t, 8) is the mean of the maximum net 
benefit for each iteration (assumes perfect informa- 
tion), maxi EeNB(t, O) is the mean net benefit of the 
treatment with the maximum mean net benefit over 
all iterations, 
" For the entire population of individuals with open 
venous leg ulcers, this translates into the popula- 
tion EVPI (PEVPI) as per equation 6: 
I PI 
PEVPI = EVPI 
i=1 (1+r)r 
(Eq. 6) 
where Pi = incidence of open venous leg ulcers at 
time i (i = 1,., I), r= discount rate, I= effective life- 
time of the new technology. 
PEVPI relates to all patients who could potential- 
ly benefit from additional research over the lifetime 
of the new technology. 
EVPI was estimated in both the prior and posteri- 
or analyses. In both stages of the analysis, a 10-year 
life span for the research findings was assumed, and 
the annual expected value of perfect information 
was discounted at 6%. To date, no data are available 
regarding the incidence of venous leg ulcers; this 
parameter was estimated using data on the preva- 
lence of venous leg ulcers in the UK general popula- 
tion aged >_ 18 years (1.5 per 1000 people). It was 
also assumed that <20% of prevalent venous leg 
ulcers are open at any time, 40% of which will not 
heal with compression treatment after 6 months and 
may require adjunct therapy to compression to 
achieve healing. 
Results 
Mean estimates of all stochastic and determinis- 
tic model parameters are described in table III. 
Prior Analysis 
In the first stage of the analysis, pentoxifylline 
was identified as a dominant therapy (i. e. in compar- 
ison with placebo, the administration of this drug 
produced greater health benefits at a lower cost). 
People in the pentoxifylline group healed an average 
of 8.28 weeks quicker (95% Cl 1.89,14.56) than 
C) ,: -, . -, _ r, 4.,,. f.. a.., ++p. r Rv Al! rirints reserved- 
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people in the placebo group, had a 0.02 gain in 
QALYs (95% CI -0.12,0.17) and an average reduc- 
tion in cost of £153.4 (95% CI -53.11,354.9) [figure 
2]. 
In the base-case analysis, the distribution of the 
incremental costs and incremental QALYs in the 
cost-effectiveness plane (figure 3) suggests substan- 
tial uncertainty is associated with the dominance of 
pentoxifylline. The largest proportion of point esti- 
mates concentrate in the southwest and southeast 
quadrants. This indicates that, in a large proportion 
of the iterations, the mean differential in costs 
favours pentoxifylline; however, the mean differen- 
tial in health benefits can go in either direction. In 
the southwest quadrant, cost savings are achieved at 
the expense of reducing the mean gain in QALYs, 
and in the southeast quadrant, pentoxifylline is both 
cheaper and produces greater health benefits (i. e. is 
a `dominant alternative'). 
The decision uncertainty associated with the 
dominance of pentoxifylline is represented in figure 
4. For a large range of considerably low willingness- 
to-pay values for an extra QALY gained, the accept- 
ability curve for pentoxifylline suggests that this 
therapy is associated with a high probability of 
being cost effective in the treatment of chronic ve- 
nous leg ulcers. For instance, a 93% probability of 
being cost effective was estimated for pentoxifylline 
at a willingness-to-pay value of £50 for an extra 
QALY. 
The Bayesian value-of-information analysis, 
based on the data from the three RCTs111-131 pub- 
lished prior to the Dale et a1.1101 study, suggested 
that, given the considerably low levels of uncertain- 
ty associated with the decision to adopt pentoxifyl- 
line as a cost-effective treatment, the acquisition of 
further primary data may not be justified (figure 5). 
For willingness-to-pay values of £0, £ 100 and £500 
per QALY gained, the EVPIs were £128 200, 
£127 100 and £126 700, respectively. The approxi- 
mate total cost of another trial on compression for 
venous leg ulcers, started in 1998 and completed in 
2001, was £3 80 000J25,281 , 28J Cross referencing this 
value with our estimates of the maximum expected 
return value associated with primary research (i. e. 
`value of perfect information'), it is only at willing- 
ness-to-pay values above £1500 for an extra QALY 
that the collection of further data to reduce the 
decision uncertainty associated with the adoption of 
pentoxifylline would have been justified. This anal- 
ysis suggests that, unless decision makers were will- 
ing to pay £1500 or more per extra QALY for people 
with chronic venous leg ulcers in 1998, the actual 
cost of primary research may have exceeded the 
expected return value associated with the informa- 
tion provided by this study. 1101 
Posterior Analysis 
In the second analysis, the clinical effectiveness 
data from Dale et al. E10I were used to ascertain 
whether or not the prior belief that this trial was 
unlikely to be a `cost effective' use of research 
resources was correct. 
Data from Dale et al., 1'°1 added to the data from 
the three earlier RCTs, 1ll-131 were used to update the 
weekly probabilities of healing. The results regard- 
ing the cost effectiveness of pentoxifylline based on 
these posterior probabilities were slightly modified. 
In the posterior analysis, pentoxifylline was associ- 
ated with a mean expected cost saving of £98.09 
(95% CI -49.21,245.00), a mean expected QALY 
gained of 0.01 (95% CI -0.09,0.13) and a reduction 
in time to healing of 6.55 weeks (95% CI 1.93, 
11.15). On average, pentoxifylline was still a domi- 
nant strategy compared with placebo. However, as 
the results in figure 2 indicate, the point estimates of 
the mean incremental costs and health benefits were 
smaller than those observed in the prior analysis. 
The distribution of differential costs and differen- 
tial QALYs in the cost-effectiveness plane followed 
a similar pattern to that observed in the prior analy- 
sis; however, the point estimates were more precise 
in the posterior analysis (figure 3). The distribution 
of points in the posterior cost-effectiveness plane 
shrank, reflecting the reduction in the posterior vari- 
ance of the measure of health benefit as a result of 
additional data from Dale et al. 11° However, while 
the posterior variance is smaller, the upward shift of 
the posterior cost-effectiveness plane results in 
greater overall decision uncertainty. 
Relative to the prior analysis, the probability of 
pentoxifylline being cost effective was slightly re- 
duced for the same range of willingness-to-pay val- 
ues. Estimated posterior probabilities of pentoxifyl- 
line being cost effective at willingness-to-pay values 
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Prior analysis Mean Posterior distribution 
(95% credibility interval) 
Incremental QALYs 0.02 (-0.12,0.17) 
10.0 
5.0 
0.0 
-0.4 -0.2 0.0 0.2 
Incremental ulcer-free weeks 8.28 (1.89,14.56) 0.15 
0.1 
0.05- 
0.0- 
-10.0 0.0 10.0 20.0 
Incremental cost £153.4 (-53.11,354.9) 
0.004 0.003 
0.002 
0.001 
0.0 
-750.0 -250.0 250.0 
Heterogeneity between studies 0.22 (0.13,0.31) 
10.0 7.5 
5.0 
2.5 
0.0 
0.0 0.2 0.4 
Posterior analysis 
Incremental QALYs 0.01 (-0.09,0.13) 
15.0- 
10.0- 
5.0 
0.0 
-0.4 -0.2 0.0 0.2 
Incremental ulcer-free weeks 6.55 (1.93,11.15) 0.2- 0.15- 
0.1 
0.05- 
0.0- 
-5.0 0.0 5.0 10.0 15.0 
Incremental cost £98.09 (49.21,245.0) 0.006 
0.004 
0.002 
0.0 
-600.0 -200.0 200.0 
Heterogeneity between studies 0.22 (0.12,0.32) 10.0- 
7.5- 
.0 5 2.5 
0.0- 
0. D 0.1 02 0.3 0.4 
Fig. 2. Main results of the prior and posterior incremental cost-effectiveness analysis (2004 values, UK NHS perspective) of pentoxifyliine 
(vs placebo) in addition to compression. For the posterior distributions, each y-axis represents frequency and each x-axis represents the 
relevant parameter (incremental QALYs, ulcer-free weeks or costs or heterogeneity). 
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Fig. 3. Cost-effectiveness plane showing the distribution of incremental costs (2004 values, UK NHS perspective) and QALYs for 
pentoxifylline vs placebo in addition to compression. 
of £0, £500 and £ 1000 per QALY gained were 0.90, 
0.91 and 0.89, respectively (figure 4). This increase 
in the level of decision uncertainty surrounding the 
cost effectiveness of pentoxifylline may be due to 
the fact that, by incorporating more information into 
the analysis, we not only reduced the size of the 
mean incremental health benefit associated with 
pentoxifylline but also changed the distribution of 
the mean incremental costs, thus significantly modi- 
fying the distribution of the posterior mean expected 
monetary benefit. 
The results from the posterior value of perfect 
information analysis depicted in figure 5 followed 
the same direction as those from the prior analysis. 
Low posterior EVPI values were associated with 
willingness-to-pay values in the range of £0 to 
£2500 per QALY gained. A comparison of the pos- 
terior EVPI values in figure 5, with the same cut-off 
value of £380 000 used in the prior analysis, sug- 
gested once again that unless a decision maker' s 
willingness-to-pay values for an extra QALY gained 
are greater than £1500, the acquisition of further 
information is unlikely to be an efficient use of 
resources. 
c 2006 
Cost-Effectiveness Analysis 
Variations in the definition of health benefit (i. e. 
ulcer-free weeks rather than QALYs), yielded simi- 
lar results to those from the base-case cost-utility 
analysis. The use of natural units merely emphasised 
the `dominance' of pentoxifylline as an adjunct ther- 
apy and reduced the decision uncertainty associated 
with its adoption, that is, the EVPI was reduced for 
the same range of willingness-to-pay values for an 
extra unit of health benefit used in the base-case 
analysis (these data are not presented but can be 
requested from the corresponding author). 
Sensitivity Analysis 
Evidence of the `dominance' of pentoxifylline as 
an adjunct therapy to compression (vs placebo) in 
the treatment of chronic venous leg ulcers was pro- 
vided in all the sensitivity analyses. The model was 
robust with regards to the length of follow-up for 
effectiveness data, and the prior distributions as- 
signed to pooled estimates of the natural logarithm 
of the odds ratio of healing or to heterogeneity 
between studies. 
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Fig. 4. Cost-effectiveness acceptability curve (prior analysis) show- 
ing the decision uncertainty around the dominance of pentoxifylline 
vs placebo (2004 values) from the UK NHS perspective. 
The EVPI was significantly influenced by varia- 
tions in the definition of the parameter describing 
the heterogeneity between studies and the length of 
follow-up. The greater degree of heterogeneity be- 
tween studies that was assumed, the higher the val- 
ues associated with the collection of further primary 
information. As previously mentioned, a small num- 
ber of studies is not sufficient to precisely estimate 
the heterogeneity between studies, thus considerable 
judgement was required to define a `realistically 
vague prior distribution' [211 (these data are not 
presented but can be requested from the correspond- 
ing author). 
Discussion 
In ascertaining the clinical and cost effectiveness 
of healthcare technologies, primary research is one 
of the most valuable and reliable sources of informa- 
tion for decision making. However, the scarcity of 
resources available for healthcare research and de=velopment 
(R&D), requires decision makers to con- 
front their need for further information with the 
possibility of substantiating their decision on ex- 
isting information, and thus freeing resources that 
can be allocated to other areas of priority. 
A Bayesian value-of-information analysis explic- 
itly quantifies the levels of uncertainty associated 
with a decision at a specific point in time and given a 
fixed amount of existing information. Whilst the 
collection of further information can reduce the de- 
gree of uncertainty inherently associated with a de- 
cision, it has been argued that R&D resources may 
be more efficiently allocated if primary research is 
substantiated only when the expected reduction in 
the levels of uncertainty attributable to the newly 
acquired information are likely to counterbalance 
the actual cost of research. 1101 
The promotion of pentoxifylline as an adjunct 
pharmaceutical therapy to compression in the treat- 
ment of venous leg ulcers has been largely prevent- 
ed because of the equivocal findings reported in the 
literature regarding this drug's ability to expedite the 
healing process of chronic venous ulcers. A series of 
RCTs of different sizes and designs have been con- 
ducted to ascertain the benefits associated with 
pentoxifylline. M However, none of these studies 
were considered to provide conclusive evidence re- 
garding the clinical effectiveness of this drug. Fur- 
thermore, to the best of our knowledge, the cost 
effectiveness of pentoxifylline had not previously 
been formally explored. 
Our findings suggest that the current degree of 
uncertainty associated with the use of pentoxifylline 
as an adjunct to compression in the treatment of 
chronic venous leg ulcers does not justify the con- 
duct of further research. Furthermore, the Bayesian 
value-of-information analysis conducted using data 
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Fig. S. Expected value of perfect information (2004 values) on the 
cost effectiveness of pentoxifylline (vs placebo) from the UK NHS 
perspective, according to a range of decision maker's willingness to 
pay for an extra QALY gained from £0 to £5000. 
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from the three studies' 1.13) published before the UK- 
based largest study in this area (prior analysis), ['°1 
suggested that pentoxifylline was already associated 
with a large probability of being not only clinically 
but also cost effective, if not cost saving. 
Whilst the Dale et al. J1°1 study on pentoxifylline 
contributed to a more precise estimate of its likely 
associated benefit, its inclusion in the estimate of the 
pooled odds ratio of healing at 24 weeks did not 
reverse the conclusion from the prior analysis that 
pentoxifylline was likely to be a cost-effective inter- 
vention. Had the results from the study by Falanga et 
al. [13] and the framework proposed by Claxton et 
al. [41 been available prior to the commissioning of 
the study by Dale et al., [101 a more efficient use of 
R&D resources could have been made. 
Interestingly, two further trials[29,30] reporting a 
statistically significant beneficial effect of pentoxi- 
fylline have been published since the trial by Dale et 
al. 1'°1 These two Italian/British studies were funded 
with grants awarded from healthcare institutions 
without any support from the pharmaceutical indus- 
try. It is intriguing that, despite the mounting evi- 
dence on the clinical and cost effectiveness of 
pentoxifylline for the treatment of venous leg ulcers, 
there is a lack of initiative from its manufacturers to 
have this drug's licence amended. In addition to the 
direct health benefit to people with chronic venous 
leg ulcers, the official recognition of pentoxifyl- 
line's indication as an adjunct to compression ther- 
apy in the treatment of venous leg ulcers may pre- 
vent further inefficient use of public resources that 
are being used worldwide to conduct primary re- 
search on the effectiveness of this drug. 
This analysis provides evidence of the valuable 
potential contribution of Bayesian value-of-infor- 
mation analysis to assist the decision-making pro- 
cess in healthcare. [41 This methodology not only 
facilitates the integration of existing evidence in a 
coherent structure, but also allows estimation of the 
level of uncertainty associated with decisions re- 
garding the adoption of new healthcare technolo- 
gies. In this analysis, the framework was further 
strengthened by making use of a comprehensive 
analytic-decision model to evaluate the cost effec- 
tiveness of pentoxifylline compared with placebo. 
This enabled us to make full allowance for potential 
inter-relationships between model parameters, in- 
corporate greater parameter uncertainty by allowing 
us to estimate the pooled population effect and any 
potential baseline heterogeneity between studies 
from the data and make a more adequate stochastic 
characterisation of existing data without unnecessa- 
rily recurring to assumptions of normality. 15) 
The current analysis only considered evidence 
from RCTs up to the publication of the findings 
from Dale et al. 1101 While this can be considered as a 
limitation, we decided to do so to exemplify the 
potential contribution of the proposed framework at 
that specific point in time and given the set of 
evidence available then. Only a few RCTs have 
investigated the effect of pentoxifylline as an ad- 
junct therapy to compression for treating chronic 
venous leg ulcers. Therefore, considerable judge- 
ment was required to characterise the prior distribu- 
tion of the parameter describing the potential hetero- 
geneity between studies. While evidence regarding 
the clinical effectiveness of pentoxifylline from a 
wider range of clinical study designs could have 
been included, such analysis would have required 
considerably more human and financial resources 
than we had available. 
Conclusion 
The available information on pentoxifylline sug- 
gests that this drug is associated with a high 
probability of being cost effective in the treatment of 
chronic venous leg ulcers. Future research in this 
area can now concentrate on ensuring an optimal use 
of this therapeutic agent, for example by evaluating 
alternative methods of administration, establishing 
an optimal dosage, identifying the patient group 
most likely to benefit and estimating the point in 
time when an adjunct therapy should be considered. 
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Methodological issues associated with clinical evidence 
Some of the most frequently reported methodological limitations associated with 
clinical studies in VLUs are: [7-9] 
i) Inadequate comparisons: for example, a recently published study reported a 
comparison between 4-layer bandage and "other available treatments", i. e. any type of 
compression and wound dressing indicated for VLUs. [17] Given the large number of 
factors that could have systematically influenced the results observed in the control 
group, any effect observed in this group cannot be reliably attributed to any specific 
treatment alternative. Inadequate comparisons like this not only introduce a 
considerable potential for confounding, but just as importantly, represent an inefficient 
use of scarce R&D resources. 
ii) Small samples reported without sample size calculations: RCTs with between 12 
and 25 participants are common in VLUs. [7-9] For example, the only RCT in the 
international literature reporting on the effectiveness of larval therapy as a treatment 
for VLUs had only 12 participants. [61] Small samples reduce the statistical power of 
the analysis to draw any reliable inferences from the data by increasing the probability 
of a type II error, i. e. not rejecting the null hypothesis when the null hypothesis is not 
true. 
iii) Inadequate duration of follow-up: RCTs reporting on the effectiveness of 
pentoxifylline as an adjunct to compression for the treatment of VLUs followed up 
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participants for between 8 and 24 weeks. [40] While between 30% - 60% of VLUs 
would heal within this period, there is a large proportion of ulcers that would fail to do 
so. [128] In studies with short duration of follow-up there will be an artificially small 
proportion of participants achieving the endpoint, in this case healing, hence the 
statistical power of the study could be compromised. Furthermore, the recurrent 
nature of VLUs highlights the relevance of monitoring individuals over longer periods 
of time. Resolving an isolated episode of ulceration is only one of the objectives of 
VLU management, the principal aim of which should be to maximise ulcer free time. 
This is consistent with a decision analytic approach to evaluation, which suggests that 
the relevant time horizon for evaluation should be that over which the health condition 
under study is likely to be active, and over which cost and health outcomes are 
expected to differ. [95] In the case of chronic conditions this will be individual's life 
time. 
iv) Imbalances between trial arms in participant's baseline characteristics: area and 
duration of current VLUs have been identified as predictors for VLU healing. [129; 130] 
A RCT of long-stretch versus short-stretch compression bandages reported baseline 
imbalances both in the median ulcer size and median ulcer duration. [131] In spite of 
this, the statistical analysis of this study did not include an adjustment for baseline 
covariates, thus potentially reporting a biased estimate of the treatment effect. [132] 
This problem of baseline imbalance is a common one in wound care studies 
generally. [133] 
v) The use of intermediate (reductions in area of ulceration) and sub-optimal 
outcomes (simple proportions of ulcers healed rather than time to healing) over an 
arbitrarily fixed period of time is frequently reported in wound care RCTs. [58; 134] 
Whilst changes in ulcer shape and size are common, ulcers may still remain unhealed 
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for considerable periods of time, hence effectiveness claims based on this type of 
outcome can be highly misleading. Similarly, simple proportions of ulcers healed at a 
specific point in time provide partial and arbitrary information about the actual effect 
associated with any therapy. [16] The most informative outcome from a clinical and 
economic perspective will be "time to ulcer free person". 
Methodological issues associated with economic evidence 
Frequently encountered shortcomings associated with economic evaluation studies on 
VLUs: 
i) Use of uninformative intermediate outcomes: in cases where the measurement of 
final outcomes is precluded, the use of intermediate outcomes may be justified, on the 
basis of a strong association between intermediate and final outcomes. However, 
rates of change in ulcer size are not associated in a known way with time to ulcer 
healing, therefore intermediate outcomes based on changes in area of ulceration may 
be misleading. [58; 134] 
ii) Estimates of cost only based on unit cost of treatments: in an earlier VLU economic 
evaluation analysis the only component of cost considered was the "unit cost" of the 
competing alternative treatments. [1 35] This approach for the estimation of total costs 
is not only incomplete but also highly misleading since overall treatment costs are 
made out of a number of items that may contribute differently to estimate overall 
treatment costs. Nursing time, i. e., time nurses dedicate to looking after patients, has 
been identified as the greatest component of VL'U treatment. [52] Thus, unless 
considerable reductions in nursing time can be associated with a treatment, a 
differential in purchasing cost does not directly imply "cost-effectiveness". 
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iii) Use of medians rather than means: estimates of the median rather than mean total 
treatment cost have been used in some analyses. [124; 135] Total treatment cost data 
usually follow positively skewed distributions, i. e., data distributes asymmetrically. 
While the median may be more appropriate to describe a "typical" observation, [84] 
budgetary decisions and decisions about which intervention is worthwhile need to be 
based on what the cost and outcomes are expected to be, i. e. the average of the 
population instead of on only 50% of it. [136; 137] Consequently, economic evaluation 
analyses need to be based on estimates of the population mean otherwise the budget 
impact would be under estimated and estimates of cost-effectiveness will be biased 
since in positively skewed distributions the median is smaller than the mean. 
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Databases: CINAHL, MEDLINE, EMBASE 
Search Strategy: 
1 skin ulcer/ or leg ulcer/ or pressure ulcer/ (1325) 
2 exp Foot Ulcer/ (647) 
3 exp Diabetic Neuropathies/ (773) 
4 Diabetic Angiopathies/ (31) 
5 Diabetes Mellitus/co [Complications] (467) 
6 diabetes mellitus, insulin-dependent/co (107) 
7 diabetes mellitus, non-insulin-dependent/co (183) 
8 Pilonidal Cyst/ (11) 
9 Surgical Wound Infection/ (301) 
10 ((plantar or diabetic or heel or venous or stasis or arterial) adj4 ulcer$). ti, ab. (433) 
11 ((decubitus or foot or diabetic or ischaemic or pressure) adj4 ulcer$). ti, ab. (732) 
12 ((pressure or bed) adj4 sore$). ti, ab. (279) 
13 (pilonidal adj4 (cyst or sinus)). ti, ab. (6) 
14 (bedsore or bedsores or (bed adj sore$)). ti, ab. (22) 
15 ((diabetic adj foot) or (cavity adj4 wound$)). ti, ab. (304) 
16 ((varicose or leg or skin) adj4 ulcer$). ti, ab. (396) 
17 ((decubitus or chronic or sinus) adj4 wound$). ti, ab. (183) 
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18 ((burn or gunshot or bite) adj4 wound$). ti, ab. (159) 
19 exp BURNS/ (957) 
20 (diabetic adj (neuropath$ or angiopath$)). ti, ab. (88) 
21 (diabetes adj4 (wound$ or ulcer$)). ti, ab. (88) 
22 (surgical adj wound adj infection). ti, ab. (10) 
23 ((dehiscen$ or sepsis or exudat$ or necrot$ or slough$) adj4 (wound$ or ulcer$)). ti, ab. 
(96) 
24 (((non adj heal) or nonheal$ or problem or difficult$ or complic$) adj4 (wound$ or cavity 
or incision$)). ti, ab. (174) 
25 ((granulating or postoperative) adj wound$). ti, ab. (14) 
26 exp dental health services/ or exp dentistry/ or exp peptic ulcer/ or exp corneal diseases/ 
(2838) 
27 case study. pt. (13526) 
28 or/26-27 (16003) 
29 exp clinical trials/ or random assignment/ or placebos/ or meta analysis/ or exp 
prospective studies/ (18475) 
30 systematic review/ or comparative studies/ or clinical trial. pt. or review. pt. or systematic 
review. pt. (22625) 
31 (clinical adj trial$). ti, ab. (1859) 
32 ((singl$ or doubl$ or trebl$ or tripl$) adj blind$). ti, ab. (1040) 
33 (control or controls or controlled or controlling or metaanalys$). ti, ab. (16772) 
34 (meta adj analys$). ti, ab. (688) 
35 (random$ or prospective$ or (comparison adj group) or (standard adj treatment$)). ti, ab. 
(11937) 
36 (placebo$ or (systematic adj review$)). ti, ab. (2809) 
37 or/29-36 (46602) 
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38 economics/ or exp "costs and cost analysis"/ or economic aspects of illness/ (4489) 
39 economics, pharmaceutical/ or economic value of life/ (108) 
40 exp "fees and charges"/ or budgets/ (1358) 
41 (cost or costs or economic$ or pharmacoeconomic$ or price$ or pricing$). ti, ab. (8446) 
42 or/38-41 (11768) 
43 (trauma adj4 (wound$ or ulcer$)). ti, ab. (33) 
44 (pilonidal adj abscess$). ti, ab. (0) 
45 or/1-25,43-44 (4624) 
46 45 not 28 (4027) 
47 46 and 37 (1201) 
48 46 and 42 (269) 
49 from 47 keep 1-1201 (1201) 
50 from 49 keep 1-1201 (1201) 
51 from 49 keep 1-1201 (1201) 
52 from 49 keep 1-1201 (1201) 
53 from 49 keep 1-1201 (1201) 
54 from 49 keep 1-1201 (1201) 
55 from 49 keep 1-1201 (1201) 
56 from 48 keep 1-269 (269) 
57 from 48 keep 1-269 (269) 
58 from 48 keep 1-269 (269) 
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Figure 2. Quorum chart of economic evidence. [55] 
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